Methods and compositions for the treatment of short telomere-related hematologic disorders

Telo-EP-CD34 cells treated with nucleoside-modified mRNA extend telomeres and reduce senescence markers, offering a viable treatment for telomeropathies and age-related hematopoietic decline by enhancing engraftment and reconstitution capacity.

WO2026236316A1PCT designated stage Publication Date: 2026-11-12REJUVENATION TECHNOLOGIES INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/026829
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-07
Filing Date
2026-05-06
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current treatments for telomeropathies, such as allogeneic hematopoietic stem cell transplantation, are poorly tolerated due to DNA-damaging conditioning regimens, leading to high treatment-related mortality, and there is a need for effective methods to transfect stem cells to address telomere-related disorders.

Method used

Administering Telo-EP-CD34 cells prepared from autologous CD34+ cells treated with nucleoside-modified mRNA encoding human telomerase reverse transcriptase, optionally with a CXCR4 antagonist like plerixafor, to extend critically short telomeres and reduce senescence markers, without myeloablative conditioning.

Benefits of technology

The method extends telomeres, reduces senescence markers, and enhances multi-lineage hematopoietic reconstitution, providing a durable engraftment advantage through serial transplantation, thus addressing telomere-related disorders and age-associated hematopoietic decline.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026026829_12112026_PF_FP_ABST
    Figure US2026026829_12112026_PF_FP_ABST
Patent Text Reader

Abstract

Methods and compositions for treating short telomere-related hematologic disorders are provided. Autologous CD34+ hematopoietic stem cells are treated ex vivo with nucleoside-modified mRNA encoding human telomerase reverse transcriptase (TERT) to produce Telo-EP-CD34 cells. The transient TERT mRNA treatment extends critically short telomeres, reduces markers of cellular senescence and exhaustion including p53, p21, PD-1, and phosphorylated-γ-H2A.X, and enhances multi-lineage colony-forming capacity without permanent genomic alteration. Treated cells demonstrate significantly higher engraftment in immunodeficient xenograft models and maintain a competitive repopulation advantage through serial transplantation, confirming rejuvenation of the long-term repopulating HSC fraction. Administration of a CXCR4 antagonist facilitates engraftment of the telomere-extended cells. The disclosed methods address telomere biology disorders, including telomeropathy-associated cytopenia and bone marrow failure, as well as age-associated hematopoietic decline.
Need to check novelty before this filing date? Find Prior Art

Description

P A T E N T Docket No. REJU14PCT METHODS AND COMPOSITIONS FOR THE TREATMENT OF SHORT TELOMERE- RELATED HEMATOLOGIC DISORDERS CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional Patent Application No. 63 / 801,734, filed May 7, 2025, the contents of which are incorporated herein by reference in their entirety.REFERENCE TO A SEQUENCE LISTING SUBMITTED VIA EFS-WEB

[0002] The contents of the XML file of die sequence listing named “REJU14PCT_Sequence_Listing,” which is 66,113 bytes in size, was created on April 7, 2026; this sequence listing is incorporated by reference in its entirety.BACKGROUND

[0003] Telomeres are specialized nucleoprotein structures comprising (TTAGGG)n repeat sequences in complex with shelterin proteins, which form a protective cap at chromosome ends to preserve genomic stability. Because standard DNA polymerases cannot fully replicate die linear ends of chromosomes, telomere length serves as a molecular clock for cell replication; each division erodes telomeric DNA, eventually triggering DNA damage checkpoint responses, senescence, or apoptosis when telomeres become critically short. Crucially, telomere dysfunction is not determined by average length alone, as the shortest telomeres in a distribution can dictate cell viability and genome stability. In healdiy individuals, tire enzyme telomerase — comprising telomerase reverse transcriptase (TERT) and an RNA template — can slow tiris shortening in highly proliferative populations, including germ cells and hematopoietic stem cells (HSCs). However, in most somatic tissues, telomerase activity is insufficient or inactive, leading to progressive telomere shortening with age.

[0004] The hematopoietic system is uniquely exposed to this constraint, as lifelong blood and immune production depends on rare self-renewing HSCs and their immediate progeny, which must sustain output across decades and surge under infectious or inflammatory stress. Critically short telomeres in these cells are not merely biomarkers but central functional determinants of stem cell fitness; they impair regenerative capacity, induce apoptosis, activate chronic DNA damage signaling, cause senescence, and bias differentiation, ultimately driving premature HSC depletion and exhaustion.

[0005] Telomeropathies, also called telomere biology disorders, short telomere syndromes, or short telomere-related disorders, are fatal genetic diseases caused by a combination of environmental and genetic factors such as mutations in telomere maintenance genes, leading to premature telomere shortening. Patients with a telomeropathy often suffer from cytopenia, either with or without myelodysplastic syndrome. Cytopenia can cause bleeding, fatigue, and increase risk of infection and cancer. It can also lead to bone marrow failure. Currently the only cure for the hematologic manifestations of telomeropathies is allogeneic hematopoietic stem cell transplantation (HSCT). However, conventional myeloablative HSCT is poorly tolerated in these patients due to their extreme sensitivity to DNA-P A T E N T Docket No. REJU14PCT damaging conditioning regimens, which further shorten telomeres and lead to high treatment-related mortality.

[0006] Beyond rare inherited syndromes, telomere dysfunction is deeply intertwined with broader human health, immune robustness, and malignancy. In the general population, leukocyte telomere length tracks with adaptive immune competence; for instance, stronger influenza vaccine responses and greater CD8+ T cell expansion associate with longer telomeres. Conversely, shorter leukocyte telomeres associate prospectively with higher risks of infection-related hospitalization and mortality. This attrition contributes to a landscape of immunosenescence and chronic inflammation that may originate upstream at the level of the stem / progenitor reserve. Furthermore, telomere crisis can drive catastrophic genomic rearrangements, such as chromothripsis, which favor malignant evolution. Autoimmune conditions, such as rheumatoid arthritis, similarly reflect this "telomerase insufficiency," where accelerated telomere loss mirrors premature immune aging.

[0007] There is a need for successful transfection of stem cells. The difficulties in transfection of stem cells lie in the stability of stem cells. Various methods have been used for stem cells transfection, including electroporation and other methods. These chemical and physical transfection methods face many challenges, leading to viral-transduction methods, where viruses are used to deliver genes into stem cells.

[0008] There remains a need for an effective treatment for telomeropathy. Treatment of telomeropathy often requires reprogramming stem cells by introducing genetic sequences addressing telomeropathy. The present invention addresses these and other related needs in the art.SUMMARY

[0009] According to certain embodiments described and contemplated herein, methods of treating cytopenia in a subject are provided, comprising administering Telo-EP-CD34 cells to a subject having, suspected of having, or at risk of cytopenia or bone marrow disease or disorder, wherein the Telo-EP-CD34 cells are prepared from autologous CD34+ cells treated with nucleoside-modified mRNA encoding human telomerase reverse transcriptase.

[0010] According to certain embodiments described herein, the treatment comprises electroporation of the cells with the nucleoside-modified mRNA.

[0011] According to certain embodiments described herein, the methods further comprise administering a CXCR4 antagonist to tire subject after administering the Telo-EP-CD34 cells. Often the CXCR4 antagonist is administered to the subject between 0 hours (under 1 horn) and 20 hours after administering the Telo-EP-CD34 cells. In certain embodiments the CXCR4 antagonist is administered between 6 horns and 9 hours after infusion of the CD34+ cells modified by telomere extension using TERT mRNA. In certain embodiments the CXCR4 antagonist is administered between 10 hours and 14 hours after infusion of the CD34+ cells modified by telomere extension using TERT mRNA. In certain embodiments the CXCR4 antagonist is administered between 4 hours and 18 hours after infusion of tireP A T E N T Docket No. REJU14PCT CD34+ cells modified by telomere extension using TERT mRNA. In certain embodiments the CXCR4 antagonist is administered between 6 hours and 14 hours after infusion of the CD34+ cells modified by telomere extension using TERT mRNA. In certain embodiments the CXCR4 antagonist is administered at or about 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours. 19 hours, 20 hours, or between 20 hours and 36 hours after infusion of the CD34+ cells modified by telomere extension using TERT mRNA to the subject.

[0012] According to certain embodiments described herein, the CXCR4 antagonist is plerixafor.

[0013] According to certain embodiments described herein, the CXCR4 antagonist is selected from one or more of: BMS-936564 / MDX-1338, LY2510924, l,r-[l,4-phenylenebis(methylene)]bis [1 ,4,8,1 1 -tetraazacyclotetradecane] (AMD3100; Plerixafor), N, N-dipropyl-N-[4-({[(lH-imidazol-2-yl)methyl)benzyl] [(1 -methyl- 1 H-imidazol-2-yl)methyl] amino] methyljbenzyl] -N-methylbutane- 1 , 4-diamine tri(2R, 3R)-tartrate (KRH-3955), ([5-(4-methyl-l-piperazinyl)-2-({methyl[(8S)-5, 6,7,8-tetrahydro-8-quinolinyl]amino}methyl)imidazo[l,2-a]pyridin-3-yl]methanol) (GSK812397), N-(1H-benzimidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-l,4-diamine (AMD11070), BKT140 (4F-Benzoyl-TN14003), MSX-122, TN14003, Mab-CXCR4, CQC-01, BL-8040 (Motixafortide), and / or G-CSF.

[0014] According to certain embodiments described herein, the subject has shortened telomeres. According to such embodiments, the shortened telomeres are often in lowest 1st, 5th, 10th, 15th, 20th, 25th, 30th, 35th, 40th, 45th, or 50thpercentile among the age-matched general population, as measured by mean telomere length, median telomere length, 10th, or 20thpercentile telomere length. Also according to such embodiments, the subject is identified as having shortened telomeres by TeSLA, STeLA, Q-FISH, long-read sequencing, qPCR, Oxford nanopore sequencing, PacBio sequencing. TRF qPCR, and / or flow-FISH.

[0015] According to certain embodiments described herein, the treatment further results in a reduction of senescence-associated markers in the Telo-EP-CD34 cells relative to untreated autologous CD34+ cells, the senescence-associated markers selected from one or more of p53, p21, PD-1, phosphorylated- y-H2A.X, and senescence-associated -galactosidase.

[0016] According to certain embodiments described herein, the Telo-EP-CD34 cells, upon administration, engraft in the subject's bone marrow and maintain multi-lineage hematopoietic reconstitution capacity through at least one round of serial transplantation in an immunodeficient xenotransplantation model.

[0017] According to certain embodiments described herein, the nucleoside-modified mRNA comprises N1 -methylpseudouridine substituted for uridine at about 100% substitution. According to embodiments described herein, the nucleoside-modified mRNA further comprises a 5' cap, 5' and 3' untranslated regions derived from human -globin, and a poly-adenosine tail of between 80 and 100 nucleotides.P A T E N T Docket No. REJU14PCT

[0018] According to certain embodiments described herein, the methods of treatment further comprise, prior to administering the Telo-EP-CD34 cells, mobilizing CD34+ cells from die subject using a combination of granulocyte colony- stimulating factor (G-CSF) and plerixafor, followed by apheresis and isolation of CD34+ cells.

[0019] According to certain embodiments described herein, the method does not comprise myeloablative conditioning of the subject prior to administering the Telo-EP-CD34 cells.

[0020] According to certain embodiments described herein, the methods furdier comprise administering a CXCR4 antagonist to the subject prior to administering the Telo-EP-CD34 cells, optionally no more than 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, 18, 20, 22, 24, 36, or 48 hours before infusion of the Telo-EP-CD34 cells.

[0021] According to certain embodiments described herein, the Telo-EP-CD34 cells are administered at a dose of about IxlO6to about 16xl06cells per kilogram of subject body weight.

[0022] According to certain embodiments described herein, die telomerase mRNA is a codon-optimized TERT mRNA comprising a nucleic acid sequence at least 90% identical to SEQ ID NO: 1.

[0023] According to embodiments described herein, die subject has bone marrow failure and / or a telomere biology disorder.

[0024] According to certain embodiments described herein, mediods of increasing engraftment of blood cells in bone marrow of a subject comprising administering a CXCR4 antagonist to die subject prior to intravenously infusing blood cells to the subject.

[0025] According to certain embodiments described herein, the CXCR4 antagonist is plerixafor.

[0026] According to certain embodiments described herein, die CXCR4 antagonist is selected from one or more of: BMS-936564 / MDX-1338, LY2510924, l,r-[l,4-phenylenebis(methylene)]bis [1,4,8,11-tetraazacyclotetradecane] (AMD3100; Plerixafor), N, N-dipropyl-N-[4-({[(lH-imidazol-2-yl)methyl)benzyl] [(1 -methyl- 1 H-imidazol-2-yl)mediyl] amino] methyljbenzyl] -N-mediylbutane- 1 , 4-diamine tri(2R, 3R)-tartrate (KRH-3955), ([5-(4-methyl-l-piperazinyl)-2-({mediyl[(8S)-5, 6,7,8-tetrahydro-8-quinolinyl]aniino}niethyl)imidazo[l,2-a]pyridin-3-yl]methanol) (GSK812397), N-(1H-benzimidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-l,4-diamine (AMD11070), BKT140 (4F-Benzoyl-TN14003), MSX-122, TN14003, Mab-CXCR4, CQC-01, BL-8040 (Motixafordde), and / or G-CSF.

[0027] According to embodiments described herein, die CXCR4 antagonist is administered no more than 1, 2, 3, 4, 5, 6, 7, 8, 10, 12. 14, 16, 18, 20, 22, 24, 36, or 48 hours before infusion of the cells.

[0028] According to certain embodiments described herein, the blood cells are CD34+ cells.

[0029] According to certain embodiments described herein, the blood cells are CD34+ hematopoietic stem and progenitor cells, CD133+ / CD34- progenitors, CD34+ / CD38- primitive HSCs, granulocyte-macrophage progenitors (GMPs), megakaryocyte-erythroid progenitors (MEPs), B cells, T cells (naive and central memory), NK cells, classical monocytes, intermediate monocytes, plasmacytoidP A T E N T Docket No. REJU14PCT dendritic cells (pDCs), conventional dendritic cells (eDCs), endothelial progenitor cells (EPCs), and / or mesenchymal stromal cells (MSCs).

[0030] According to certain embodiments described herein, the methods further comprise administering a CXCR4 antagonist to the subject after intravenously infusing blood cells to the subject.

[0031] According to certain embodiments described herein, a CXCR4 antagonist is administered to the subject between 0 hours (under 1 hour) and 20 hours after intravenously infusing blood cells to the subject.

[0032] According to certain embodiments described herein, the subject has shortened telomeres. According to such embodiments, the shortened telomeres are often in lowest 1st, 5th, 10th, 15th, 20th, 25th, 30th, 35th, 40th, 45th, or 50thpercentile among the age-matched general population, as measured by mean telomere length, median telomere length, 10th, or 20thpercentile telomere length. Also, according to such embodiments, the subject is identified as having shortened telomeres by TeSLA, STeLA. Q-FISH, long-read sequencing, qPCR, Oxford nanopore sequencing, PacBio sequencing. TRF qPCR, and / or flow-FISH.

[0033] According to certain embodiments described herein, the subject has bone marrow failure and / or a telomere biology disorder.

[0034] According to certain embodiments described herein, a composition comprising a Telo-EP-CD34 cell is provided. In related embodiments, a Telo-EP-CD34 cell is provided. According to embodiments described herein, the telomerase mRNA comprises SEQ ID NOS: 1-5, 7, 9, 11, 13, 15, 17, 19 or 21. According to embodiments described herein, the telomerase mRNA encodes telomerase having a sequence defined by SEQ ID NOS: 6, 8, 10, 12, 14, 16, 18, or 20.

[0035] According to certain embodiments described herein, the Telo-EP-CD34 cells are suspended in Plasma-Lyte A as a fresh, non-cryopreserved product.

[0036] According to certain embodiments described herein, a method of producing a Telo-EP-CD34 cell is provided, comprising contacting a CD34+ cell with a composition comprising telomerase mRNA under conditions such that the CD34+ cell is transfected with tire telomerase mRNA in a manner such that tire telomerase mRNA is capable of expression.

[0037] According to certain embodiments described herein, the conditions such that tire CD34+ cell is transformed with tire telomerase mRNA comprise electroporation conditions.

[0038] According to certain embodiments described herein, the conditions such that the CD34+ cell is transformed with tire telomerase mRNA comprise squeeze transfection, calcium phosphate mediated transfer, nucleofection, sonoporation, heat shock, magnetofection, microprojectile mediated transfer, or cationic polymer mediated transfer conditions.

[0039] According to certain embodiments described herein, the telomerase mRNA comprises SEQ ID NOS: 1-5, 7, 9, 11, 13, 15, 17, 19 or 21.P A T E N T Docket No. REJU14PCT

[0040] According to certain embodiments described herein, the telomerase mRNA encodes telomerase having a sequence defined by SEQ ID NOS: 6, 8. 10, 12, 14, 16, 18, or 20.

[0041] According to certain related embodiments described herein, the CD34+ cells are cultured ex vivo for one day prior to and three days post treatment with the telomerase mRNA to allow telomere extension during S-phase of the cell cycle.

[0042] According to certain embodiments described herein, the electroporation is performed using the MaxCyte GTX electroporation platform.

[0043] According to certain embodiments described herein, methods of rejuvenating hematopoietic stem cells are provided, comprising treating autologous CD34+ cells with nucleoside -modified mRNA encoding human telomerase reverse transcriptase, wherein the treatment extends critically short telomeres in the CD34+ cells, reduces markers of cellular senescence and exhaustion including p53, p21, PD-1, and phosphorylated-y-H2A.X, and enhances multi-lineage colony- forming capacity. In certain embodiments, a single transient dose of TERT mRNA confers a durable cngraftmcnt advantage dial persists through serial transplantation, confirming rejuvenation of the longterm repopulating HSC fraction.

[0044] According to certain embodiments described herein, methods of rejuvenating long-term repopulating hematopoietic stem cells (LT-HSCs) in a subject are provided, comprising administering Telo-EP-CD34 cells to the subject, wherein the Telo-EP-CD34 cells are prepared from autologous CD34+ cells treated with nucleoside-modified mRNA encoding human telomerase reverse transcriptase, and wherein the Telo-EP-CD34 cells, upon engraftment, maintain a competitive repopulation advantage through at least one round of serial transplantation. According to embodiments described herein, the Telo-EP-CD34 cells achieve at least a 3-fold increase in engraftment levels relative to control cells in an immunodeficient xenotransplantation model. Also according to embodiments described herein, the Telo-EP-CD34 cells maintain enhanced multi-lineage colonyforming capacity at 6 months post-engraftment.

[0045] According to certain embodiments described herein, methods of treating age-associated hematopoietic decline in a subject are provided, comprising administering Telo-EP-CD34 cells to the subject, wherein the Telo-EP-CD34 cells are prepared from autologous CD34+ cells treated with nucleoside-modified mRNA encoding human telomerase reverse transcriptase, and wherein the treatment extends critically short telomeres in the CD34+ cells witiiout driving telomere lengtii beyond die physiological range. Also according to embodiments described herein, the critically short telomeres are extended by an average of approximately 0.5 to 2.0 kilobases.

[0046] According to certain embodiments described herein, methods of reducing cellular senescence in CD34+ hematopoietic stem cells are provided, comprising treating die CD34+ ceds ex vivo widi nucleoside-modified mRNA encoding human telomerase reverse transcriptase, wherein die treatment reduces expression of one or more of p53, p21, PD-1, phosphorylated-y-I I2A.X. or senescence-associated |3-galactosidase relative to untreated control ceds. Also according toP A T E N T Docket No. REJU14PCT embodiments described herein, such methods further comprise administering the treated CD 34+ cells to a subject having, suspected of having, or at risk of a telomere biology disorder or age-associated hematopoietic decline.

[0047] According to certain embodiments described herein, methods of enhancing colonyforming capacity of CD34+ hematopoietic stem cells are provided, comprising treating the CD34+ cells ex vivo with nucleoside -modified mRNA encoding human telomerase reverse transcriptase, wherein the treatment increases colony formation across CFU-GM. BFU-E. and CFU-GEMM subtypes relative to untreated or control mRNA-treated cells. According to embodiments described herein, methods the colony formation is increased by approximately 1.3- to 2.6-fold relative to control mRNA-treated cells.

[0048] According to certain embodiments described herein, methods of treating a telomere biology disorder in a subject are provided, comprising: (a) mobilizing CD34+ cells from the subject using a combination of G-CSF and a CXCR4 antagonist; (b) collecting CD34+ cells by apheresis; (c) treating the CD34+ cells ex vivo with nucleoside-modified mRNA encoding human telomerase reverse transcriptase to produce Telo-EP-CD34 cells; (d) administering a CXCR4 antagonist to the subject; and (e) infusing the Telo-EP-CD34 cells into the subject. According to related embodiments, the CXCR4 antagonist of step (d) is plerixafor administered subcutaneously 3 to 6 hours prior to infusion of the Telo-EP-CD34 cells. Also or alternatively, according to related embodiments, step (c) comprises electroporating the CD34+ cells with the nucleoside-modified mRNA and expanding the electroporated cells ex vivo for approximately three days to allow telomere extension.

[0049] According to certain embodiments described herein, the disclosed methods and compositions are applicable not only to telomere biology disorders but also to age-associated hematopoietic decline. By resetting the replicative clock of the long-term repopulating HSC fraction without the risks of permanent immortalization, transient TERT mRNA provides a clinically viable pathway to overcome the primary telomeric limit on human hematopoiesis and restore the curative capacity of the hematopoietic system.

[0050] These and other embodiments, features, and advantages will become apparent to those skilled in the art when taken with reference to the following more detailed description of various exemplary embodiments of the present disclosure in conjunction with the accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS

[0051] The skilled person in the art will understand that the drawings, described below, are for illustration purposes only.

[0052] FIG. 1 depicts examples of telomere lengths in blood cells of patients with pulmonary fibrosis, blood dyscrasia, liver cirrhosis and with no disease. The blue band represents the 10th to 90th percentiles of telomere length, with the middle black line representing the 50th percentile. Telomere lengths are short in patients with telomeropathy relative to age-matched controls. (Source: Data adapted from Diaz de Leon, 2010.).P A T E N T Docket No. REJU14PCT

[0053] FIG. 2 depicts an exemplary formulation of the present disclosure, including TERT mRNA having a cap, untranslated regions optimized for stability and translational efficiency, die TERT coding sequence, and a poly(A) tail.

[0054] FIG. 3 depicts a flowchart outlining the process of manufacturing TERT mRNA. TERT mRNA is synthesized by an in vitro enzymatic RNA polymerase reaction from a DNA template that polymerizes ribonucleotide triphosphates into TERT mRNA. The resulting solution is dien incubated with DNase to remove the template prior to purification of the TERT mRNA. The TERT mRNA is then purified and sterile-filtered.

[0055] FIG. 4 depicts effect of TERT mRNA on Telomerase Activity in Primary Human Cells.

[0056] FIG. 5 depicts the effect of TERT mRNA on Telomere Length in Human Primary Cells.

[0057] FIG. 6 depicts die effect of TERT mRNA on Proliferative Capacity of Human Fibroblasts.

[0058] FIG. 7 depicts the effect of TERT mRNA on Proliferative Capacity of Telomeropathy Patient Fibroblasts.

[0059] FIG. 8 depicts the effect of Electroporation of TERT mRNA on CD34 Expression.

[0060] FIG. 9 depicts the effect of MaxCyte STx Electroporation of TERT mRNA on CD34+ Cell Viability.

[0061] FIG. 10 depicts the effect of TERT mRNA Electroporation on CD34+ Cell Purity.

[0062] FIG.11 depicts die effect of TERT mRNA Electroporation on CD34+ Cell Telomerase Activity.

[0063] FIG. 12 depicts the effect of TERT mRNA Electroporation on CD34+ Cell Expansion.

[0064] FIG. 13 depicts the effect of TERT mRNA Electroporation on CD34+ Cell Colony-Forming Potential.

[0065] FIG. 14 depicts die effect of TERT mRNA on differentiation potential of CD34+ cells.

[0066] FIG. 15 depicts the effect of TERT mRNA Electroporation on CD34+ Cell Telomere Length.

[0067] FIG. 16 depicts an exemplary time Course of HSPC (LSK) Cell Mobilization Following Plerixafor Injection.

[0068] FIG. 17 depicts die effect of Plerixafor on Engraftment of HSPC (LSK) in Short Telomere Mouse.

[0069] FIG. 18 depicts the effect of TERT mRNA Electroporation on Engraftment of Human CD34+ Cells in Immunocompromised Mice.

[0070] FIG. 19 depicts an exemplary treatment sequence according to the present disclosure.

[0071] FIGS. 20A-20G depict telomerase mRNA extending telomeres in human CD34+HSCs. FIG. 20A: Long-term expansion of mobilized peripheral blood sorted for CD34 with (FIG. 20B) telomere length analysis. FIG. 20C: Flow cytometry analysis of transfection efficiency of mCherry andP A T E N T Docket No. REJU14PCT turboRFP-TERT into mobilized CD34+HSCs and (FIG. 20D) quantification 48-hours later. FIG. 20E: Single length telomere analysis after transfection with TERT niRNA at various times during short-term culture. FIG. 20F: Population doublings post-introduction of TERT mRNA followed by secondary transfection 2-weeks into culture. FIG. 20G: Degree of telomere extension as a function of donor age. Data is represented as mean ± s.e.m with at least n = 3 / group.

[0072] FIGS. 21A-21E depict telomerase mRNA inhibiting senescence and exhaustion in CD34+HSCs. FIGS. 21A-21B: Immunohistochemistry on CD34+HSCs after treatment with TERT or fluorescent protein encoding mRNA with quantification (FIG. 21C). FIG. 2 ID) immuno fluorescent staining for senescence after TERT mRNA treatment with quantification (FIG. 2 IE). Data is represented as mean ± s.e.m with at least n = 3 / group.

[0073] FIGS. 22A-22I depict telomerase mRNA improving colony-forming capacity in CD34+HSCs. FIG. 22A: Brightfield images of CFUs after TERT treatment with quantification (FIG. 22B) and percentage distribution of CFUs (FIG. 22C). FIG. 22D: Total number of cells after CFU assay and TERT treatment relative to baseline (Day 0). FIGS. 22E-22H: Telomere length analysis of differentiated CD34+HPSCs after CFU assay and transfection with TERT mRNA. FIG. 221: Brightfield of CFUs after treatment with catalytically-inactive TERT mRNA relative to active TERT mRNA. CFU-GM (granulocyte-macrophage), BFU-E / CFU-E (erythroid bursts / colonies), or CFU-GEMM (granulocyte-erythrocyte-monocyte-megakaryocyte mixed colonies). Data is represented as mean ± s.e.m with at least n = 3 / group.

[0074] FIGS. 23A-23G depict telomerase mRNA enhancing HSC engraftment in immunocompromised recipients. FIGS. 23A: NBSGW humanization with CD34+HSCs after treatment with TERT mRNA or fluorescent protein encoding mRNA. Data represents the percentage of hCD45+cells circulating in peripheral blood quantified by multi-color flow cytometry. FIGS. 23B: Complete blood counts 6-months post-humanization. FIGS. 23C: Total percent of hCD45+ cells in the bone marrow of humanized NBSGW mice 6-months post-transplant with CD34+HSCs with (FIGS. 23D) telomere length analysis on sorted CD34+HSCs from total NBSGW bone marrow 6-months posthumanization and treatment with TERT mRNA. FIGS. 23E: CFU assay on sorted CD34+HSCs from NBSGW bone marrow 6-months post-transplant and treatment with TERT mRNA with quantification (FIGS. 23F) between control mRNA. FIGS. 23G: Serial CD34+HSC engraftment in NBSGW mice with cells treated with TERT mRNA and transplanted to NBSGW mice 6-months prior to the 3-month serial transplant. CFU-GM (granulocyte-macrophage), BFU-E / CFU-E (erythroid bursts / colonies), or CFU-GEMM (granulocyte-erythrocyte-monocyte-megakaryocyte mixed colonies). Data is represented as mean + s.e.m with at least n = 3 / group.

[0075] FIGS.24A-24B depict histopatiiology and karyotype after TERT mRNA treatment. FIG.24A: Necropsy from humanized NBSGW mice 6-months post-transplant with CD34+HSCs treated with TERT mRNA. Scoring key: 0 = normal, 1 = minimal change, 2 = mild change, 3 = moderate change, 4P A T E N T Docket No. REJU14PCT = severe change. FIG. 24B: Karyotype of CD34+HSCs after treatment with TERT mRNA or mRNA encoding for fluorescent protein.DETAILED DESCRIPTION

[0076] For clarity of disclosure, and not by way of limitation, the detailed description of the invention is divided into the subsections that follow.

[0077] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art to which this invention belongs. All patents, applications, published applications and other publications referred to herein are incorporated by reference in their entirety. If a definition set forth in this section is contrary to or otherwise inconsistent with a definition set forth in the patents, applications, published applications and other publications that are herein incorporated by reference, the definition set forth in this section prevails over the definition that is incorporated herein by reference.

[0078] As used herein, “a” or “an” means “at least one” or “one or more.”

[0079] As used herein, the term “and / or” may mean “and,” it may mean “or,” it may mean “cxclusivc-or,” it may mean “one,” it may mean “some, but not all,” it may mean “neither,” and / or it may mean “both.”

[0080] As used herein, the term “approximately” or “about.” as applied to one or more values of interest, refers to a value that is similar in magnitude and / or within a similar range to a stated reference value. In certain embodiments, the term “approximately” or “about” may refer to a range of values that fall within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%. 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%. 3%, 2%, 1%, or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context (except where such number would exceed 100% of a possible value). Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the disclosure. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges is also encompassed within the disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure.

[0081] The term “bone marrow” as used herein generally includes cells present or originating in bone marrow. Bone marrow contains a diverse range of cells involved in the production of blood and immune cells. The main types of bone marrow cells can be broadly classified into the following categories: hematopoietic stem and progenitor cells (HSPCs), including hematopoietic stem cells (HSCs) that arc multipotcnt cells that can self -renew and differentiate into all types of blood cells and progenitor cells that give rise to specific lineages (myeloid or lymphoid); myeloid lineage cells (from HSCs via myeloid progenitors) including erythroblasts, megakaryocytes: Large cells that produce platelets,P A T E N T Docket No. REJU14PCT myeloblasts, granulocytes, neutrophils, eosinophils, basophils, and monocytes; lymphoid lineage cells (from HSCs via lymphoid progenitors) such as B lymphocyte precursors, T lymphocyte precursors (some migrate to the diymus for maturation), and natural killer (NK) cell precursors; stromal cells, including mesenchymal stem cells (MSCs), fibroblasts, endothelial cells, osteoblasts and osteoclasts; adipocytes; macrophages and reticular cells. According to frequent embodiments described and contemplated herein, bone marrow cells or blood cells to be engrafted in bone marrow herein include CD34+ stem and progenitor cells, including: CD34+ hematopoietic stem and progenitor cells, CD133+ / CD34-progenitors, CD34+ / CD38- primitive HSCs, granulocyte-macrophage progenitors (GMPs), megakaryocyte-erythroid progenitors (MEPs), B cells, T cells (naive and central memory), NK cells, classical monocytes, intermediate monocytes, plasmacytoid dendritic cells (pDCs), conventional dendritic cells (eDCs), endothelial progenitor cells (EPCs), and / or mesenchymal stromal cells (MSCs). Thus, according o often included embodiments, “blood cells” refers to CD34+ hematopoietic stem and progenitor cells, CD1 3+ / CD34- progenitors. CD34+ / CD38- primitive HSCs, granulocyte-macrophage progenitors (GMPs), megakaryocyte-erythroid progenitors (MEPs), B cells, T cells (naive and central memory), NK cells, classical monocytes, intermediate monocytes, plasmacytoid dendritic cells (pDCs), conventional dendritic cells (eDCs), endothelial progenitor cells (EPCs), and / or mesenchymal stromal cells (MSCs).

[0082] The term “CXCR4 antagonist” as used herein generally includes any available CXCR4 antagonist, including small chemical compounds, peptides, and antibodies drat bind to or block the CXCR4 receptor or prevent the activation of CXCR4 antagonist by its natural ligand CXCL12. Thus, a CXCR4 antagonist may also be an agent that binds to CXCL12 and inhibits its interaction with CXCR4, or odierwise inhibits the activity of CXCL12 relative to CXCR4. Examples of CXCR4 antagonists contemplated for use in embodiments described herein include, but are not limited to the following: BMS-936564 / MDX-1338, LY2510924, l,l'-[l,4-phenylenebis (methylene)] bis [1,4,8,11-tetraazacyclotelradecane] (AMD3100; Plerixafor), N, N-dipropyl-N-[4-({[(lH-imidazol-2-yl)methyl)benzyl] [( 1 -methyl- lH-imidazol-2-yl)methyl] amino] methyl)benzyl] -N-methylbutane- 1 , 4-diamine tri(2R, 3R)-tartrate (KRH-3955), ([5-(4-methyl-l-piperazinyl)-2-({methyl[(8S)-5, 6,7,8-tetrahydro-8-quinolinyl]amino}methyl)imidazo[1.2-a]pyridin-3-yl]methanol) (GSK812397). N-(1H-benzimidazol-2-ylmethyl)-N'-(5 ,6,7 ,8-tetrahydroquinolin- 8-yl)butane- 1 ,4-diamine (AMD 11070) , BKT140 (4F-Benzoyl-TN14003), MSX-122, TN14003, Mab-CXCR4, CQC-01, and / or BL-8040 (Motixafortide). including derivatives thereof any of the foregoing. A CXCR4 antagonist may also include indirect antagonists such as G-CSF. While not being intended to be bound by any particular theory, since CXCR4 and CXCL12 operate in the same pathway, for purposes of the present disclosure a CXCR4 antagonist may also be or be referred to herein as a CXCL12 antagonist.

[0083] The term “immune cells” as used herein generally includes white blood cells (leukocytes) which are derived from hematopoietic stem cells (HSC) produced in the bone marrow. “Immune cells” includes, e.g., lymphocytes (T cells, B cells, natural killer (NK) (CD3- CD56+) cells) and myeloid-P A T E N T Docket No. REJU14PCT derived cells (neutrophil, eosinophil, basophil, monocyte, macrophage, dendritic cells). “T cells” include all types of immune cells expressing CD3 including T-helper cells (CD4+ cells), cytotoxic T-cells (CD8+ cells), T- regulatory cells (Treg) and gamma-delta T cells, and NK T cells (CD3+ and CD56+). A person of skill in tire art will understand that the terms T cells and / or NK cells, as used throughout the disclosure, can include only T cells, only NK cells, or both T cells and NK cells. A “cytotoxic cell” includes CD8+ T cells, natural-killer (NK) cells, NK-T cells, y8 T cells, and neutrophils, which are cells capable of mediating cytotoxicity responses.

[0084] The terms “individual.” “subject.” and “patient” are used interchangeably herein and refer to any subject for whom diagnosis, prevention, or treatment is desired. The subject may be a mammalian subject. Mammalian subjects include, e.g.. humans, non-human primates, rodents, (e.g., rats, mice), lagomorphs (e.g., rabbits), ungulates (e.g., cows, sheep, pigs, horses, goats, and the like), etc. In some embodiments, the subject is a human. In some embodiments, the subject is a non-human primate, for example a cynomolgus monkey. In some embodiments, the subject is a companion or service animal (e.g. cats or dogs).

[0085] The term “nucleic acid” refers to deoxyribonucleotides or ribonucleotides and polymers thereof in either single- or double-stranded form, composed of monomers (nucleotides) containing a sugar, phosphate and a base that is either a purine or pyrimidine. Unless specifically limited, the term encompasses nucleic acids containing known analogs of natural nucleotides that have similar binding properties as the reference nucleic acid and are metabolized in a manner similar to naturally occurring nucleotides. Unless otherwise indicated, a particular nucleic acid sequence also encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions) and complementary sequences, as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating nucleic acid sequences which, upon being translated (if RNA) or transcribed and translated (if DNA), produce the same sequence of amino acid residues as the original nucleic acid sequence; or, in which the third position of one or more selected (or all) codons is substituted with mixed-base and / or deoxyinosine residues.

[0086] The term “nucleotide sequence” refers to a polymer of DNA or RNA that can be single-or double-stranded, optionally containing synthetic, non-natural or altered nucleotide bases capable of incorporation into DNA or RNA polymers.

[0087] As used herein, “ribonucleic acid” means a polymer of ribonucleotides.

[0088] Telomeropathies are life-threatening genetic conditions caused by mutations in telomere maintenance genes (TERT, TERC, DKC1, etc.) causing accelerated telomere shortening with each cell division. People with telomeropathies typically have leukocyte telomere length below the 10thcentile for age. Short telomeres cause gene dysregulation via the telomere position effect (TPE) and, when telomeres become too short (< approximately 1.5kb) they are unable to protect the DNA tip, causing it to become exposed to the cell’s DNA damage detection system, resulting in a chronic DNA damage response, including p53 activation, driving apoptosis, mitochondrial dysregulation, chromosome-chromosomeP A T E N T Docket No. REJU14PCT fusions, and senescence. Further, senescent cells secrete senescence associated secretory phenotype (SASP) factors that drive chronic inflammation. Further still, the infections and bleeding consequent to cytopenia further drive proliferative demand on HSCs, accelerating telomere shortening in a vicious cycle. Via these mechanisms, HSCs exhaust their capacity to produce new blood cells, resulting in cytopenia.

[0089] The term “stem cell” as used herein generally includes pluripotent or multipotent stem cells. The term “stem cells” is intended to include, e.g., embryonic stem cells, mesenchymal stem cells, induced- pluripotent stem cells, committed progenitor cells, bone marrow derived cells, etc.

[0090] The terms “individual,” “subject,” and “patient” are used interchangeably herein and refer to any subject for whom treatment or therapy is desired. The subject may be a mammalian subject. Mammalian subjects include, e.g., humans, non-human primates, rodents, (e.g., rats, mice), lagomorphs (e.g., rabbits), ungulates (e.g., cows, sheep, pigs, horses, goats, and the like), etc. In some embodiments, the subject is a human. In some embodiments, the subject is a non-human primate, for example a cynomolgus monkey. In some embodiments, the subject is a companion or service animal (e.g. cats or dogs).

[0091] Telomere biology disorders are likely underdiagnosed, especially in adults, because they often present as “idiopathic” aplastic anemia, pulmonary fibrosis, cirrhosis, or other organ failure without the classic skin / nail changes of DC. The prevalence of telomeropathy-related cytopenia (TC) in the U.S. is estimated to exceed 30,000 cases. This figure includes many patients misidentified as suffering from aplastic anemia or other bone marrow failure syndromes. For example, among the -600,000-700,000 Americans with liver cirrhosis, about 6% carry germline TERT mutations - a striking proportion given that >75% of patients with cirrhosis also have cytopenias (commonly from hypersplenism). Similarly, approximately 3% of patients with idiopathic pulmonary fibrosis (IPF) harbor heterozygous TERT or TERC mutations. IPF is the most common telomere-mediated disorder; those who undergo lung transplantation (the only definitive treatment for IPF) often experience severe cytopenias post-transplant, due to hematopoietic stress and immunosuppression intolerance in the setting of short telomeres. Currently, diagnostic tests for telomeropathies - such as leukocyte telomere length measurement (Flow-FISH or qPCR assays) and multigene panel sequencing - are available but not yet widely utilized in clinical practice. As a result, many patients with telomere-related disease may go unrecognized until advanced complications arise. It is noteworthy that the majority will exhibit cytopenia at some stage of their illness, underscoring the need for heightened clinical awareness and early intervention to mitigate hematologic decline.

[0092] TC causes fatigue, recurrent infections, and bleeding complications. Cytopenias are also a key driver of morbidity and mortality, with lack of blood cells causing infections and bleeding that in turn put additional proliferative demand on CD34 cells, further driving telomere shortening. TC often progresses to bone marrow failure and clonal evolution into malignancies (e.g., myelodysplastic syndromes, acute myeloid leukemia). Indeed, by middle age a substantial fraction of patients withP A T E N T Docket No. REJU14PCT telomeropathy have evolved MDS / AML or solid tumors (such as head and neck squamous cell carcinomas or liver tumors), reflecting die genomic instability and impaired immune surveillance associated with telomere shortening.

[0093] Mutations in telomere maintenance genes cause a spectrum of inherited disorders collectively called telomere biology disorders (TBDs) or telomeropadiies. They range from severe early-onset forms to milder adult-onset forms. A unifying clinical feature is cytopenia - inadequate blood cell production due to telomere-mediated HSC dysfunction. The prototypical telomeropathy is dyskeratosis congenita (DC), classically presenting in childhood with the triad of abnormal skin hyperpigmentation, nail dystrophy, and oral leukoplakia. Children with DC have extremely short telomeres (often cist percentile for age) and develop multi-system complications: bone marrow failure (in >80% by young adulthood), pulmonary fibrosis, hepatic cirrhosis, and high cancer risk. Importantly, many patients with telomere disorders do not display the full DC triad - they may present later in life with isolated marrow failure or isolated fibrosis in one organ. For example, some heterozygous TERT mutation carriers present in mid-life with isolated aplastic anemia or IPF, and only retrospective testing reveals short telomeres. Regardless of presentation, these patients are at high risk of progressive marrow failure and malignancy if untreated, owing to critically short telomeres driving chromosomal instability and impaired immune surveillance of emerging tumors. Early intervention targeting the telomere defect is therefore warranted before irreversible organ damage ensues, especially in tire hematopoietic system which undergoes rapid telomere attrition and is crucial for immune defense against cancer.

[0094] As described herein, transient delivery of synthetic mRNA encoding TERT offers a safety-by-design regenerative strategy to pulse telomerase activity in a controlled maimer without genomic integration. By incorporating modified nucleosides such as N1 -methylpseudouridine to suppress innate immune sensing, TERT mRNA can rapidly extend telomeres in human cells without inducing tumorigenic transformation. Unlike constitutive expression systems or integrating viral vectors, the transient nature of the mRNA approach ensures that telomerase activity dissipates as the RNA degrades, providing a defined temporal pulse that resets telomere reserve without the risks of permanent immortalization. This "hit-and-run" approach provides a clinically viable pathway to overcome the primary telomeric limit on human hematopoiesis and restore the curative capacity of the hematopoietic system, both in subjects with telomere biology disorders and in age-associated hematopoietic decline.

[0095] For the purposes of the present disclosure, subjects are those with telomere-mediated cytopenias, often without overt malignancy. This includes subjects with DC or TBDs who have significant bone marrow failure (e.g. transfusion-dependent anemia or thrombocytopenia, or severe neutropenia) but no MDS / AML at enrollment. Telomeropathies encompass a broad spectrum of primary diagnoses, some examples of which are listed in Table 1 below. Notably, telomeropathies can underlie a subset of cases of seemingly unrelated diseases (e.g., ~6% of cryptogenic cirrhosis, ~3% of IPF, etc., as noted earlier). Identification of these subjects relies on telomere length testing and genetic screening, which testing and screening is a component of certain embodiments described herein.P A T E N T Docket No. REJU14PCT Table 1 Selected Primary Diagnoses in Patients with a Telomeropatliy Frequently Associated with CytopeniaDiagnosis Association with TERT Estimated U.S. Cytopenia Association Mutations PrevalenceDyskeratosis Mutations in DKC1, <1,000 (ultra-rare) Nearly universal bone marrow congenita TERT, TERC, etc. (X- failure by young adulthood (classic) linked or AD) (Fernandez Garcia, 2014) Cryptogenic liver -6% of cases have -30,000 of >75% have cytopenias (anemia, cirrhosis pathogenic TERT 600,000+ cirrhosis thrombocytopenia); telomere variants (Calado, 2011) patients mutation carriers often develop marrow failureIdiopathic -3% of sporadic cases -4,000 (with High - many develop leukopenia, pulmonary (15% familial) have telomerase especially post lung-transplant fibrosis (IPF) TERT or TERC mutations) out of (due to poor tolerance of variants (Armanios, -130,000 patients immunosuppression)2007) with IPFAplastic anemia A subset due to TBD -1,000 new High - defined by pancytopenia; (idiopathic) (e.g. cryptic TERT cases / yr telomere testing can identify mutations) occult TBDs (Savage, 2010) Hoyeraal- Mutations in telomere <1,000 (ultra-rare) Severe cytopenias in infancy; Hreidarsson genes (e.g. DKC1) - immunodeficiency and cerebellar syndrome (DC very short telomeres hypoplasia presentsevere variant)Coats plus Mutations in <1 ,000 (ultra-rare) Bone marrow failure and syndrome STN1 / CST complex cerebrovascular issues; (telomere -related) (telomere cytopenias commonmaintenance)(AD = autosomal dominant. Note: Prevalences are rough estimates for the U.S.; many adult-onset cases are likely unrecognized.)

[0096] In certain embodiments subjects are evaluated for baseline telomere length (by Flow-FISH. Q-FISH, or long read sequencing), and only those with significantly shortened telomeres (e.g., below the 10th percentile) and cytopenias not fully explained by other causes are included. This ensures that the population most likely to benefit from telomere elongation therapy is targeted.

[0097] Despite the significant burden of telomeropathy-related cytopenias, treatment options remain mostly supportive and do not reverse the underlying telomere defect. Key approaches include:

[0098] Supportive Care: Patients often require chronic transfusions of red blood cells and platelets to manage anemia and thrombocytopenia. While life-saving, long-term transfusion therapy leads to complications such as alloimmunization (development of antibodies against donor blood antigens) and iron overload in vital organs. Hematopoietic growth factors like erythropoietin (EPO) or G-CSF, commonly used in other bone marrow failure syndromes, have limited efficacy in telomere disorders and are generally not recommended - they rarely produce durable count improvements and could potentially drive residual stem cells into exhausting divisions. Similarly, thrombopoietin agonists (e.g., eltrombopag) have not shown meaningful hematologic responses in patients with telomeropathy.

[0099] Telomere Extension Therapies (Androgens): Attenuating telomere attrition via pharmacologic activation of telomerase has been attempted with anabolic androgens. Danazol, anP A T E N T Docket No. REJU14PCT attenuated androgen, has been used in patients with short telomere syndromes with some success. In a pivotal example, oral danazol for 24 months stabilized blood counts and actually lengthened telomeres (+301 00 bp on average) in a majority of patients. However, responses to androgens are often partial and transient (lasting months to a few years), and many patients cannot tolerate long-term therapy due to toxicities such as hepatotoxicity, virilization, and mood disturbances. Once androgens are discontinued, telomeres resume shortening and cytopenias typically worsen. Of note, danazol’ s telomerase activation effect provided proof-of-concept that therapeutic telomere elongation can improve hematopoiesis in patients with critically short telomeres. Another experimental approach has been a gene therapy delivering an mRNA for the embryonic factor ZSCAN4, which can elongate telomeres through homologous recombination. Early results from a first-in-human trial of a viral vector expressing ZSCAN4 showed telomere lengthening and some hematologic improvement without significant toxicity. This highlights the feasibility of telomere-targeted therapies, though that approach is distinct (telomeraseindependent) and still in investigation.

[0100] Hematopoietic Stem Cell Transplantation (HSCT): Allogeneic HSCT remains the only potentially curative intervention for the hematologic complications of telomeropathies, by replacing the patient’s HSCs with donor stem cells that have normal telomere biology. However, HSCT in patients with telomeropathy is exceptionally challenging. Historically, conventional myeloablative conditioning (with high-dose cyclophosphamide and total body irradiation, for example) led to unacceptably high transplant-related mortality in DC - often >50% - due to organ toxicity, graft failure, and severe graft-versus-host disease (GVHD). Telomere-deficient tissues (lungs, liver, mucosa, etc.) are exquisitely sensitive to chemotherapy and radiation, frequently resulting in fatal pulmonary fibrosis or hepatic cirrhosis post-transplant even if die marrow is rescued. Furthermore, finding well-matched donors can be difficult, as telomeropathies are rare and often familial (related donors might share the telomerase mutation). In recent years, reduced- in tensity conditioning (RIC) regimens have been explored to improve outcomes. Nelson et al. (2016) reported successful engraftmenl and improved survival in patients widi telomeropadiy using a RIC regimen of alemtuzumab, fludarabine, and reduced-dose melphalan (no radiation). More recently, an ongoing trial tested an even lower-intensity conditioning regimen (alemtuzumab and fludarabine without any alkylator or TBI) in patients widi DC. These RIC approaches appear to reduce early toxicity and have enabled some long-term survivors. However, HSCT still carries substantial risks in this population - chronic GVHD, late-onset organ failure, and secondary malignancies remain issues, and some patients experience graft loss or relapse of marrow failure. To date, there is no consensus that HSCT should be first-line for telomeropathy-associated bone marrow failure, especially in older patients; the decision must balance the high transplant risks against the inevitability of marrow failure without transplant.

[0101] Given tire high morbidity and mortality associated with telomeropathies, there is a critical unmet need for novel, disease-modifying therapies. Current treatments (androgens, supportive care, transplant) provide only temporary or incomplete benefit, and none address the fundamentalP A T E N T Docket No. REJU14PCT problem of short telomeres in stem cells. The growing recognition that telomere biology disorders contribute to many cases of “idiopathic” bone marrow failure and fibrotic lung / liver disease adds urgency to developing new treatments. In response to this need, the present disclosure provides compositions, formulations and therapies to restore telomere length in tire patient’s own HSCs, thereby rejuvenating the hematopoietic compartment without undue toxicity. The present formulations fulfill this need by directly extending telomeres in autologous stem cells, potentially stabilizing or improving blood counts and preventing progression to marrow failure or MDS / AML. While not intending to be bound by theory, the presently described approach delays or obviates the need for allogeneic transplant and significantly improve quality of life and survival for patients with telomere-driven cytopenias.

[0102] Example of bone marrow-related diseases and disorders include: Aplastic anemia, Myelodysplastic syndromes (MDS), Acute myeloid leukemia (AML), Acute lymphoblastic leukemia (ALL), Chronic myeloid leukemia (CML), Chronic lymphocytic leukemia (CLL), Multiple myeloma, Myelofibrosis, Polycythemia vera, Essential thrombocythemia, Myeloproliferative neoplasms (MPNs), Bone marrow failure syndrome, Fanconi anemia, Diamond-Blackfan anemia, Shwachman-Diamond syndrome, Severe combined immunodeficiency (SCID), Hemophagocytic lymphohistiocytosis (HLH), Paroxysmal nocturnal hemoglobinuria (PNH), Langerhans cell histiocytosis, Leukemoid reaction, Bone marrow metastases, Pure red cell aplasia, Agranulocytosis, Neutropenia, Thrombocytopenia, Anemia of chronic disease, Sideroblastic anemia, Storage diseases affecting marrow (e.g., Gaucher disease), Bone marrow edema syndrome, and sickle cell disease.

[0103] The presently provided compositions comprise autologous CD34+ cells treated by electroporation of a synthetic, nucleoside-modified mRNA encoding human telomerase reverse transcriptase (TERT) (Telo-EP-CD34). For example, autologous CD34+ cells electroporated with TERT mRNA and suspended in Plasma-Lyte A 100 mL for reinfusion. TERT is tire catalytic protein component of telomerase, the enzyme that adds telomeric DNA repeats to chromosome ends. The mRNA is modified with 1 -methylpseudouridine in place of uridine, to reduce innate immune activation and increase stability / translation. The structure and mechanism of action of TERT mRNA is described, for example, in FIG. 2.

[0104] By delivering TERT mRNA to subject cells, the present disclosure temporarily increases telomerase activity and extends telomeres in those cells without otherwise permanently altering the genome. When delivered to cells, TERT mRNA is translated to TERT protein that is translocated to the nucleus where it binds to and preferentially extends short telomeres, by approximately 500 base pairs within a few days. The brief treatment ends when the mRNA and protein are degraded, after which the extended telomeres resume shortening at their normal rate.

[0105] Before tire present disclosure of TERT mRNA, previous methods of extending telomeres generally fell into three categories. DNA-based approaches: Viral vectors encoding TERT DNA have been shown to activate telomerase, but they carry risks of insertional mutagenesis and constitutive ovcrcxpression. Unlike mRNA, a DNA vector can integrate into the host genome - even supposedly non-P A T E N T Docket No. REJU14PCT integrating adeno-associated virus (AAV) vectors can integrate at a low frequency (~1 in 10,000 cells). Constitutive telomerase expression via integrating vectors can immortalize cells, which raises oncogenic potential. Indeed, overexpressing telomerase in mice leads to higher tumor incidence. Thus, DNA approaches might eliminate the tumor-suppressive mechanism of telomere shortening and are not considered safe for human therapy. Small-molecule approaches: The best small molecule activator of telomerase, cycloastragenol (marketed as TA-65), acts very slowly, requires daily dosing, and even after a year in conjunction with lifestyle and diet modification, shows no effect in about half of subjects. Furthermore, cycloastragenol acts indirectly, resulting in potential off-target effects. Thymidine can increase telomere extension rate if telomerase is present, however high thymidine can also drive mutagenesis. In contrast, it should be noted that TERT itself is not an oncogene, and transiently increasing telomerase activity levels for a few hours, as TERT mRNA does, is not expected to be oncogenic. Protein-based approaches: A version of TERT protein with a protein transduction domain attached has been delivered to cells in vitro but requires high concentrations and prolonged exposure that limit its applicability. Other approaches: Direct administration of recombinant TERT protein presents currently insurmountable difficulties with folding and delivery. As telomerase is a multi-component ribonucleoprotein complex, expression and purification of properly folded, enzymatically active recombinant TERT has proven to be exceptionally difficult. More recently an embryonic transcription factor, ZSCAN4, has been delivered to CD34 cells ex vivo via a viral vector carrying mRNA.

[0106] Given the lack of a safe, effective telomere-lengthening therapy, tire present disclosure provides the use of TERT mRNA as a transient, non-genome-altering approach. The present approach provides several key advantages of TERT mRNA therapy. Transient Expression: Crucial for safety, tire mRNA provides only a burst of telomerase activity for a short duration (days). The introduced mRNA is degraded within hours, and tire telomerase protein produced is naturally turned over in days. Thus, telomerase is not continuously active - it extends telomeres during this brief window, then shuts off. Afterward, telomeres again undergo normal regulated shortening, preserving the anlicancer safety mechanism. Rapid Telomere Extension: Telomeres can be significantly lengthened in a single treatment. During the active period (a few cell divisions), TERT mRNA has been shown to add on the order of 0.5 kilobases of telomere DNA. This roughly corresponds to “turning back the clock” over five years for telomere length. Crucially, this happens quickly (within days) - much faster than any small molecule or physiological process, making it potentially therapeutically practical, and yet allows the telomere lengths to remain well within the normal healthy range. Hypoimmunogenic: By incorporating naturally occurring RNA modifications such as N-l -methylpseudouridine into synthetic RNA, it is possible to avoid the innate immune response caused by unmodified mRNAs. Highly tolerability: As shown herein, initial testing of TERT mRNA at a dose that increases HSC engraftment capacity caused no discernible change in cell viability compared to control cells. Biodegradable: TERT mRNA comprises nucleotides that are endogenous to human cells and is thus fully biodegradable to endogenous component nucleotides. NonIntegrating, Non-Immortalizing: Because our therapy uses RNA, it cannot integrate into the genome.P A T E N T Docket No. REJU14PCT Integration would require an enzyme to reverse-transcribe the RNA and insert it into DNA, which is not present. Furthermore, since telomeres will resume normal shortening after tire transient boost, the cells are not permanently immortalized. This markedly lowers theoretical risks of oncogenesis. Studies have shown that while telomerase induction extends cell lifespan, it does not by itself cause malignant transformation. The present approaches essentially “reset” telomere length to a healthier range, not bypassing senescence indefinitely. Highly Specific Mechanism: TERT mRNA directly targets tire core deficit in telomeropathies - short telomeres. Unlike promiscuous small molecules, telomerase has one principal substrate (telomeric DNA ends). By encoding the natural telomere-extending enzyme, a physiological process is restored. There are no known telomerase functions that would cause off-target organ damage at transient, moderate levels - telomerase mainly acts at telomeres and possibly in mitochondria at high levels, but transient elevation is not known to harm cells. In summary, the presently described TERT mRNA treatment of CD34+ HSPCs offers a transient, controlled telomerase therapy that is well suited to address telomeropathy-related bone marrow failure without the risks of permanent genetic modification.

[0107] According to further embodiments described herein, a single transfection of active TERT mRNA into CD34+ HSCs results in elongation of telomeric repeats by an average of approximately 1.4 kilobases relative to controls, as measured by single telomere length analysis (STELA), irrespective of the time of transfection within the first week of culture. This degree of extension corresponds to approximately 42 years of chronological aging reversed. Larger changes in telomere extension are observed in older donors compared to younger donors, presumably due to shorter starting telomere length, indicating preferential rescue of aged HSCs. High-resolution analysis using Tclo-Scq long-read sequencing and STELA confirms that TERT mRNA treatment specifically rescues critically short telomeres — those that trigger DNA damage responses — without driving telomeres beyond physiological ranges.

[0108] Also according to embodiments described herein, transient TERT mRNA treatment of CD34+ HSCs attenuates in vitro markers of exhaustion, senescence, and cell cycle arrest. Immunohistochemistry of CD34+ HSCs after transfection with TERT mRNA reveals significantly lower levels of PD-1. P53, P21, and the DNA damage marker phosphorylated-y-H2A.X relative to cells transfected with control mRNA. Moreover, immunofluorescent staining for senescence-associated -galactosidase demonstrates significantly lower levels after TERT mRNA treatment relative to control. Without intending to be bound by theory, TERT mRNA reverses p53 / p21 -mediated senescence pathways and significantly enhances the multi-lineage colony-forming capacity of the progenitor pool.

[0109] Also according to embodiments described herein, transient telomerase activity is sufficient to enhance the clonogenic capacity of CD34+ HSCs. Using colony-forming unit (CFU) assays, CD34+ cells that receive active TERT mRNA demonstrate increased colony formation across all CFU subtypes, including approximately 1.3- to 2.6-fold increases in vitro, with the largest effect observed in CFU-GEMM (granulocyte-erythrocyte-monocyte-megakaryocyte mixed colonies), compared to controlP A T E N T Docket No. REJU14PCT mRNA-treated cells, without perturbing the homeostatic composition of CFUs. Telomere length analysis from differentiated CD34+ cells collected two weeks post-CFU assay diat were originally treated with TERT mRNA as CD34+ cells demonstrates significantly longer telomeres and fewer critically short telomeres after differentiation. In striking contrast, cells transfected with a catalytically inactive form of TERT mRNA (D712A mutant) fail to form any significant colonies, indicating a severe proliferative defect consistent with a dominant-negative mechanism, wherein the inactive TERT protein occupies telomere ends or telomerase RNA components without adding repeats, thereby blocking residual telomerase activity.

[0110] Also according to embodiments described herein, when TERT mRNA-treated CD34+ cells are transplanted into immunodeficient NBSGW (NOD.B6.SCID I12rg— / — KitW41 / W41) xenograft mice, TERT treatment results in significantly higher human CD45+ occupancy within the bone marrow niche compared to control mRNA. TERT -treated HSCs achieve roughly 3-fold higher engraftment levels in the peripheral blood, a trend that remains stable through 16 weeks post-injection. Despite this dramatic increase in cell numbers, the complete blood count (CBC) distribution remains indistinguishable from controls, demonstrating that telomere modulation does not induce the patiiological myeloid skewing that defines human immunosenescence. Analysis of human CD34+ cells harvested 6 months post-engraftment confirms that TERT-treated cells maintain significantly longer telomeres, providing a molecular buffer to withstand die massive proliferative stress required for hematopoietic reconstitution.

[0111] Also according to embodiments described herein, the most compelling evidence of HSC preservation is found in serial transplantation data. TERT-treated cells maintain their competitive advantage in secondary recipients at 9 months post initial transplant, confirming that the treatment acts on the long-term repopulating HSC (LT-HSC) fraction rather than merely expanding transient progenitors. The persistence of diis benefit dirough serial transplantation, which is die most stringent operational test of stem cell self-renewal, supports the conclusion that TERT mRNA treatment augments bona fide long-term repopulating HSCs. Without intending to be bound by theory, a single, transient dose of TERT mRNA — delivered only once prior to the initial transplant — is sufficient to confer a lasting engraftment advantage tiiat persists tiirough nine months and multiple rounds of serial transplantation, suggesting tiiat telomere length itself, rather titan continuous telomerase activity, is the primary limiting factor for HSC self-renewal.

[0112] Also according to embodiments described herein, several lines of evidence support a favorable safety profile for the TERT mRNA approach. First, unlike viral integration, modified mRNA provides a defined temporal pulse of activity that dissipates as the RNA degrades. Critically short telomeres are themselves a source of genomic instability, driving chromothripsis and breakage-fusion-bridge cycles; stabilizing these ends may actually reduce the risk of spontaneous transformation. A single dose of TERT mRNA extends telomeres by approximately 5-10%, keeping them well within the normal physiological range for healthy human cells. As used herein, the “normal physiological range” for human telomere length refers to telomere lengths falling between approximately the 10th and 90th percentilesP A T E N T Docket No. REJU14PCT for age-matched healthy human leukocytes, which typically corresponds to approximately 5 to 15 kilobases in adults as measured by flow-FISH, quantitative fluorescence in situ hybridization (Q-FISH), terminal restriction fragment (TRF) analysis, TeSLA, STeLA, Telo-Seq, qPCR, or long -read sequencing (e.g., PacBio or Oxford nanopore sequencing) (TeloSeq). Representative age-stratified reference values for peripheral blood leukocytes include approximately 9 to 15 kilobases at birth, approximately 7 to 10 kilobases in young adults (ages 20 to 40), and approximately 4 to 8 kilobases in elderly subjects (ages 70 and above), with telomeres generally considered “critically short” and prone to uncapping when below approximately 3 to 5 kilobases (e.g., below the 1 Oth percentile for age). In certain embodiments, telomere lengths that remain between the 10thand 90th, 15thand 85th, 20thand 80th, 25thand 75th, 30thand 70th, percentiles, respectively, of the middle two quartiles or middle tertile, of an age-matched healthy reference population are considered to be within the normal physiological range. Alternatively, since telomere pathologies tend to be driven by absolute telomere lengths being short, rather than age-matched telomere lengths per se, absolute telomere lengths that remain between the 10thand 90th, 15thand 85th, 20thand 80th, 25thand 75th, 30thand 70th, percentiles, respectively, of the middle two quartiles or middle tertile, of a healthy reference population spanning a wide range of ages from newborns through to supercenentarians are considered to be within the normal physiological range. No evidence of blast transformation or abnormal proliferation is observed in vitro, and no human-derived tumors are observed in xenograft models. Necropsy and histopathology of humanized NBSGW mice 6 months post-transplant with TERT mRNA-treated CD34+ cells show normal findings. Karyotype analysis of TERT mRNA-treated CD34+ cells confirms normal chromosomal complement. While not intending to be bound by theory, a clinical path for telomere-extended HSCs should incorporate rigorous safeguards, including baseline sequencing for myeloid driver mutations and longitudinal clonal tracking.

[0113] Also according to embodiments described herein, the results establish drat telomere length is a modifiable detenninant of stem cell health, and drat restoring telomere reserve can effectively reset die replicative clock of die entire hemalopoiedc system. By restoring proliferative headroom at die stem cell apex, die disclosed methods and compositions provide a foundation for sustained multi-lineage output — from the rapid replenishment of the innate immune response to the vital requirements of systemic oxygen transport and hemostasis. This establishes telomere reserve as a modifiable master-regulator of hematopoietic healdispan, offering a pathway to reverse die broad physiological exhaustion that characterizes both clinical bone marrow failure and the process of human aging. These findings lay the groundwork for 1’ERT RNA-based therapies for telomere biology disorders and age-associated hematopoietic decline.

[0114] The methods, compositions, and formulations of the present disclosure offer a number of advantages over existing approaches to telomere-mediated hematologic disorders and age-associated hematopoietic decline. By employing nucleoside-modified mRNA encoding human TERT — rather than DNA-based viral vectors, small molecules, or recombinant protein — the present invention provides transient, controlled telomerase activity that rapidly extends critically short telomeres (on the order ofP A T E N T Docket No. REJU14PCT 0.5 to 1.4 kilobases in a single treatment) without integrating into the genome or permanently immortalizing tire treated cells, thereby preserving tire endogenous tumor-suppressive mechanism of telomere shortening. The incorporation of N1 -methylpseudouridine renders the mRNA hypoimmunogenic and biodegradable to endogenous nucleotide components, while the highly specific mechanism of TERT — whose principal substrate is telomeric DNA ends — minimizes off-target effects. Because tire therapy is autologous, utilizing the subject’s own mobilized CD34+ hematopoietic stem cells, the present methods eliminate tire risks of graft-versus-host disease, donor matching requirements, and the immunosuppressive conditioning regimens that contribute to the unacceptably high morbidity and mortality associated with allogeneic hematopoietic stem cell transplantation in telomeropathy patients. The use of a CXCR4 antagonist, such as plerixafor. administered before or after cell infusion to transiently open bone marrow niches, further enhances engraftment without resorting to myeloablative conditioning, thereby making die therapy accessible to subjects with fragile hematopoiesis. Functionally, the TERT mRNA-treated CD34+ cells exhibit reduced markers of cellular senescence and exhaustion (including p53, p21, PD-1, phosphorylated-y-H2A.X, and senescence-associated P-galactosidase), enhanced multi-lineage colony- forming capacity (approximately 1.3- to 2.6-fold increase across CFU-GM, BFU-E, and CFU-GEMM subtypes), roughly 3-fold higher engraftment in immunodeficient xenograft models, and a durable competitive repopulation advantage that persists through serial transplantation — confirming rejuvenation of the long-term repopulating HSC fraction rather than mere transient progenitor expansion. As used herein, a “durable competitive repopulation advantage” refers to a statistically significant, sustained increase in the donor-cell contribution of the Telo-EP-CD34 cells (or their progeny) relative to control mRNA-treated or untreated CD34+ cells, where the increase (i) is at least approximately 1.5-fold, 2-fold, 3-fold, 4-fold, or 5-fold, (ii) is maintained for at least 2 weeks, 4 weeks, 8 weeks, 12 weeks, 16 weeks, 24 weeks, 6 months, or 9 months following initial transplantation, and (iii) persists through at least one round of serial transplantation into a secondary recipient. Donor-cell contribution may be quantified by any suitable objective method, including long read sequencing or flow cytometric measurement of human CD45+ cells (total human leukocyte chimerism) and of lineage-specific sub -populations (e.g., CD33+ myeloid cells, CD19+ B-lymphoid cells, CD3+ T-lymphoid cells, CD4+ T-cells, CD8+ T-cells, neutrophils, and CD34+ or GDI 17+ progenitor cells) in the peripheral blood, bone marrow, and / or spleen of an immunodeficient xenotransplantation recipient (e.g.. NBSGW (NOD.B6.SCID I12rg— / — KitW41 / W41), NSG, or NSGS mice), or by short-tandem-repeat (STR) or single-nucleotide-polymorphism (SNP)-based chimerism assays in a clinical subject. In representative embodiments, the Telo-EP-CD34 cells exhibit approximately 3-fold higher human CD45+ chimerism in peripheral blood relative to control mRNA-treated CD34+ cells, with this advantage remaining stable through 16 weeks post-transplantation in primary recipients and through at least 9 months following transfer into secondary recipients. Importantly, the treated cells maintain a normal karyotype, produce balanced multi-lineage blood counts indistinguishable from controls without pathological myeloid skewing, andP A T E N T Docket No. REJU14PCT show no evidence of blast transformation or tumorigenicity in vivo, supporting a favorable safety profile. The fresh (non-cryopreserved) drug product formulation, GMP-compatible manufacturing process utilizing clinically validated electroporation platforms, and tire applicability of the disclosed methods to both inherited telomere biology disorders and tire broader population affected by age-associated hematopoietic decline collectively position the present invention as a versatile, diseasemodifying therapeutic approach that addresses the fundamental molecular defect underlying these conditions.

[0115] According to embodiments described herein, Telo-EP-CD34 is produced and administered through the following steps:1. Establishment of baseline levels of telomere length and CB C via three weekly peripheral blood draws 2. Mobilization of subject CD34+ cells using a combination of G-CSF and plerixafor3. Apheresis of peripheral blood from which CD34 cells are isolated using the Miltenyi CliniMACS 4. Culture of the CD34+ cells for one day in a G-RexlOOM-CS (closed system) to induce proliferation, which is necessary for telomere extension as the telomeres are only accessible during S-phase of the cell cycle5. Electroporation of the CD34+ cells with TERT mRNA, using the MaxCyte GTX6. Expansion of the cells for three days in a G-RexlOOM-CS to allow TERT mRNA to extend telomeres while the cells are dividing7. Quality control of the Telo-EP-CD34 cells with respect to cell viability and number8. A second mobilization of CD34+ cells with plerixafor (6 days after tire first mobilization) to liberate CD34+ niches for engraftment9. Infusion of the Telo-EP-CD34 cells10. Follow-up measurement of telomere length and blood cell counts via periodic peripheral blood draws.

[0116] Based on nonclinical data prepared by the inventors, it is believed that based on the strong match between tire disease mechanism (short telomeres) and tire drug mechanism of action (telomere extension), Telo-EP-CD34 reinfusion results in a significant increase in telomere length in circulating cells and amelioration of cytopenia measurable using periodic blood draws within six months of reinfusion. This time frame allows for the telomere-extended cells to contribute to several cycles of blood cell replacement and enables average levels over time to be measured, allowing for normal transient variations in blood cell counts.Blood Cell Engraftment

[0117] Also according to embodiments described herein, methods of increasing engraftment of blood cells in bone marrow of a subject comprising administering a CXCR4 antagonist to die subject prior to intravenously infusing blood cells to the subject.

[0118] According to embodiments described herein, the CXCR4 antagonist is plerixafor.

[0119] According to embodiments described herein, die CXCR4 antagonist is selected from one or more of: BMS-936564 / MDX-1338, LY2510924, l,l'-[l,4-phenylenebis(methylene)]bis [1,4,8,11-P A T E N T Docket No. REJU14PCT tetraazacyclotetradecane] (AMD3100; Plerixafor), N, N-dipropyl-N-[4-({[(lH-imidazol-2-yl)methyl)benzyl] [( 1 -methyl- lH-imidazol-2-yl)methyl] amino] methyl)benzyl] -N-methylbutane- 1 , 4-diamine tri(2R, 3R)-tartrate (KRH-3955), ([5-(4-methyl-l-piperazinyl)-2-({methyl[(8S)-5,6,7,8-tetrahydro-8-quinolinyl]amino}methyl)imidazo[l,2-a]pyridin-3-yl]methanol) (GSK812397), N-(1H-benzimidazol-2-yhnethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-l,4-diamine (AMD11070), BKT140 (4F-Benzoyl-TN14003), MSX-122, TN14003. Mab-CXCR4, CQC-01, BL-8040 (Motixafortide), and / or G-CSF.

[0120] According to embodiments described herein, the CXCR4 antagonist is administered no more than 1, 2, 3, 4, 5, 6, 7, 8, 10, 12. 14. 16, 18, 20, 22.24, 36 or 48 hours before infusion of the cells.

[0121] According to embodiments described herein, the blood cells are CD34+ cells.

[0122] According to embodiments described herein, the blood cells are CD34+ hematopoietic stem and progenitor cells, CD133+ / CD34- progenitors, CD34+ / CD38- primitive HSCs, granulocytemacrophage progenitors (GMPs), megakaryocyte-erythroid progenitors (MEPs), B cells, T cells (naive and central memory), NK cells, classical monocytes, intermediate monocytes, plasmacytoid dendritic cells (pDCs), conventional dendritic cells (eDCs), endothelial progenitor cells (EPCs), and / or mesenchymal stromal cells (MSCs).

[0123] According to embodiments described herein, the methods further comprise administering a CXCR4 antagonist to the subject after intravenously infusing blood cells to tire subject.

[0124] According to embodiments described herein, a CXCR4 antagonist is administered to the subject between 1 hour and 20 hours after intravenously infusing blood cells to the subject.

[0125] According to embodiments described herein, the subject has shortened telomeres. According to such embodiments, the shortened telomeres are often in lowest 1st, 5th, 10th. 15th, 20th, 25th, 30th, 35th, 40th, 45th, or 50thpercentile among the age-matched general population, as measured by mean telomere length, median telomere length, 10th, or 20thpercentile telomere length. Also according to such embodiments, tire subject is identified as having shortened telomeres by TeSLA, STeLA. Q-FISH, long-read sequencing, Oxford nanopore sequencing, PacBio sequencing, TRF qPCR, and / or flow-FISH.Synthetic TERT mRNA

[0126] The present invention disclosure use of TERT mRNA. A synthetic ribonucleic acid (RNA) as used herein may refer to any RNA sequence comprising a mutation (point or deletion) or additional nucleotides not found in the wild type sequence. For example, a messenger RNA (mRNA) may refer to a wild type sequence encoding a human sequence, flanked by tire addition of 1, 2, 3, 10, 100 or more nucleotides. Similarly, the nucleotides themselves may encode amino acids distinct from the wild type, or be modified to reduce immunogenicity in the cell or tissue. An mRNA sequence in some embodiments may comprise any of the following modifications, including but not limited to anP A T E N T Docket No. REJU14PCT untranslated region (UTR), a 5' cap, and a poly-adenosine tail. In some embodiments, the RNA may be circular and / or self-replicating.

[0127] Illustrative methods of making circular mRNAs are provided in Chen et al. Science. 1995 Apr 21;268(5209):415-7; Perriman R. (2002) Circular mRNA Encoding for Monomeric and Polymeric Green Fluorescent Protein. In: Hicks B.W. (eds) Green Fluorescent Protein. Methods in Molecular Biology, vol 183. Humana Press; Wang et al. RNA. 2015 Feb;21(2): 172-9. doi: 10.1261 / ma.048272.114. Epub 2014 Dec 1; Wesselhoeft et al. Nat Commun. 2018 Jul 6;9(1):2629; and Wesselhoeft et al. Mol Cell. 2019 May 2;74(3):508-520.e4. Illustrative methods of making self-replicating mRNAs are provided in Tews B.A.. Meyers G. (2017) Self-Replicating RNA. In: Kramps T., Elbers K. (eds) RNA Vaccines. Methods in Molecular Biology, vol 1499. Humana Press; Leyman et al. Mol Pharm. 2018 Feb 5 ; 15(2):377-384; and Huysmans et al. Mol Ther Nucleic Acids. 2019 Sep 6;17:388-395.

[0128] In some embodiments, a mRNA may comprise a codon-optimized sequence. In some embodiments, a mRNA may comprise a uridine depleted sequence.

[0129] In some embodiments, the 5' cap of the ribonucleic acid is a non-immunogenic cap. In some embodiments, the 5' cap may increase the translation of the ribonucleic acid. In some embodiments, tire 5' cap may be treated with phosphatase to modulate the innate immunogenicity of tire ribonucleic acid. In some embodiments, tire 5' cap is an anti-reverse cap analog (“ARCA”), such as a 3'-0-Me-m7G(5')ppp(5')G RNA cap structure analog. In some embodiments, tire 5' cap is m7G(5')ppp(5')(2'OmeA)pG (also known as CleanCap® AG). In some embodiments, tire 5' cap is m7(3'OmeG)(5')ppp(5')(2'OmeA)pG (also known as CleanCap®AG (3' OMe)).

[0130] The above features, or others, may increase translation of tire protein encoded by the ribonucleic acid, may increase or decrease the stability of the ribonucleic acid itself in a cell type- specific or cell type-independent manner, or may do both. In some embodiments, the 5' UTR and / or the 3' UTR are from a gene that has a very stable mRNA and / or an mRNA that is rapidly translated, for example, a-globin or 0-globin, c-fos, or tobacco etch virus. In some embodiments, the 5' UTR and 3' UTR are from different genes or are from different species than the species into which the compositions are being delivered. The UTRs may also be assemblies of parts of UTRs from the mRNAs of different genes, where the parts are selected to achieve a certain combination of stability and efficiency of translation. The UTRs may also comprise designed sequences that confer properties to the RNA such as cell type-specific stability or cell type-independent stability.

[0131] The ribonucleic acids of die present disclosure may comprise one or more modified nucleosides, and / or comprise primary sequences of nucleosides, that modulate translation, stability, or immunogenicity of the RNA. Most mature RNA molecules in eukaryotic cells contain nucleosides that are modified versions of tire canonical unmodified RNA nucleosides, adenine, cytidine, guanosine, and uridine. For example, the 5' cap of mature RNA comprises a modified nucleoside, and other modified nucleosides often occur elsewhere in tire RNA. Those modifications may prevent the RNA from being recognized as a foreign RNA. Synthetic RNA molecules made using certain nucleosides are much lessP A T E N T Docket No. REJU14PCT immunogenic than unmodified RNA. The immunogenicity can be reduced even further by purifying the synthetic mRNA, for example by using high performance liquid chromatography (HPLC). The modified nucleosides may be, for example, chosen from the nucleosides listed below. The nucleosides are, in some embodiments, pseudouridine. 1 -methylpseudouridine, 2-thiouridine, 5-methoxyuridine, or 5-methylcytidine. The primary sequence may be modified in ways that increase or decrease immunogenicity. Under some circumstances, it may be desirable for the modified RNA to retain some immunogenicity.

[0132] Accordingly, in some embodiments, the ribonucleic acids of the instant compositions comprise a 1 -methylpseudouridine, pseudouridine, a 5-methoxyuridine (5-moU), a 2-thiouridine, a 5-methylcytidine, or another modified nucleoside. Modified nucleosides found in eukaryotic cells include mlA 1 -methyladenosine, m6A N6-methyladenosine, Am 2'-O-methyladenosine, i6A N6-isopentenyladenosine, io6A N6-(cis-hydroxyisopentenyl)adenosine, ms2io6A 2-methylthio-N6-(cis-hydroxyisopentenyl) adenosine, g6A N6-glycinylcarbamoyladenosine, t6A N6-threonylcarbamoyladenosine, ms2t6A 2-methylthio-N6-threonyl carbamoyladenosine, Ar(p) 2'-O-ribosyladenosine (phosphate), m6 2A N6,N6-dimethyladenosine, m6Am N6,2'-O-dimethyladenosine, m6 2Am N6,N6,2'-O-trimethyladenosine, mlAm l,2'-O-dimethyladenosine, m3C 3-methylcytidine, m5C 5-methylcytidine, Cm 2'-O-methylcytidine, ac4C N4-acetylcytidine, f5C 5 -formylcytidine, m4C N4-methylcytidine, hm5C 5-hydroxymethylcytidine, f5Cm 5-formyl-2'-O-methylcytidine, mlG 1-methylguanosine, m2G N2-methylguanosine, m7G 7-methylguanosine, Gm 2'-O-methylguanosine, m2 2G N2,N2-dimethylguanosine, Gr(p) 2'-O-ribosylguanosine (phosphate), yW wybutosine, o2yW pcroxywybutosinc, OhyW hydroxywybutosinc, OhyW* undermodified hydroxy wybutosine, imG wyosine, m2,7G N2,7-dimethylguanosine, m2,2,7G N2,N2,7-trimethylguanosine I inosine, mil 1-methylinosine, Im 2'-O-methylinosine, Q queuosine, galQ galactosyl-queuosine, manQ mannosyl-queuosine, T pseudouridine, D dihydrouridine, m5U 5 -methyluridine, Um 2'-O-methyluridine, m5Um 5.2'-O-dimethyluridine, in I 1-melhylpseudouridine, in 2'-O-methylpseudouridine, s2U 2-thiouridine, ho5U 5-hydroxyuridine, chm5U 5-(carboxyhydroxymethyl)uridine. mchm5U 5-(carboxyhydroxymethyl)uridine, methyl ester mcm5U 5-methoxycarbonylmethyluridine. mcm5Um 5-methoxycarbonylmethyl-2'-O-methyluridine, mcm5s2U 5-methoxycarbonylmethyl-2-thiouridine, ncm5U 5 -carbamoylmethyluridine, ncm5Um 5-carbamoylmethyl-2'-O-methyluridine, cmnm5U 5-carboxymethylaminomethyluridine, m3U 3-methyluridine, nilacp3 l-methyl-3-(3-amino-3-carboxypropyl) pseudouridine. cm5U 5-carboxymethyluridine, m3Um 3,2'-O-dimethyluridine, m5D 5-methyldihydrouridine. rm5U 5-taurinomethyluridine. rm5s2U 5-taurinomethyl-2-thiouridine, 2-Aminoadenosine, 2-Amino-6-chloropurineriboside, 8-Azaadenosine. 6-Chloropurineriboside, 5-lodocytidine, 5-Iodouridine, Inosine, 2'-O-Methylinosine, Xanthosine, 4-Thiouridine, 06-Methylguanosine, 5,6-Dihydrouridine, 2-Thiocytidine, 6-Azacytidine, 6-Azauridine, 2'-O-Methyl-2-aminoadenosine, 2'-O-Methylpseudouridine, N1 -Methyladenosine, 2'-O-Methyl-5-methyluridine, 7-Deazaguanosine, 8-Azidoadenosine, 5-Bromocytidine, 5-Bromouridine, 7-Deazaadenosine, 5-P A T E N T Docket No. REJU14PCT Aminoallyluridine, 5-Aminoallylcytidine, 8-Oxoguanosine, 2-Aminopurine-riboside, Pseudoisocytidine, N1 -Methylpseudouridine, 5,6-Dihydro-5-Methyluridine, N6-Methyl-2-Aminoadenosine, 5-Carboxycytidine, 5-Hydroxymethyluridine, Thienoguanosine, 5-Hydroxycytidine, 5-Formyluridine, 5-Carboxyuridine, 5-Methoxyuridine, 5-Methoxycytidine, Thienouridine, 5-Carboxymethylesteruridine, Thienocytidine, 8-Oxoadenoosine, Isoguanosine, N1 -Ethylpseudouridine, Nl-Methyl-2'-O-Methylpseudouridine, N1 -Methoxymethylpseudouridine, N1 -Propylpseudouridine, 2'-O-Methyl-N6-Methyladenosine, 2-Amino-6-Cl-purine-2'-deoxyriboside, 2-Amino-2'-deoxyadenosine, 2-Aminopurine-2'-deoxyriboside, 5-Bromo-2'-deoxy cytidine, 5-Bromo-2'-deoxyuridine, 6-Chloropurine-2'-deoxyriboside, 7-Deaza-2'-deoxyadenosine, 7-Deaza-2'-deoxyguanosine, 2'-Deoxyinosine, 5-Propynyl-2'-deoxycytidine, 5-Propynyl-2'-deoxyuridine, 5-Fluoro-2'-deoxyuridine, 5-Iodo-2'-deoxycytidine, 5-Iodo-2'-deoxyuridine, N6-Methyl-2'-deoxyadenosine, 5-Methyl-2'-deoxy cytidine, 06-Methyl-2'-deoxyguanosine, N2-Methyl-2'-deoxyguanosine, 8-Oxo-2'-deoxyadenosine, 8-Oxo-2'-deoxy guanosine, 2-Thiothymidine, 2'-Deoxy-P-nucleoside, 5-Hydroxy-2'-deoxycytidine, 4-Thiothymidine, 2-Thio-2'-deoxycytidine, 6-Aza-2'-deoxyuridine, 6-Thio-2'-deoxyguanosine, 8-Chloro-2'-deoxyadenosine, 5-Aminoallyl-2'-deoxycytidine, 5-Aminoallyl-2'-deoxyuridine, N4-Methyl-2'-deoxycytidine, 2'-Deoxyzebularine, 5-Hydroxymethyl-2'-deoxyuridine, 5-Hydroxymethyl-2'-deoxy cytidine, 5-Propargylamino-2'-deoxycytidine, 5-Propargylamino-2'-deoxyuridine, 5-Carboxy-2'-deoxycytidine, 5-Formyl-2'-deoxycytidine, 5-[(3-Indolyl)propionamide-N-allyl]-2'-deoxyuridine, 5-Carboxy-2'-deoxyuridine, 5-Formyl-2'-deoxyuridine, 7-Deaza-7-Propargylamino-2'-deoxyadenosine, 7-Deaza-7-Propargylamino-2'-deoxyguanosine, Biotin- 16- Aminoallyl-2'-dUTP, Biotin-16-Aminoallyl-2'-dCTP, Biotin- 16- Aminoallylcytidine, N4-Biotin-OBEA-2'-deoxycytidine, Biotin-16-Aminoallyluridine, Dabcyl -5-3-Aminoallyl-2'-dUTP, Desthiobiotin-6- Aminoallyl-2'-deoxycytidine, Desthiobiotin-16-Aminoallyl-Uridinc, Biotin- 16-7-Dcaza-7-Propargylamino-2'-dcoxyguanosinc, Cyanine 3-5-Propargylamino-2'-deoxycytidine, Cyanine 3-6-Propargylamino-2'-deoxyuridine, Cyanine 5-6-Propargylamino-2'-deoxycytidine, Cyanine 5-6-Propargylamino-2'-deoxyuridine, Cyanine 3-Aminoallylcytidine, Cyanine 3-Aminoallyluridine, Cyanine 5-Aminoallylcytidine, Cyanine 5-Aminoallyluridine, Cyanine 7-Aminoallyluridine, 2'-Fluoro-2'-deoxyadenosine, 2'-Fluoro-2'-deoxycytidine, 2'-Fluoro-2'-deoxyguanosine, 2'-Fluoro-2'-deoxyuridine, 2'-O-Methyladenosine, 2'-0-Methylcytidine, 2'-O-Methylguanosine, 2'-0-Methyluridine, Puromycin, 2'-Amino-2'-deoxycytidine. 2'-Amino-2'-deoxyuridine, 2'-Azido-2'-deoxycytidine, 2'-Azido-2'-deoxyuridine, Aracytidine, Arauridine, 2'-Azido-2'-deoxyadenosine, 2'-Amino-2'-deoxyadenosine, Araadenosine, 2'-Fluoro-thymidine, 3'-0-Methyladenosine, 3'-0-Methylcytidine, 3'-O-Methylguanosine, 3'-0-Methyluridine, 2'-Azido-2'-deoxyguanosine, Araguanosine, 2'-Deoxyuridine, 3'-O-(2-nitrobenzyl)-2'-Deoxyadenosine, 3'-O-(2-nitrobenzyl)-2'-Deoxyinosine, 3'-Deoxyadenosine, 3'-Deoxy guanosine, 3'-Deoxy cytidine, 3'-Deoxy-5-Methyluridine, 3'-Deoxyuridine, 2'.3'-Dideoxyadenosine, 2'.3'-Dideoxyguanosine, 2',3'-Dideoxyuridine, 2',3'-Dideoxythymidine, 2',3'-Dideoxycytidine, 3'-Azido-2',3'-dideoxyadenosine, 3'-Azido-2',3'-dideoxythymidine, 3'-Amino-2',3'-dideoxyadenosine, 3'-Amino-2',3'-dideoxycytidine, 3'-Amino-2',3'-P A T E N T Docket No. REJU14PCT dideoxyguanosine, 3'-Amino-2',3'-dideoxythymidine, 3'-Azido-2',3'-dideoxycytidine, 3'-Azido-2',3'-dideoxyuridine, 5-Bromo-2',3'-dideoxyuridine, 2',3'-Dideoxymosine, 2'-Deoxyadenosine-5'-O-(l-Thiophosphate), 2'-Deoxycytidine-5'-O-(l-Thiophosphate), 2'-Deoxyguanosine-5'-O-(l-Thiophosphate), 2'-Deoxythymidine-5'-O-(l-Thiophosphate), Adenosine-5'-O-(l -Thiophosphate), Cytidine -5'-O-(l -Thiophosphate), Guanosine-5'-O-(l -Thiophosphate), Uridine-5'-O-(l -Thiophosphate), 2',3'-Dideoxyadenosine-5'-O-(l -Thiophosphate), 2',3'-Dideoxycytidine-5'-O-(l -Thiophosphate), 2' ,3'-Dideoxyguanosine-5'-O-(l-Thiophosphate). 3'-Deoxythymidine-5'-O-(l-Thiophosphate), 3'-Azido-2',3'-dideoxythymidine-5'-O-(l-Thiophosphate), 2'.3'-Dideoxyuridine-5'-O-(l-Thiophosphate), 2'-Deoxyadenosine-5'-O-(l-Boranophosphate), 2'-Deoxycytidine-5'-O-(l-Boranophosphate), 2'-Deoxyguanosine-5'-O-(l-Boranophosphate), and 2'-Deoxythymidine-5'-O-(l-Boranophosphate).

[0133] Without intending to be bound by theory, the presence of the modified nucleosides, and / or sequences of nucleosides that alter secondary structure of the RNA and / or binding of RNA to RNA binding proteins or microRNA, may enable mRNA to avoid activation of an immune response mediated by various receptors, including the Toll-like receptors and RIG-1. Non-immunogenic mRNA has been used as a therapeutic agent in mice via topical delivery. Kormann et al. (2011) Nature Biotechnology 29:154-157. In some embodiments, the ribonucleic acids comprise more than one of the above nucleosides or combination of the above nucleosides. In some embodiments, the ribonucleic acids comprise 1 -methylpseudouridine, 5-methoxyuridine, or pseudouridine and 5-methylcytidine.

[0134] In some embodiments, an immune response to tire mRNA may be desired, and tire RNA may be modified to induce an optimal level of innate immunity. In other embodiments, an immune response to the mRNA may not be desired, and tire RNA may be modified in order to minimize such a reaction. The RNA can be modified for either situation.

[0135] The ribonucleic acid molecules can be synthetic ribonucleic acids. The term “synthetic”, as used herein, can mean that the ribonucleic acids are in some embodiments prepared using the tools of molecular biology under the direction of a human, for example as described below. The synthetic ribonucleic acids may, for example, be prepared by in vitro synthesis using cellular extracts or purified enzymes and nucleic acid templates. The synthetic ribonucleic acids may in some embodiments be prepared by chemical synthesis, either partially or completely. Alternatively, or in addition, the synthetic ribonucleic acids may in some embodiments be prepared by engineered expression in a cell, followed by disruption of the cell and at least partial purification of the ribonucleic acid.

[0136] The ribonucleic acids of the present disclosure may be prepared using a variety of techniques, as would be understood by one of ordinary skill in tire art. In some embodiments, the ribonucleic acids may be prepared by in vitro synthesis. In some embodiments, the ribonucleic acids may be prepared by chemical synthesis. In some embodiments, the ribonucleic acids may be prepared by a combination of in vitro synthesis and chemical synthesis. As described above, the term “synthetic” should be understood to include ribonucleic acids drat are prepared either by chemical synthesis, by in vitroP A T E N T Docket No. REJU14PCT synthesis, by expression in vivo and at least partial purification, or by a combination of such, or other, chemical or molecular biological methods.

[0137] The ribonucleic acids may, in some embodiments, be purified. As noted above, purification may reduce immunogenicity of the ribonucleic acids and may be advantageous in some circumstances. In some embodiments, the ribonucleic acids are purified by one or more of HPLC, DNAse treatment, protease treatment, or by affinity capture and elution.

[0138] In some embodiments, an mRNA sequence may be synthesized as an unmodified or modified mRNA. An mRNA may be modified to enhance stability and / or evade immune detection and degradation. A modified mRNA may include, for example, one or more of a nucleotide modification, a nucleoside modification, a backbone modification, a sugar modification, and / or a base modification. In some embodiments, the modified nucleoside is pseudouridine or a pseudouridine analog. In some embodiments, the pseudouridine analog is N-l -methylpseudouridine. In some embodiments, the modified nucleoside is 5-methoxyuridine. In some embodiments a modified nucleoside as used herein may comprise any of the moieties listed in Table 2.Table 2Common name Common namepseudouridine 2'-Azido-2'-deoxyadenosineN-l -methylpseudouridine 2'-Azido-2'-deoxycytidine5 -me thoxy uridine 2'-Azido-2'-deoxyguanosine1 ,2'-O-dimethyladenosine 2'-Azido-2'-deoxyuridinel-methyl-3-(3-amino-3-carboxypropyl) 2'-Deoxyinosinepseudouridine 2'-Deoxy-P-nucleoside1 -methyladenosine 2'-Deoxyuridine1 -methylguanosine 2'-Deoxyzebularine1 -methylinosine 2'-Fluoro-2'-deoxyadenosine1 -methylpseudouridine 2'-Fluoro-2'-deoxycytidine2,2-dimethyl-guanosine 2'-Fluoro-2'-deoxyguanosine2',3'-dideoxyadenosine 2'-Fluoro-2'-deoxyuridine2',3'-Dideoxycytidine 2'-Fluoro-thymidine2', 3'-Dideoxygu anosine 2-methyl-adenosine2',3'-Dideoxyinosine 2-methyl-guanosine2'.3'-dideoxynucleosides 2- me thy 1 thio-M- ( czT-hydroxyi sopentenyl) 2',3'-Dideoxythymidine adenosine2',3'-dideoxythymine 2-methylthio-N-6-isopentenyl-adenosine 2',3'-Dideoxyuridine 2-methylthio-iV6- 2,6-diaminopurine threonylcarbamoyladenosine2'-O-ribosyladenosine (phosphate) 2'-O-Methyl-2-aminoadenosine2'-Amino-2'-deoxyadenosine 2'-O-Methyl-5-methyluridine2-Amino-2'-deoxyadenosine 2'-O-methyladenosine2'-Amino-2'-deoxyuridine 2'-O-methylcytidine2-Amino-6-chloropurineriboside 2'-O-methylguanosine2-Amino-6-Cl-purine-2'-deoxyriboside 2'-O-methylinosine2-aminoadenosine 2'-O-Methyl-N6-Methyladenosine2 - Amino adeno sine 2'-O-methylpseudouridine2-Aminopurine-2'-deoxyriboside 2'-O-melhyl uridine2-Aminopurine-riboside 2'-O-ribosylguanosine (phosphate)P A T E N T Docket No. REJU14PCT Common name Common name2-Thio-2'-deoxycytidine 5-carboxymethylaminomethyl-2-thio-uridine 2 -Thiocytidine 5-carboxymethylaminomethyluridine 2-Thiothymidine 5-Carboxymethylesteruridine2-thiouridine 5-carboxymethyluridine3.2'-<9-di inethy l uridine 5-Carboxyuridine3'-Amino-2',3'-dideoxyadenosine 5-Fluoro-2'-deoxyuridine3'-Amino-2',3'-didcoxycytidinc 5-fluoro-uridinc3'-Amino-2',3'-dideoxyguanosine 5 -Formyl -2'-deoxy cytidine3'-Amino-2',3'-dideoxythymidine 5-Formyl-2'-deoxyuridine3'-Azido-2',3'-dideoxyadenosine 5 -formyl-2'- C- methyl cy tidine3 Azido-2 ',3 '-di deoxycytidine 5 -formylcytidine3 '-Azido-2 ',3 '-dideoxythymidine 5 -Formyluridine3'- Azido-2', 3'-dideoxyuridine 5-Hydroxy-2'-deoxycytidine3'-Deoxy-5-Methyluridine 5 -Hydroxy cytidine3'-Deoxyadenosine 5-Hydroxymethyl-2'-deoxycytidine3'-deoxyadenosine (cordycepin) 5 -Hydroxymethyl-2 '-deoxyuridine3 '-Deoxy cytidine 5 -hy droxymediy Icy tidine3'-Deoxyguanosine 5 -Hydroxymethyl uridine3 '-deoxy thymine 5 -hydroxyuridine3'-Deoxyuridine 5-Iodo-2'-deoxycytidine3 -methylcytidine 5 -Iodo-2 '-deoxyuridine3 -methyluridine 5 -lodocy tidine3'-O-(2-nitrobenzyl)-2'-Deoxyadenosine 5-Iodouridine3'-O-(2-nitrobenzyl)-2'-Deoxyinosine 5-methoxyaminomethyl-2-drio-uridine 3'-O-Methyladenosine 5-methoxycarbonylmethy 1 -T-O- 3'-O-Methylcytidine methyluridine3'-O-Methylguanosine 5-methoxycarbonylmethyl-2-thiouridine 3'-O-Methyluridine 5'-methoxycarbony]methyl-uridine4-acetyl-cytidine 5 -methoxy carbonylmedry luridine4-Thiothymidine 5 -Methoxy cytidine4-Thiouridine 5 -Methoxyuridine5-(carboxyhydroxymethyl) uridine methyl 5 -methoxy-uridineester 5 -Methyl-2 '-deoxycytidine5-(carboxyhydroxymelhyl)uridine 5-inethyl-2-thio-uridine5.2'-O-dimelhyl uridine 5-methylaminomethyl-uridine5,6-Dihydro-5-Mcthyluridinc 5 -mcthylcy tidine5 ,6-Dihydrouridine 5 -methyl dihydrouridine5 - [(3 -Indolyl)propionamide-N-allyl] -2 '- 5 -methyluridinedeoxyuridine 5-Propargylamino-2'-deoxycytidine 5 - Aminoallyl-2'-deoxy cytidine 5-Propargylamino-2'-deoxyuridine5-Aminoallyl-2'-deoxyuridine 5-Propynyl-2'-deoxycytidine5 - Aminoallylcytidine 5-taurinomethyl-2-thiouridine5 -Aminoallyluridine 5 -taurinomethy luridine5-Bromo-2',3'-dideoxyuridine 6-Aza-2'-deoxyuridine5-Bromo-2'-deoxy cytidine 6- Azacytidine5-Bromo-2'-deoxyuridine 6- Azauridine5 -Bromocytidine 6-chloropurine riboside5-Bromouridine 6-Chloropurinc-2'-dcoxyribosidc5 -carbamoyhnethy 1 -I'-O- methyl uridine 6-O-methylguanosine5 -carbamoylmethyluridine 6-Thio-2'-deoxyguanosine5-Carboxy-2'-deoxy cytidine 7-Deaza-2'-deoxyadenosine5-Carboxycytidine7-Deaza-2'-deoxyguanosineP A T E N T Docket No. REJU14PCT Common name Common name7 -Deaza-7-Propargylamino-2'- Desthiobiotin-6- Aminoallyl-2'-deoxycytidine deoxyadenosine dihydrouridine7 -Deaza-7 -Propargylamino-2'- 5 -formylcytidinedeoxyguanosine 5 -formyl -2 '- O-methylcytidine7 -Deazaadenosine N6-glycinylcarbamoyladenosine7 -Deazaguanosine galactosyl-queuosine7 -methyl guanosine 2 '-0 -mcdrylguanosinc7 -methyl-guanosine 2'-O-ribosylguanosine (phosphate)8 -Azaadenosine 5 -hydroxymethylcytidine8 - Azidoadenosine 5 -hydroxyuridine8-Chloro-2'-deoxyadenosine hydroxywybutosine8-Oxo-2'-deoxyadenosine N6-isopentenyladenosine8-Oxo-2'-deoxyguanosine 2'-O-methylinosine8-Oxoadenoosine wyosine8-Oxoguanosine inosinea 2'-deoxynucleoside N6-(cis-hydroxyisopentenyl)adenosine ac4C N4- acetylcytidine IsoguanosineAm 2'-O-methyladenosine 1-methylguanosinean -O-methylnucleoside 1 -methyladenosineAr(p) 2'-O-ribosyladenosine (phosphate) l-methyl-3-(3-amino-3-carboxypropyl) Araadenosine pseudouridineAracytidine 1 ,2'-O-dimethyladenosine Araguanosine 1 -methyl guanosineArauridin 1-mcthylinosincbenzimidazole riboside 1 -methylpseudouridinebeta-D-mannosyl-queosine N2,N2-dimethylguanosineBiotin-16-7-Deaza-7-Propargylamino-2'- N2,N2,7-trimethylguanosine I inosine deoxyguanosine N2 ,7-dimethyl guanosineB iotin- 16- Aminoallyl-2 '-dCTP N2-methylguanosineBiotin- 16- Aminoallyl-2'-dUTP 3-methylcytidineB iotin- 16- Aminoallylcytidine 3-methyluridineBiotin- 16- Aminoallyluridine 3,2'-O-dimethyluridinechm5U 5-(carboxyhydroxymethyl)uridine N4-methylcytidine2'-O-methylcytidine 5-methylcytidine5 -carboxymethyluridine 5-methyldihydrouridine5-carboxymethylaminomediyluridine 5-mcthyluridincCyanine 3-5-Propargylamino-2'- 5,2'-O-dimethyluridinedeoxycytidine N6,N6-dimethyladenosineCyanine 3-6-Propargylamino-2'- N6 ,N6 ,2 O-trimethyladenosine deoxyuridine N6-methyladenosineCyanine 3-Aminoallylcytidine N6,2'-O-dimethyladenosineCyanine 3-Aminoallyluridine 7-methylguanosineCyanine 5-6-Propargylamino-2'- mannosyl-queuosinedeoxycytidine 5-(carboxyhydroxymethyl)uridine Cyanine 5-6-Propargylamino-2'- 5-methoxycarbonylmethyl-2-thiouridine deoxyuridine 5-iiiethoxycarbony hiicihy l-2'-O- Cyanine 5- Aminoallylcytidine methyluridineCyanine 5-Aminoallyluridine 5 -methoxycarbonylmethyluridine Cyanine 7- Aminoally luridme 2-methylthio-N6-(cis-hydroxyisopentenyl) dihydrouridine adenosineDabcyl-5-3-Aminoallyl-2'-dUTP 2-methylthio-N6-threonylDesthiobiotin-16-Aminoallyl-UridinecarbamoyladenosineP A T E N T Docket No. REJU14PCT Common name Common name _N 1 -Ethylpseudouridine wyosine _N 1 -Methoxymethylpseudouridine Xanthosine _N 1 -Methyl-2'-O-Methylpseudouridine 5-taurinoinethyl-2-thiouridineN 1 -Methyladenosine 5 -taurinomethyluridine _N 1 -Propylpse udo uridine2'-O-nielhylpseiidouridineAC 7 -dimethylguanosineN2,N2,1 -tri mclhy IguanosincA2, A2-dimethylguanosineN2-Methyl-2'-deoxygu anosineA2-methylguanosineA4-acetylcytidineN4-Biotin-OBEA-2'-deoxy cytidineN4-Methyl-2'-deoxycytidineA4-methylcytidineM’Ccis-hydroxyisopentenyP-adenosineA^'-O-dimethyladenosineA6A^,2'-O-trimethyladenosineA6, A6- di methyl adeno sineA^glycinylcarbamoyladenosineA'MsopentenyladenosineN6-isopentenyl-adenosineN6-Methyl-2-AminoadenosineN6-Methyl-2'-deoxyadenosineM'-nielhyladenosincN6-methyl-adenosine;VMhreonylcarhamoyl adenosinencm5U 5-carbamoylmethyluridinencm5Um 5-carbamoylmethyl-2'-O- methyluridineNl-methyladenosineN-uridine-5-oxyaceticacidmethylesterperoxywybutosineO6-Methyl-2'-deoxygu anosineO6-Methylguanosinehydroxywybutosineundcnnodificd hydroxywybutosineO-MethylpseudouridineperoxywybutosinePseudoisocytidinePuromycinqueosine2-thiouridineN6-threonylcarbamoyladenosineThienocytidineThienogu anosineThieno uridine2'-O-methyluridineundcnnodificd hydroxywybutosineuridine-5 -oxyaceticacid(v)uridine-5-oxyaceticacidmethylesterwybutosinewybutoxosineP A T E N T Docket No. REJU14PCT

[0139] In some embodiments, an RNA, e.g. an mRNA, may be synthesized from naturally occurring bases and / or base analogs (modified bases) including, but not limited to, purines (adenine (A), guanine (G)) or pyrimidines (thymine (T), cytosine (C), uracil (U)), and analogues and derivatives thereof, e.g. 1-methyl-adenine. 2-methyl-adenine, 2- methylthio-N-6-isopentenyl-adenine, N6-methyl-adenine, N6-isopentenyl-adenine, 2-thio- cytosine, 3-methyl-cytosine, 4-acetyl-cytosine, 5-methyl-cytosine, 2.6-diaminopurine, 1-methyl- guanine, 2-methyl-guanine, 2,2-dimethyl-guanine, 7-methyl-guanine, inosine, 1-methyl-inosine, pseudouracil (5-uracil), pseudouridine, N-l-methyl-pseudouridine, dihydro-uracil, 2-thio-uracil, 4-thio-uracil, 5-carboxymethylaminomethyl-2-thio-uracil, 5-(carboxyhydroxymethyl)-uracil, 5-fluoro-uracil, 5 -bromo-uracil, 5-carboxymethylaminomethyl-uracil, 5-methyl-2-thio-uracil. 5-methyl-uracil. N- uracil-5 -oxyacetic acid methyl ester, 5-methylaminomethyl-uracil, 5-methoxyaminomethyl-2-thio-uracil, 5'-methoxycarbonylmethyl-uracil, 5-methoxy-uracil, uracil-5-oxyacetic acid methyl ester, uracil-5 -oxyacetic acid (v), 1-methyl-pseudouracil, queosine, beta-D-mannosyl-queosine, wybutoxosine, and phosphoramidates, phosphorothioates, peptide nucleotides, methylphosphonates, 7-deazaguanosine, 5 -methylcytosine and inosine.

[0140] In some embodiments, an RNA, e.g., an mRNA, may be synthesized from naturally occurring nucleosides and / or nucleoside analogs (modified nucleosides) including, but not limited to, nucleosides comprising adenosine (A), guanosine (G)) or pyrimidines (thymine (T), cytidine (C), uridine (U)), and nucleoside comprising analogues and derivatives thereof, e.g., 3'-deoxyadenosine (cordycepin), 3'-deoxyuridine, 3'-deoxycytosine, 3'-deoxyguanosine, 3'-deoxythymine, 2',3'-dideoxynucleosides, 2',3'-dideoxyadenosine, 2',3'-dideoxyuridine, 2',3'-dideoxycytosine, 2', 3'- dideoxy guanosine, 2',3'-dideoxythymine, a 2'-deoxynucleoside, -O- methylnucleoside, I -methyl -adenine. 2-melhyl -adenine, 2-methylthio-N-6-isopentenyl-adenine, N6-methyl-adenine, N6-isopentenyl-adenine, 2-thio-cytosine, 3-methyl-cytosine, 4-acetyl-cytosine, 5-methyl-cytosine, 2,6-diaminopurine, 1-methyl-guanine, 2-methyl-guanine, 2,2-dimethyl-guanine, 7-methyl-guanine. inosine, 1-methyl-inosine, pseudouridine, N-l-methyl-pseudouridine, dihydro-uracil, 2-thio-uracil, 4 -thio -uridine, 5-carboxymethylaminomethyl-2-thio-uridine. 5-(carboxyhydroxymethyl)-uridine, 5 -fluoro-uridine, 5 -bromo -uridine, 5-carboxymethylaminomethyl-uridine, 5 -methyl-2-thio-uridine, 5 -methyl-uridine, N-uridine-5 -oxyacetic acid methyl ester. 5-methylaminomethyl-uridine. 5-methoxyaminomethyl-2-thio-uridine. 5'-methoxycarbonylmethyl-uracil, 5-methoxy-uracil, uracil-5-oxyacetic acid methyl ester, uracil-5-oxyacetic acid (v), 1-methyl-pseudouridine. queosine. beta-D-mannosyl-queosine, wybutoxosine. 7-deazaguanosine.5 -methylcytosine, and inosine.

[0141] The preparation of such base, nucleoside, nucleotide, and backbone analogues, modifications, and derivatives is known to a person skilled in the art e.g. from the U.S. Patent Nos.4,373,071, U.S. Patent No.4,401,796, U.S. Patent No.4,415,732, U.S. Patent No. 4,458,066, U.S. Patent No. 4,500,707, U.S. Patent No. 4,668,777, U.S. Patent No. 4,973,679, U.S. Patent No. 5,047,524, U.S. Patent No. 5,132,418, U.S. Patent No. 5,153,319, U.S. Patent Nos. 5,262,530 and 5,700,642, all of which are incorporated by reference in their entirety.P A T E N T Docket No. REJU14PCT

[0142] In some embodiments, uracil nucleosides of tire mRNA are about 80%, about 90%, 95%, 99%, or 100% depleted and replaced with a uracil nucleoside analog, e.g., pseudouridine, 5-methoxyuridine, or N-l-methyl-pseudouridine.

[0143] In some embodiments, an RNA may contain an RNA backbone modification. Typically, a backbone modification is a modification in which the phosphates of the backbone of the nucleotides contained in the RNA are chemically modified. Exemplary backbone modifications may include, but are not limited to. modifications in which the phosphodiester linkage is replaced with a member from the group consisting of peptides, methylphosphonates, methylphosphoramidates, phosphoramidates, phosphorothioates (e.g., cytidine 5'-0-(l-thiophosphate)), boranophosphates, and / or positively charged guanidimum groups, or other means of replacing the phosphodiester linkage.

[0144] In some embodiments, an RNA may contain sugar modifications. A sugar modification may include but is not limited to, 2' O-methyl sugar modifications, 2' fluoro sugar modifications (e.g. 2'-fluororibose), 3' amino sugar modifications, 2' thio sugar modifications, 2'-O-alkyl sugar modifications, 5-methylthioribose, and sugar modifications of 2'-deoxy-2'-fluoro-ribonucleotide (2'-fluoro-2'-deoxycytidine, 2'-fluoro-2'-deoxyuridine), 2'-deoxy-2'-deamine-ribonucleotide (2'-amino-2'-dcoxycytidine, 2,-amino-2'-dcoxyuridinc), 2'-O-alkylribonuclcotidc, 2'-dcoxy-2'-C-alkylribonuclcotidc (2'-O-methylcytidine, 2'-methyluridine), 2'-C-alkylribonucleotide, and isomers thereof (2'-aracytidine, 2'-arauridine), or azidophosphates (2'-azido-2'-deoxycytidine, 2'-azido-2'-deoxyuridine).

[0145] In some embodiments, an RNA may be synthesized from one or more of the nucleotide triphosphates comprising any of the nucleosides and nucleotides disclosed herein, or any of the following nucleoside triphosphates: 2'-Deoxyadenosine-5'-O-( 1 -Thiotriphosphate), 2'-Deoxycytidine-5'-O-( 1 -Thiotriphosphate), 2'-Deoxyguanosine-5'-O-(l-Thiotriphosphate), 2'-Deoxythymidine-5'-O-(l- Thiotriphosphate), Adenosine-5'-O-(l-Thiotriphosphate), Cytidine-5'-O-(l-Thiotriphosphate), Guanosine-5'-O-(l -Thiotriphosphate), Uridine-5'-O-(l-Thiotriphosphate), 2',3'-Dideoxyadenosine-5'-O-(1 -Thio triphosphate), 2',3'-Dideoxycytidine-5'-O-(l-Thiotriphosphate), 2',3'-Dideoxyguanosine-5'-O-(1 -Thio triphosphate), 3'-Deoxythymidine-5'-O-(l-Thiotriphosphate), 3'-Azido-2',3'-dideoxythymidine-5'-O-( 1 -Thiotriphosphate), 2',3'-Dideoxyuridine-5'-O-(l-Thiotriphosphate), 2'-Deoxyadenosine-5'-O-(1-Boranotriphosphate), 2'-Deoxycytidine-5'-O-(l-Boranotriphosphate), 2'-Deoxyguanosine-5'-O-(l-Boranotriphosphate), and 2'-Deoxythymidine-5'-O-(l-Boranotriphosphate).

[0146] In some embodiments, an mRNA may include the addition of a “cap” on the N-terminal (5') end, and a “tail” on the C-terminal (3') end. The presence of the cap may provide resistance to nucleases found in eukaryotic cells. The presence of a “tail” may protect the mRNA from exonuclease degradation.Cap structure

[0147] In some embodiments, an mRNA may include a 5' cap structure. A 5' cap may comprise for example, a triphosphate linkage and a guanine nucleotide in which the 7-nitrogen is methylated. Examples of cap structures include, but are not limited to, m7G(5')ppp (5') A, G(5')ppp(5')A, andP A T E N T Docket No. REJU14PCT G(5')ppp(5')G. Naturally occurring cap structures comprise a 7-methyl guanosine that is linked via a triphosphate bridge to the 5'-end of the first transcribed nucleotide, resulting in a dinucleotide cap of m7G(5')ppp(5')N, where N is any nucleoside. In vivo, the cap is added in the nucleus by the enzyme guanylyl transferase immediately after initiation of transcription.

[0148] In some embodiments, a 5'cap may comprise an m7(3'OmeG)(5')ppp(5')(2'OmeA)pG or (CleanCap® 3' OMe) structure. In some embodiments, a 5' cap may comprise a m7G(5')ppp(5')G. In some embodiments, the Anti-Reverse Cap Analog (“ARCA”) or modified ARCA, is a 5' cap in which the 2' or 3' OH group is replaced with -OCH3. In some embodiments, the ARCA comprises an 3'-0-Me-m7G(5')ppp(5')G structure. In some embodiments, the 5' cap comprises m7G(5')ppp(5')(2'OmeA)pG. Additional mRNA caps may include, but are not limited to, a chemical structures selected from the group consisting of m7GpppG, m7GpppA, m7GpppC; unmethylated caps (e.g., GpppG); a memethylated cap (e.g., m2'7GpppG), a trimethylated cap analog, or anti reverse cap analogs (e.g., ARCA; m7,2'0meGpppG, m72'dGpppG, m7’3'0meGpppG, m7,3 dGpppG and their tetraphosphate derivatives) (see, e.g., Jemielity, J. et al, ‘Wove anti-reverse cap analogs with superior translational properties”, RNA, 9: 1108-1122 (2003)).

[0149] In some embodiments, a suitable cap is a 7-methyl guanylate (“m7G”) linked via a triphosphate bridge to the 5 ‘-end of the first transcribed nucleotide, resulting in m7G(5')ppp(5')N, where N is any nucleoside. An embodiment of an m7G cap utilized in embodiments of the disclosure is m7G(5')ppp(5')G. In some embodiments, the cap is a CapO structure. CapO structures lack a 2'-0- methyl residue of the ribose attached to bases 1 and 2. In some embodiments, the cap is a Capl structure. Capl structures have a 2'-0-methyl residue at base 2. In some embodiments, the cap is a Cap2 structure. Cap2 structures have a 2'-0-methyl residue attached to both bases 2 and 3.

[0150] A variety of m7G cap analogs are known in the art, many of which are commercially available. These include the m7 GpppG described above, as well as the ARCA 3'- OCH3 and 2'-OCH3 cap analogs (Jemielity, J. et al., RNA, 9: 1108-1122 (2003)). Additional cap analogs for use in embodiments of the disclosure include N7-benzylated dinucleoside tetraphosphate analogs (described in Grudzien, E. et at, RNA, 10: 1479-1487 (2004)), phosphorothioate cap analogs (described in Grudzien-Nogalska, E„ et al, RNA, 13: 1745-1755 (2007)), and cap analogs (including biotinylated cap analogs) described in U.S. Patent Nos. 8,093,367 and 8,304,529, incorporated by reference herein.

[0151] In some embodiments, the 5' cap is inosine, Nl-methyl-guanosine, 2'fluoro-guanosine, 7-deaza-guanosine, m7(3'OmeG)(5')ppp(5')(2'OmeA)pG, CleanCap®, m7(3'OmeG)(5')ppp(5')(2'OmeA)pG, 8-oxo-guanosine, 2-amino-guanosine, LNA-guanosine, 2-azido-guanosine, Cap2, Cap4, CAP-003, or CAP-225.

[0152] In some embodiments, the 5' cap comprises or consists of an internal ribosome entry site (IRES). In some embodiments the IRES is within the 5' UTR. In some embodiments, the 5' cap comprises or consists of a 2 A self-cleavage peptide, e.g., one or more of P2A, T2A, E2A and F2A.Tail structureP A T E N T Docket No. REJU14PCT

[0153] The presence of a “tail” may serve to protect an mRNA from exonuclease degradation. The poly-A tail is drought to stabilize natural messengers and syndretic sense RNA. Therefore, in certain embodiments a long poly-A tail can be added to an mRNA molecule thus rendering the RNA more stable. Poly-A tails can be added using a variety of art-recognized techniques. For example, long poly-A tails can be added to synthetic or in vitro transcribed RNA using poly-A polymerase (Yokoe, et al. Nature Biotechnology. 1996; 14: 1252-1256). A transcription vector can also encode long poly-A tails. In addition, poly-A tails can be added by transcription directly from PCR products. Poly-A may also be ligated to the 3' end of a sense RNA with RNA ligase (see, e.g. , Molecular Cloning A Laboratory Manual, 2ndEd., ed. By Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory Press: 1991 edition)).

[0154] In some embodiments, an mRNA may include a 3' poly(A) tail structure. The length of the poly-A tail may be at least about 10, 50, 100, 200, 300, 400 or at least about 500 nucleotides. In some embodiments, a poly-A tail on the 3' terminus of an mRNA may include about 10 to 300 adenosine nucleotides (e.g., about 10 to 200 adenosine nucleotides, about 10 to 150 adenosine nucleotides, about 10 to 100 adenosine nucleotides, about 20 to 70 adenosine nucleotides, or about 20 to 60 adenosine nucleotides). In some embodiments, the poly A tail is 120 adenosine nucleotides.

[0155] In some embodiments, an mRNA may include a 3' poly-C tail structure. A poly-C tail on die 3' terminus of mRNA may include about 10 to 200 cytosine nucleotides (e.g. , about 10 to 150 cytosine nucleotides, about 10 to 100 cytosine nucleotides, about 20 to 70 cytosine nucleotides, about 20 to 60 cytosine nucleotides, or about 10 to 40 cytosine nucleotides). The poly-C tail may be added to tire poly-A tail or may substitute tire poly-A tail. In some embodiments, the length of tire poly-A or poly C tail is associated with the stability of a modified sense mRNA and, therefore, tire transcription of the protein. For example, because tire length of the poly-A tail may influence the half-life of a sense mRNA molecule, the length of the poly-A tail may be adjusted to modify the level of resistance of the mRNA to nucleases, thereby providing more control over the time course of polynucleotide expression and / or polypeptide production.5’ and 3’ Untranslated Regions (UTRs)

[0156] In some embodiments, an mRNA may include 5' untranslated region (UTR) and / or a 3' UTR. In some embodiments, a 5' UTR may include one or more elements that affect the stability or translation of an mRNA. In some embodiments, the 5'UTR for example, may include an iron responsive element. In some embodiments, 5' UTR may be between about 50 to about 100, or from about 50 to about 500 nucleotides in length. In some embodiments, 3' UTR includes one or more of a poly-A signal, a binding site for proteins that may affect mRNA stability or localization, or one or more binding sites for miRNAs. In some embodiments, 3' UTR may be between about 0 and about 50 nucleotides, or about 50 to about 100 nucleotides in lengdr

[0157] Example 3' an’ 5' UTR sequences may be derived from mRNAs widr relatively long half-lives (e.g., globin, actin, GAPDII, tubulin, histone, or citric acid cycle enzymes) to increase die stability of the sense mRNA molecule. For example, 5' UTR sequence may include a partial sequence ofP A T E N T Docket No. REJU14PCT a cytomegalovirus (CMV) immediate-early 1 (IE1) gene, or a fragment thereof to improve the nuclease resistance and / or improve die half-life of the polynucleotide. In another example, the 5’ UTR could include tire sequence of the tobacco etch virus (TEV). Generally, these modifications improve tire stability and / or pharmacokinetic properties (e.g., half-life) of tire polynucleotide relative to their unmodified counterparts, and include, for example modifications made to improve such polynucleotides resistance to in vivo nuclease digestion.

[0158] In some embodiments, a UTR may improve tissue specific expression, e.g., in various tissues and cell types throughout the mammalian body, including stem cells, progenitor cells, germ cells, differentiated cells, or terminally differentiated cells, cancer cells, endothelial cells, epithelial cells, spleen cells, hepatocytes, kidney cells and / or bone cells. In some embodiments, the UTR may be any of, or functional variants of, those described in any of PCT Application No. WO2017053297A1 and Patent No. US10519189B2, both of which are incorporated herein in their entirety.TERT RNAs

[0159] In some embodiments, a composition may comprise a reverse transcriptase telomerase (TERT) mRNA sequence to treat one or more phenotypes or symptoms associated with a fibrotic disease or liver disease. In some embodiments, a TERT mRNA refers to an mRNA encoding any full lengdi, functional fragment or portion of a TERT protein, including wild type sequences or variants thereof.

[0160] In some embodiments, a TERT mRNA may comprise a codon-optimized sequence. In some embodiments, a TERT mRNA may comprise a uridine depleted human TERT sequence. In some embodiments, the codon-optimized sequence may comprise a sequence at least 70%, at least 75%. at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO 1.

[0161] In some embodiments, a 1’ERT mRNA may comprise a mutant human TERI’ sequence. In some embodiments, the mutant human TERT mRNA may encode a Y707F mutation in the resulting peptide sequence. In some embodiments a mutation in the TERT mRNA sequence encodes a mutation in the nuclear export signal which may result in nuclear retention of the TERT peptide. In some embodiments, the mutant TERT mRNA sequence may comprise a sequence at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO 2.

[0162] In some embodiments, a mouse TERT mRNA may comprise a codon-optimized sequence. In some embodiments, a TERT mRNA may comprise a uridine depleted mouse TERT sequence. In some embodiments, die codon-optimized sequence may comprise a sequence at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO 3.

[0163] In some embodiments, a mouse TERT mRNA may comprise a mutant mouse TERT sequence. In some embodiments, the mutant mouse TERT mRNA may encode a Y7O7F mutation in theP A T E N T Docket No. REJU14PCT resulting peptide sequence. In some embodiments a mutation in the TERT mRNA sequence encodes a mutation in the nuclear export signal which may result in nuclear retention of the TERT peptide. In some embodiments, tire mutant mouse TERT mRNA sequence may comprise a sequence at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO 4.

[0164] In some embodiments, a mouse TERT mRNA may comprise a mutant mouse TERT sequence. In some embodiments, the mutant mouse TERT mRNA may encode a Y697F mutation in the resulting peptide sequence. In some embodiments a mutation in the TERT mRNA sequence encodes a mutation in the nuclear export signal which may result in nuclear retention of the TERT peptide. In some embodiments, the mutant mouse TERT mRNA sequence may comprise a sequence at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or 100% identical to SEQ ID NO 5.

[0165] The protein structure of TERT can include at least three distinct domains: a long extension at the amino-terminus (tire N-terminal extension, NTE) that contains conserved domains and an unstructured linker region; a catalytic reverse-transcriptase domain in the middle of the primary sequence that includes seven conserved reverse transcriptase (RT) motifs; and a short extension at the carboxyl-terminus. In some embodiments, the ribonucleic acid codes for a full-length TERT. In some embodiments, the ribonucleic acid codes for a catalytic reverse transcriptase domain of TERT. In some embodiments, the ribonucleic acid codes for a polypeptide having TERT activity. TERT activity may be measured using known methods including the telomerase repeat amplification protocol (TRAP).

[0166] The TERT encoded by the ribonucleic acids of the instant disclosure may be a mammalian, avian, reptilian, or fish TERT. In some embodiments, the TERT is a mammalian TERT, such as human TERT. Meyerson et al. (1997) Cell 90:785-795; Nakamura et al. (1997) Science 277:955-959; Wick et al. (1999) Gene 232:97-106.

[0167] The amino acid sequence of two human TERT isoforms are available as NCBI Reference Sequences: NP_937983.2 and NPJX) 1180305.1.

[0168] The amino acid sequence of human TERT isoform 1 may comprise or consist of the sequence of SEQ ID NO: 6 (also described at GenBank Accession No. NP_937983.2).

[0169] The nucleic acid sequence of human TERT isoform 1 may comprise or consist of the sequence of SEQ ID NO: 7 (also described at GenBank Accession No. NM_198253.3).

[0170] The amino acid sequence of human TERT isoform 2 may comprise or consist of tire sequence of SEQ ID NO: 8 (also described at GenBank Accession No. NP_001180305.1).

[0171] The amino acid sequence of human TERT isoform 2 may comprise or consist of the sequence of SEQ ID NO: 9 (also described at GenBank Accession No. NMJX11193376.3).

[0172] In some embodiments, a TERT mRNA may comprise a nucleic acid sequence at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, atP A T E N T Docket No. REJU14PCT least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to any one of SEQ ID NOS: 1-5, 7, 9 or 30.

[0173] In some embodiments, a TERT mRNA may encode a modified TERT protein containing one or more amino acid substitutions, deletions, and / or insertions as compared to SEQ ID NOS: 6 or 8, while retaining substantial TERT activity. In some embodiments, a TERT mRNA may encode an amino acid sequence at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to SEQ ID NO: 6 or SEQ ID NO: 8.

[0174] In other embodiments, a TERT mRNA may encode an amino acid sequence with a mutation of L55Q, P65A, V70M, A202T, A279T, V299M, H412Y, a deletion of residue 441, R522K, K570N, R631Q, G682D, V694M, Y697F, P704S, Y707F, A716T, P721R, T726M, Y772C, P785L, V791I, R811C, L841F, R865H, V867M, R901W, K902N, P923L, S948R, R979W, V1025F, A1062T, V1090M, T1110M, and / or F1127L relative to the amino acid sequences of SEQ ID NO: 6. In some embodiments, the TERT mRNA may encode a TERT isoform in which the translated protein lacks amino acid residues 711-722, 764-807, 808-1132, or 885-947 relative to the amino acid sequences of SEQ ID NO: 6. In some embodiments about 1, about 5, about 10, about 20, or about 100 amino acids preceding or following die domain are also deleted from the amino acid sequence of SEQ ID NO: 6.

[0175] In some embodiments, die TERT mRNA may encode an amino acid sequence in which one or more of the protein regions are deleted or repeated relative to die amino acid sequences of SEQ ID NO: 6: residues 1-230 corresponding to the RNA-interacting domain 1, residues 58- 197 corresponding to a “GQ” residue motif, residues 137-141 associated with the specificity of telomeric DNA and primer elongation, residues 210-320 corresponding to a disordered region, residues 231-324 associated with a linker sequence, residues 301-538 associated with oligomerization, residues 325-550 or 460-594 corresponding to an RNA-interacting domain, residues 376-521 corresponding to a “QFP” residue motif, residues 397-417 corresponding to a “CP” residue motif, residues 825-884 corresponding to a DNA repeat template, residues 618-729 corresponding to a reverse transcriptase like element, residues 914-928 associated with oligomerization, residues 930-934 associated with a primer grip sequence, and / or residues 936-1132 corresponding to the C-terminus. In some embodiments about 1, about 5. about 10, about 20, or about 100 amino acids preceding or following the domain are also deleted or repeated.

[0176] In some embodiments, a TERT mRNA may comprise or consist of a nucleotide sequence at least at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or more identical to any of discloses nucleic acid sequences, or to any subsequence of a disclosed nucleic acid sequence, e.g., any 100 base pair (bp), 200 bp, 300 bp, 400 bp, 500 bp, or more of a disclosed nucleic acid sequence. In some embodiments, a TERT mRNA may encode an amino acid sequence at least at least 50%, at least 55%, at least 60%, at least 65%, at leastP A T E N T Docket No. REJU14PCT 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or more identical to any of one of the disclosed polypeptide sequences, or to any subsequence of a disclosed polypeptide sequence, e.g., any 50 amino acid (aa), 100 aa, 200 aa, 300 aa, 400 aa, 500 aa, or more of a disclosed polypeptide sequence.

[0177] Non-limiting TERT sequences of the disclosure, include TERT nucleic acid and amino acid sequences listed in Table 3.Table 3TERT Species Amino Acid Amino Acid Example Nucleic Acid Sequence SEQ ID NO: SequenceCat ASO67359.1 KX620456.1Dog NP_001026800.1 NM_001031630.1Mouse AAI27069.1 BC127068.1Mouse, isoform 1 10 NPJ133380.1 NMJ109354.2Mouse, isoform 2 11 NPJJ01349316.1 NMJJ01362387.1Mouse, isoform 3 12 NP_001349317.1 NMJJ01362388.1Mouse EDL37055.1 Machine reverse translation of EDL37055.1Cow NPJ101039707.1 NMJ101046242.1Sheep, isoform 1 XPJJ27835754.1 XMJJ27979953.1Sheep, isoform 2 XP_027835755.1 XMJJ27979954.1Pig NPJJ01231229.1 NMJJ01244300.1African Elephant XPJJ23401395.1 XMJJ23545627.1Chicken NPJ101026178.1 NMJ101031007.1Rat 13 NP_445875.1 NMJJ53423.1Zebrafish NP_001077335.1 NMJJ01083866.1Japanese medaka NP_001098286.1 NM_001104816.1Horse, isoform 1 XP_023481649.1 XMJJ23625881.1Horse, isoform 2 XP.023481650.1 XMJJ23625882.1Horse, isoform 3 XP_023481651.1 XMJJ23625883.1

[0178] The amino acid sequence of non-human primate TERT isoform 1 may comprise or consist of the sequence of SEQ ID NO: 10 (also described at GenBank Accession No. XP_016808391.2).

[0179] The nucleic acid sequence of non-human primate TERT isoform 1 may comprise or consist of the sequence of SEQ ID NO: 11 (also described at GenBank Accession No. XM_016952902.2).

[0180] The amino acid sequence of non-human primate TERT isoform 2 may comprise or consist of the sequence of SEQ ID NO: 12, GenBank Accession No. PNI27662.1.

[0181] The nucleic acid sequence of non-human primate TERT isoform 2 may comprise or consist of the sequence of SEQ ID NO: 13 (reverse machine translation of GenBank Accession No. PNI27662.1).

[0182] The amino acid sequence of non-human primate TERT isoform 3 may comprise or consist of the sequence of SEQ ID NO: 14 (also described at GenBank Accession No. PNI27663.1).P A T E N T Docket No. REJU14PCT

[0183] The nucleic acid sequence of non-human primate TERT isoform 3 may comprise or consist of (lie sequence of SEQ ID NO: 15 (reverse machine translation of GenBank Accession No. PNI27663.1).

[0184] The amino acid sequence of non-human primate TERT isoform 4 may comprise or consist of the sequence of SEQ ID NO: 16 (also described at GenBank Accession No. PNI27664.1).

[0185] The nucleic acid sequence of non-human primate TERT isoform 4 may comprise or consist of the sequence of SEQ ID NO: 17 (reverse machine translation of GenBank Accession No. PNI27664.1).

[0186] The amino acid sequence of non-human primate TERT isoform 5 may comprise or consist of the sequence of SEQ ID NO: 18 (also described at GenBank Accession No. PNI27665.1).

[0187] The nucleic acid sequence of non-human primate TERT isoform 5 may comprise or consist of the sequence of SEQ ID NO: 19 (reverse machine translation of GenBank Accession No. PNI27665.1).

[0188] The amino acid sequence of non-human primate TERT isoform 6 may comprise or consist of the sequence of SEQ ID NO: 20 (also described at GenBank Accession No. PNI27666.1 ).

[0189] The nucleic acid sequence of non-human primate TERT isoform 6 may comprise or consist of the sequence of SEQ ID NO: 21 (reverse machine translation of GenBank Accession No. PNI27666.1).Electroporation

[0190] In some embodiments, the methods involve the use of electroporation to introduce the TERT mRNA to the stem cells, T cells and / or NK cells. Electroporation applies an electric field to cells to introduce pores, termed electropores, to the cell membrane through which (usually charged) macromolecules or agents can flow into the cell. Removal of the field permits the pores to re-seal, with the introduced molecules inside the cell. In certain embodiments, the electroporation module comprises a flow electroporation chamber. For example, a system described in U.S. Patent Nos. 5,720,921, 6,074,605 and / or 7,141,425, each of which is incorporated herein by reference in its entirety. Alternative non-limiting exemplary systems for electroporation are contemplated, for example, those detailed in U.S. Patent Nos. 7,521,224, 8,673,623, and U.S. Patent App. Pub. Nos. 20070128708A1, 20080182251A1, US20130196441, 20170233716A1, and Kim et al., Biosens Bioelectron 2008 23(9): 1353-60, each of which is incorporated herein by reference in its entirety.

[0191] Electroporation occurs when the transmembrane potential exceeds a critical threshold value (generally about 0.25-1 V). The transmembrane potential (AyE) is determined by A\| / E=0.75 g(X)aE cosO, where g(X) is a function of the membrane and buffer conductivities, a is the diameter of the cell, E is the field strength and 0 is the angle between the normal to the membrane surface and the field direction (Weaver & Chizmadzhev, Bioelectrochem. Bioener. 41:135-160 (1996)). A pulsed field of alternating strengths is often used to beneficial effect - it has been proposed that a first pulse of a strongerP A T E N T Docket No. REJU14PCT field strength generates an electropore, and a subsequent pulse at lower strength pushes die desired molecules, e.g., nucleic acid, through die pore dirough electrophoresis.

[0192] Electroporation has been used for decades to introduce nucleic acids and odier molecules to prokaryotic and eukaryotic cells. One of the advantages of electroporation is that it is not particularly cell-type dependent - while exact conditions may vary for optimal delivery, most cell types can be successfully electroporated to deliver, e.g., nucleic acids, proteins or odier agents to the cell.

[0193] Methods and devices for electroporation of mammalian cells are known in the art and can be adapted for use in the methods and systems described herein. Electroporation methods and devices are described, for example, in U.S. Pat. No. 4,695,547; U.S. Pat. No. 4,764,473; U.S. Pat. No. 4,882,281; 4,946,793; 4,906,576; 4,923,814; and 4,849,089, each of which are incorporated herein by reference in their entireties.

[0194] Important parameters for successful electroporation include the maximum voltage applied and the duration of tire current pulse. The voltage and capacitance settings should also be optimized for each cell type, with the resistance of the electroporation buffer being important for choosing the initial instrument settings. Optimal stable and transient transformation occur at about tire same instrument settings, so transient expression can be used to optimize conditions when adapting to a new cell type.

[0195] For low-resistance (high-salt) buffers such as PBS, HeBS, or tissue culture medium, one can start with a capacitor setting of 25 pF and a voltage of 1200 V for an arrangement in which electrodes are 0.4 cm apart, then increase or decrease the voltage until optimal transfection is obtained. For many cell types, the choice between PBS, HeBS, and tissue culture medium makes little difference. However, primary cells, such as nucleated blood cells removed from a patient, tend to be easily killed and thus electroporate poorly at the high voltages needed for PBS or HeBS electroporation buffers. For these cells, tissue culture medium can be better for electroporation, although it has been noted that calcium and magnesium ions in such medium lower the electroporation efficiency. Phosphate-buffered sucrose can be optimized at voltages several hundred volts below those used with PBS or HeBS. Alternatively, many sensitive cells electroporated more effectively in HeBS with a low voltage / high capacitance setting that provided an at least 10-fold longer pulse duration. For example, one can start at 250 V / 960 pF and increase the voltage up to 350 V or decrease down to 100 V in steps to determine optimal settings.

[0196] The application of high-voltage electrical pulses rapidly generates heat, which can kill the cells; keeping cells cold (e.g., at 0°C) often improves cell viability and thus results in higher effective transfection frequency - in one embodiment, the system described herein includes a means for cooling a cell preparation or for maintaining a low temperature to counter heating that occurs during electroporation. That said, some have found that better electroporation efficiencies are achieved at room temperature, so cooling is not always critical.P A T E N T Docket No. REJU14PCT

[0197] Another factor contributing to loss of viability appears to be the pH change that results from electrolysis at the electrodes. The impact of this can be reduced, for example by replacing some of the ionic strength of the PBS with extra buffer (e.g., 20 mM HEPES, pH 7.5).

[0198] Electroporation has most often been performed in batch form, in relatively small volumes (around 1 ml, and often about 1 x 106 cells) by placing a suspension of cells and macromolecules to be introduced into a cuvette including two electrodes which are connected to a pulse generator and arranged to deliver current through the suspension. In the batch format, one or more electric field pulses are applied to the cells, and treated cells are generally transferred to medium to permit the cells to recover. In one embodiment, a batch processing mode can be used in the methods and systems described herein, e.g., by shunting a suspension of collected target cells into an electroporation chamber when a given concentration of target cells is reached (and detected by a detector), adding TERT mRNA to the chamber, and applying one or more electric pulses from a pulse generator to the cell suspension. In one embodiment, the cells are washed before the electroporation step, e.g., to remove plasma proteins and / or to put the cells into a solution with ionic properties better-suited than plasma for electroporation -generally, electroporation is performed in solutions of relatively low ionic strength. Buffers and solutions suited for electroporation are known in the art and described herein below.

[0199] While batch electroporation can be used in the methods and systems described herein, certain advantages may be provided by flow-through or continuous-flow electroporation. In this process, cells, together with TERT mRNA are passed through an electroporation unit through which a voltage is constantly applied. Systems for continuous flow electroporation are described, for example, by Wei & Li, Methods Mol. Biol. 1121: 99-110 (2014) (titled “Continuous cell electroporation for efficient DNA and siRNA delivery based on laminar microfluidic chips”) and Geng et al., J. Controlled Release 144: 91-100 (2010) (titled “Flow-through electroporation based on constant voltage for large volume transfection of cells”), both of which are incorporated herein by reference. Geng et al. not only describe an effective design for flow-through electroporation of mammalian cells (CHO cells), but they describe in detail the scale-up of a prototype to achieve treatment of up to 20 ml of cell suspension per minute, with efficiency as high as 75%. U.S. Patent No. 10,253,316, incorporated herein by reference, suggests treatment of up to 1 to over 1000 cells per second or batches of cells ranging from 1 cell to over 1000 cells in a single transformation procedure with efficiency rates ranging up to 95% or greater. The devices described by Geng et al. incorporate a fluidic channel that has constant depth, but varies in width over its length, such that some portions are narrow, and others are wider. The electric field at any point is determined by the width of the channel, with narrower portions having a stronger field than wider ones. Widths and current are selected such that the field only exceeds the transmembrane potential permitting electroporation at the narrow points and alternating narrow and wider sections over the lengdi of the channel provides an effect that approximates that of a pulsed field, without the need for a pulsed field generator. The flow rate through the channel, as well as the respective lengths of the wide and narrow sections, can be adjusted to adjust the time during which cells are exposed to current strong enough toP A T E N T Docket No. REJU14PCT electroporate them. Other flow-through electroporation devices are described, for example, in U.S.6,617,154, 6,673,669, 7,029,916, 7,771,984, 9,546,350, each of which is incorporated herein by reference in its entirety.

[0200] In some embodiments, a flow-through electroporation system or module employs a fluidic system fabricated from polydimethylsiloxane (PDMS) on a glass substrate, incorporating channels of with alternating wide (10,000-5,000 pm. e.g., about 7,500 pm) and narrow (500-700 pm, e.g., about 500 pm) stretches. Wire electrodes inserted into the inlet and outlet of the flow-through module are connected to a constant voltage power supply. Cells in suspension in electroporation buffer and including TERT mRNA are pumped through the fluidic channel while DC voltage is applied across the channel. Throughput can be increased, for example, by incorporating more than one such fluidic construct in the system, e.g., arranged in parallel.Squeeze Transfection

[0201] In some embodiments, TERT mRNA can be introduced to stem cells, T cells and / or NK cells by forcing the cells under pressure through a constriction smaller in diameter than the cell in the presence of TERT mRNA. The rapid stretching, rapid compression, or pulse of high shear rate leads to uptake of molecules into the cytoplasm of the cell from the surrounding cell medium. This so-called “cell squeeze” microfluidic technology is applicable to a wide number of cell types, and well-suited for introducing materials to nucleated blood cells.

[0202] Cell squeeze microfluidic technology is described, for example, in WO2013059343 and US2014287509, which are incorporated herein by reference in their entireties. In the design described therein, the delivery of molecules into the cell is proportional, e.g., linearly or monotonically with cell velocity through a constriction and / or pressure. For example, 50 pl of cell suspension goes through the device in a few seconds. The throughput ranges between 1 cell / second per channel (or even less) to over 1,000 cells / second per channel. Typical cell velocities through the constriction include 10 mm / second to 500 mm / second. although cell velocities can be up to 10 m / s (or even higher). Additional channels can be placed in parallel to increase the overall throughput of the system. Using the design in the WO2013059343 or US2014287509, the uptake of customization agent is diffusion-based rather than endocytosis-mediated, i.e., the agent is in the cytoplasm rather than in endosomes following passage through the device. Little or none of the customization agent appears in endosomes following cell treatment. For example, large molecules are taken up more slowly than smaller molecules. Controlled cell stretching and velocity of movement of the cells through the constriction leads to effective delivery of customization agent while preserving the viability and integrity of the cells. After treatment, cell viability is generally between 70-100%, e.g., typical viability is 90% after treatment.

[0203] A combination of cell squeeze microfluidic cell transfection and electroporation has also been described. Passing cells at high speed through microfluidic constrictions smaller than the cell diameter mechanically disrupts the cell membrane, allowing a subsequent electric field to further disrupt tire nuclear envelope and drive nucleic acid molecules into the cytoplasm and nucleus. Sec, e.g., Ding ctP A T E N T Docket No. REJU14PCT al., Nature Biomed. Eng 1: 0039 (2017), titled “High-throughput nuclear delivery and rapid expression of DNA via mechanical and electrical cell-membrane disruption.” This combination can also be included in the present methods as described herein.

[0204] Other features and advantages of the invention will be apparent from the detailed description, and from the claims.

[0205] The following enumerated embodiments are intended to complement, not limit, the disclosure set forth above. Where an embodiment refers to another embodiment, any combination of features is contemplated unless expressly disclaimed.

[0206] Embodiment 1. A method of treating cytopenia or age-associated hematopoietic decline in a subject, comprising administering Telo-EP-CD34 cells to a subject having, suspected of having, or at risk of cytopenia, a bone marrow disease or disorder, or age-associated hematopoietic decline, wherein the Telo-EP-CD34 cells are prepared from autologous CD34+ cells treated with nucleoside -modified mRNA encoding human telomerase reverse transcriptase.

[0207] Embodiment 2. The medrod of Embodiment 1, wherein the treatment comprises electroporation of the cells with the nucleoside-modified mRNA.

[0208] Embodiment 3. The method of any one of Embodiments 1-2, further comprising administering a CXCR4 antagonist to the subject after administering the Telo-EP-CD34 cells, optionally between 0 hours and 20 hours after administering the Telo-EP-CD34 cells.

[0209] Embodiment 4. The method of any one of Embodiments 1-2. further comprising administering a CXCR4 antagonist to the subject prior to administering the Telo-EP-CD34 cells, optionally no more than 1.2. 3, 4, 5, 6, 7. 8. 10. 12, 14, 16, 18. 20, 22, 24, 36. or 48 hours before infusion of the cells.

[0210] Embodiment 5. The method of Embodiment 3 or 4, wherein the CXCR4 antagonist is plerixafor.

[0211] Embodiment 6. The method of Embodiment 3 or 4, wherein the CXCR4 antagonist is selected from one or more of: BMS-936564 / MDX-1338, LY2510924, AMD3100 (Plerixafor), KRH-3955, GSK812397, AMD11070, BKT140 (4F-Benzoyl-TN 14003), MSX-122, TN14003, Mab-CXCR4, CQC-01, BL-8040 (Motixafortidc), and / or G-CSF.

[0212] Embodiment 7. The method of any one of Embodiments 1-6, wherein the subject has shortened telomeres, optionally in the lowest 1st, 5th, 10th, 15th, 20th, 25th, 30tii, 35th, 40th, 45th, or 50th percentile among the age-matched general population, as measured by mean telomere length, median telomere length, 10th, or 20th percentile telomere length.

[0213] Embodiment 8. The method of Embodiment 7, wherein the subject is identified as having shortened telomeres by TeSLA. STeLA. Telo-Seq. Q-FISH, long-read sequencing. qPCR, Oxford nanopore sequencing, PacBio sequencing. TRF qPCR. and / or flow-FISH.P A T E N T Docket No. REJU14PCT

[0214] Embodiment 9. The method of any one of Embodiments 1-8, wherein the subject has bone marrow failure and / or a telomere biology disorder, optionally caused by a germline mutation in one or more of TERT, TERC, DKC1, NOPIO, NHP2, TINF2, CTC1, PARN, RTEL1, ACD. NAF1, ZCCHC8, or WRAP53.

[0215] Embodiment 10. The method of any one of Embodiments 1-9, wherein the nucleoside -modified mRNA comprises N1 -methylpseudouridine substituted for uridine, optionally at about 80%, 90%, 95%, 99%, or 100% substitution.

[0216] Embodiment 11. The method of any one of Embodiments 1-10, wherein the nucleoside-modified mRNA comprises a 5' cap structure, 5' and 3' untranslated regions derived from human P-globin, and a poly-adenosine tail of between 80 and 100 nucleotides.

[0217] Embodiment 12. The method of any one of Embodiments 1-11, wherein the telomerase mRNA comprises a nucleic acid sequence at least 90% identical to any one of SEQ ID NOS: 1-5, 7, , 11, 13, 15, 17, 19, or 21, or encodes a telomerase having an amino acid sequence at least 90% identical to any one of SEQ ID NOS: 6, 8, 10, 12, 14, 16, 18, or 20.

[0218] Embodiment 13. The method of any one of Embodiments 1-12, further comprising mobilizing CD34+ cells from the subject using a combination of granulocyte colony-stimulating factor (G-CSF) and plerixafor prior to apheresis and treatment of the cells with the nucleoside-modified mRNA.

[0219] Embodiment 14. The method of any one of Embodiments 1-13, wherein the method does not comprise myeloablative conditioning of the subject prior to administering the Telo-EP-CD34 cells.

[0220] Embodiment 15. The method of any one of Embodiments 1-14, wherein the nucleoside-modified mRNA provides transient telomerase expression that dissipates as the mRNA degrades, thereby extending telomeres without permanent genomic integration or cell immortalization.

[0221] Embodiment 16. The method of any one of Embodiments 1-15, wherein the treatment extends critically short telomeres in die CD34+ cells by approximately 0.5 to 2.0 kilobases without driving telomere lengdi beyond the physiological range for healdiy human cells.

[0222] Embodiment 17. The method of any one of Embodiments 1-16, wherein the treatment reduces expression of one or more senescence-associated markers selected from p53, p21, PD-1, phosphorylated-y-H2A.X, and senescence-associated P-galactosidase in the Telo-EP-CD34 cells relative to untreated or control mRNA-treated CD34+ cells.

[0223] Embodiment 18. The method of any one of Embodiments 1-17, wherein the Telo-EP-CD34 cells demonstrate enhanced multi-lineage colony-forming capacity, including increased colony formation across CFU-GM, BFU-E, and CFU-GEMM subtypes, relative to untreated or control mRNA-treated cells.P A T E N T Docket No. REJU14PCT

[0224] Embodiment 19. The method of any one of Embodiments 1-18, wherein the Telo-EP-CD34 cells, upon engraftment, maintain a competitive repopulalion advantage through at least one round of serial transplantation, confirming rejuvenation of the long-term repopulating HSC fraction.

[0225] Embodiment 20. A method of increasing engraftment of blood cells in bone marrow of a subject comprising administering a CXCR4 antagonist to the subject prior to intravenously infusing blood cells into the subject, optionally wherein the blood cells are CD34+ cells or Telo-EP-CD34 cells as defined in any one of Embodiments 1-19.

[0226] Embodiment 21. The method of Embodiment 20, further comprising administering a CXCR4 antagonist to the subject after intravenously infusing the blood cells, optionally between 0 hours and 20 hours after infusion.

[0227] Embodiment 22. A composition comprising a Telo-EP-CD34 cell, optionally wherein the Telo-EP-CD34 cell comprises telomerase mRNA having the features of any one of Embodiments 10-12, optionally suspended in an infusion buffer.

[0228] Embodiment 23. A method of producing a Telo-EP-CD34 cell, comprising contacting a CD 34+ cell with a composition comprising telomerase mRNA under conditions such drat the CD34+ cell is transfected with the telomerase mRNA. wherein the transfection conditions comprise electroporation, squeeze transfection, calcium phosphate mediated transfer, nucleofection, sonoporation, heat shock, magnetofection, microprojectile mediated transfer, or cationic polymer mediated transfer, and wherein the telomerase mRNA optionally has the features of any one of Embodiments 10-12.

[0229] Embodiment 24. The method of Embodiment 23, wherein the electroporation is performed using a flow-through electroporation system or a batch electroporation system, optionally using the MaxCyte GTX electroporation platform.

[0230] Embodiment 25. A method of rejuvenating long-term repopulating hematopoietic stem cells (LT-HSCs) in a subject, comprising administering Telo-EP-CD34 cells as defined in any one of Embodiments 1-19 to the subject, wherein the Telo-EP-CD34 cells achieve at least a 3-fold increase in engraftment levels relative to control cells.

[0231] Embodiment 26. A method of reducing cellular senescence in CD34+ hematopoietic stem cells, comprising treating die CD34+ cells ex vivo with nucleoside-modified mRNA encoding human telomerase reverse transcriptase as defined in any one of Embodiments 10-12, wherein die treatment reduces expression of one or more of p53, p21, PD-1, phosphorylated-y-H2A.X, or senescence-associated -galactosidase, optionally furdier comprising administering the treated cells to a subject as in any one of Embodiments 1-9.

[0232] Embodiment 27. A method of enhancing colony-forming capacity of CD34+ hematopoietic stem cells, comprising treating the CD34+ cells ex vivo with nucleoside-modified mRNA encoding human telomerase reverse transcriptase as defined in any one of Embodiments 10-12.P A T E N T Docket No. REJU14PCT wherein the treatment increases colony formation across CFU-GM, BFU-E, and CFU-GEMM subtypes by approximately 1.3- to 2.6-fold relative to control mRNA-treated cells.

[0233] Embodiment 28. The method, composition, or use of any preceding Embodiment, wherein the telomerase mRNA is a codon-optimized and / or uridine-depleted TERT mRNA synthesized by in vitro transcription, optionally comprising a sequence at least 90% identical to SEQ ID NO: 1.

[0234] Embodiment 29. The method of any one of Embodiments 1-21 or 25-27, wherein the Telo-EP-CD34 cells are administered at a dose of about IxlO6to about 20x10scells per kilogram of subject body weight.

[0235] Embodiment 30. The method of any one of Embodiments 1-21 or 25-27, wherein the CD34+ cells are cultured ex vivo for one day prior to and three days post treatment with the nucleoside-modified mRNA to allow telomere extension during S-phase of the cell cycle.

[0236] Embodiment 31. The method of any one of Embodiments 1-21 or 25-27, wherein the Telo-EP-CD34 cells are provided as a fresh, non-cryopreserved product and are infused within 6 days of electroporation.

[0237] Embodiment 32. The method, composition, or use of any preceding Embodiment, wherein the Telo-EP-CD34 cells exhibit a normal karyotype and no evidence of tumorigenic transformation following treatment with the nucleoside-modified mRNA.

[0238] The present invention is further described by the following examples. The examples are provided solely to illustrate the invention by reference to specific embodiments. These exemplifications, while illustrating certain specific aspects of the invention, do not portray the limitations or circumscribe the scope of the disclosed invention. It is appreciated that certain features of the disclosure, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable sub-combination. All combinations of the embodiments pertaining to the invention are specifically embraced by the present invention and are disclosed herein just as if each and every combination was individually and explicitly disclosed. In addition, all sub-combinations of the various embodiments and elements thereof are also specifically embraced by the present invention and are disclosed herein just as if each and every such sub- combination was individually and explicitly disclosed herein.EXAMPLES

[0239] The proposed starting materials for the manufacture of an exemplary form of Tclo-EP-CD34 are listed in Table 4.Table 4 Raw materials for Telo-EP-CD34 ManufactureStarting Material Provider Purpose Infusion buffer (Plasma-Lyte A) Sigma- Aldrich Drug productinfusionP A T E N T Docket No. REJU14PCT Starting Material Provider Purpose mRNA Nucleoside triphosphates (NTPs) (adenosine triphosphate, Southern RNAguanosine triphosphate, cytidine triphosphate, and N-l- synthesis methylpseudouridine triphosphate).Capping reagent (m7-guanosine-(5’)ppp(3’)-(2'-O- Southern RNA medryl)guanosine)hi vitro transcription (IVT) buffer salts Southern RNAPlasmid DNA template for in vitro transcription of mRNA, Aldevronsynthesized in E. coli and purifiedDNase New England Biolabs Restriction enzyme New England Biolabs Electroporation buffer MaxCyte Cell processing Cell culture media to expand CD34+ cells before / after STEMCELL Technology, electroporation, as telomeres are only extended in dividing Sigmacells, and to generate sufficient cell numbers in subjectsfrom whom insufficient numbers of CD34+ cells areapheresed. Supplemented with vitamins and nucleotides tosupport telomere extension.1.1. Proposed Qualification of Raw Materials

[0240] Characterization of the components for qualification for use as a starting material are shown in Table 5.Table 5 Proposed Qualification of Raw MaterialsStarting Material QualificationInfusion buffer (Plasma-Lytc pH and osmolalityA) Sterility (USP <71»Endotoxin (LAL assay)Identity and concentration of components (e.g., ion chromatography or ICP-MS)Nucleoside triphosphates Identity (HPLC or NMR)(NTPs) Purity (HPLC, UV absorbance)(ATP, GTP, CTP, Nl- medrylpseudouridine-TP)Capping reagent Identity (HPLC, MS)(m7G(5’)ppp(3’)G or ARCA) Purity (HPLC)IVT buffer salts Identity and concentration (ion chromatography. ICP-MS)pHSterility or bioburdenPlasmid DNA template Identity (Restriction digest + gel or sequencing)(synthesized in E. coli) Purity (A260 / A280 ratio, residual RNA / protein testing)Endotoxin (LAL assay)Residual E. coli genomic DNA (qPCR)Sterility (USP <71>)Dnase Identity and purity (SDS-PAGE, activity assay)Enzymatic activity (dsDNA digestion assay)P A T E N T Docket No. REJU14PCT Starting Material QualificationRestriction enzyme Identity and activity (enzyme digestion assay)Purity (SDS-PAGE)Endotoxin (LAL assay)Electroporation buffer pH and osmolalitySterilityConductivityIdentity and purity of critical excipients (e.g., ions, sugars) Cell culture media Sterility (USP <71>)(supplemented) Endotoxin (LAL assay)Mycoplasma (PCR or culture)Identity and concentration of supplements (e.g., B vitamins, nucleotides - HPLC)pH and osmolality1.2. Designation of Starting Materials

[0241] The starting materials are the isolated CD34+ cells from the subject, and TERT mRNA.1.3. mRNA Manufacturing Process

[0242] Development, engineering, and GMP batches of TERT mRNA are manufactured by Southern RNA using in vitro transcription (IVT), for example, as depicted in the flowchart in FIG. 3.

[0243] TERT mRNA is an mRNA 3,752 nucleotides (nt) long. TERT RNA has a 5’ cap, 5’ and 3’ untranslated regions (UTRs), and a poly-adenosine (poly- A) tail downstream of the 3’ UTR, and has 100% substitution of uridine with N-l -methylpseudouridine.

[0244] The 5’ cap is N7-methylguanosine (m7G) with a methyl group at the 2’ O of the first nucleotide (cap 1 structure). The UTRs are from the human P-globin (HBB) NCBI reference sequence and are 44 and 132 nt in length for the 5’ and 3’ regions, respectively. The poly-A tail is between 80 and 100 nt in length.

[0245] The coding sequence of the TERT mRNA is tire NCBI reference sequence of human TERT (3,399 nt) encoding NP_937983.2 which is the most common naturally occurring active form of TERT in humans. The drug substance, when delivered to the cytoplasm of tire target cells, is translated into TERT protein which is the active compound performing tire therapeutic mechanism.

[0246] The entire mRNA is synthesized with an in vitro transcription (IVT) reaction using a linearized plasmid template. The nucleotide triphosphates used are adenosine triphosphate, guanosine triphosphate, cytidine triphosphate, and N-l -methylpseudouridine triphosphate. N-l-methylpseudouridine is incorporated at 100% substitution for uridine to reduce the innate immune response and improve translational efficiency of the drug substance.

[0247] The mRNA capped during the IVT reaction by inclusion of a co-transcriptional capping reagent. The resulting mixture is treated with DNAse to remove residual plasmid, purified by poly-dT column, C4 column purification and tangential flow filtration, and then filter-sterilized using a 0.2 pM PVDF filter. Quality and impurities are characterized per the assays described herein.P A T E N T Docket No. REJU14PCT 1.4. Stability of TERT-mRNA

[0248] The TERT mRNA solution are cryopreserved at -20 to -80°C without cryoprotectant. After thawing, the mRNA does not have detectable transcript impurities not already present in the fresh formulation as measured by CGE.1.5. Drug Substance and Drug Product

[0249] The drug product is Telo-EP-CD34, consisting of autologous CD34+ cells electroporated with TERI’ mRNA suspended in 100 mL Plasma-Lyte A in a CryoMACS breezing Bag 250 (250 L, Miltenyi Cat # 200- 074-401). The drug product is provided as fresh.1.5.1. Cell Collection, Processing, and Infusion Site

[0250] The cells are collected, processed, and re-infused at the Royal Brisbane and Women’s Hospital (RBWH), Brisbane, Australia and the Cell Processing Center (CPC) therein.1.5.2. Cell Apheresis, Isolation, Culture, and Electroporation

[0251] Peripheral blood mononuclear cells (PBMNCs) are collected via leukapheresis using a Spectra Oplia Apheresis System al die clinical site. The collection occurs under sterile conditions according to institutional standard operating procedures. CD34+ cells are isolated from the PBMNCs using a Miltenyi CliniMACS Prodigy instrument. Cells are cultured in G-Rex plates for one day prior to and three days post electroporation with a MaxCyte GTX.1.5.3. Treatment Administration

[0252] Telo-EP-CD34 are infused intravenously without filter from placed access at 3.3 mL / min infusion rate for 30 mins. An upper and lower limit for the number of cells to be infused may be imposed pending upcoming studies.1.5.4. Cell Storage, Handling, and Transport Conditions

[0253] Telo-EP-CD34 is fresh product which is used before die time described in the label. Following cell processing and formulation, Tclo-EP-CD34 is maintained at 2-8°C in a validated temperature-controlled shipper or refrigerator. The product is not frozen or exposed to temperatures outside this range. Continuous temperature monitoring is required from the time of formulation until administration to die subject. The total time from electroporation to infusion must not exceed 6 days, as per the labeled expiration. Transport from die processing facility to the clinical site is conducted under Good Distribution Practice (GDP) conditions.1.5.5. Drug Product Stability

[0254] The drug product is assessed for stability, for example, according to Table 6 below.P A T E N T Docket No. REJU14PCT Table 6: Proposed Telo-EP-CD34 Drug Product Stability DesignTests Initial Storage Condition2-8° C24hr 48hr 72hr 96hr 120hr 144hr Identity & Purity V V A / V V V Viability V V A / V V V Total cell concentration V V V V V Sterility V V A / A / Endotoxin V V VMycoplasma •V V A / VPotency V V V Mouse in vivo potency1- - -V - V • Assaying the in vivo potency of the cells over time in engraftment and expansion, at multiple time points (every two weeks for 4 months)

[0255] In support of developing TERT mRNA for treatment of TC, the present inventors have completed several in vitro and in vivo nonclinical studies. These studies have demonstrated drat TERT mRNA increases the proliferative capacity of telomeropathy subject cells. TERT mRNA increases telomerase activity and extends shortened telomeres in multiple cell types including CD34+ cells, and increases CD34 cell proliferative capacity, colony formation capacity. It has therefore been demonstrated that TERT mRNA increases the in vivo engraftment and reconstitution capacity of human CD34+ cells in immunocompromised mice.1.6. Effects of TERT mRNA on cellular telomerase activity, telomere length, and proliferative capacity

[0256] ERT mRNA was delivered to primary human fibroblasts and myoblasts via cationic lipid to quantify telomerase activity, telomere length, and proliferative capacity as shown in FIG. 4 - FIG. 7. As shown in FIG. 4, telomerase activity is detected using die TRAP assay, in which the presence of a regularly spaced ladder pattern indicates telomerase activity. Arrow indicates internal controls for PCR efficiency. Left to right: Delivery of 1 pg / ml TERT but not CI TERT mRNA increased telomerase activity in fibroblasts and myoblasts, and in fibroblasts telomerase activity returned to baseline levels by 48 h aftertreatment. Fibroblasts electroporated widi the following concentrations of TERT mRNA (0, 10, 40, or 80 gg / ml) exhibited telomerase activity in a dose-dependent manner.

[0257] As shown in FIG. 5, treatment of primary human fibroblasts (left) or myoblasts (right) three times with TERT mRNA, extended telomeres by 0.9 and 0.7 kb, respectively. CI TERT is a catalytically inactive negative control. *P < 0.05, **P < 0.01, ***P < 0.001 vs untreated or vehicle.

[0258] As shown in FIG. 6, treatment of primary human fibroblasts widi 1 pg / rnl of TERT mRNA once, twice, or three times at 48- hour intervals (vertical arrows) increased proliferative capacity in a dose-dependent manner. Waiting 5 weeks and treating the cells again conferred an amount ofP A T E N T Docket No. REJU14PCT proliferative capacity similar to that conferred by the first dose, suggesting that TERT mRNA may enable prolonged maintenance of telomere length by infrequent treatments.

[0259] As shown in FIG. 7, treatment of primary human fibroblasts from a patient with a TERT mutation, with 1 pg / ml of TERT mRNA once or twice at a 48- hour interval (vertical arrows) increased proliferative capacity in a dose-dependent manner. Waiting 7 weeks and treating the cells again conferred additional proliferative capacity.

[0260] TERT mRNA increased telomerase activity, telomere length, and proliferative capacity in primary human cells, motivating therapeutic development.E7. Effects of Electroporation of TERT mRNA in Human CD34+ Cells

[0261] To evaluate the efficacy of telomerase (TERT) mRNA in human G-CSF-mobilized CD34+ cells in vitro, cells from healthy donors are electroporated using the Neon electroporation system with mRNA encoding either TERT; a catalytically inactive variant of TERT (CI TERT); or mCherry. mCherry is an mRNA encoding a fluorescent reporter serving as a control for the biological activity of TERT and to confirm transfection efficiency. The mRNA was electroporated at a concentration of 0.15 mg / ml. The cells were then assessed at various endpoints as presented in the following figures (FIG. 8 -FIG. 17).

[0262] As depicted in FIG. 8, CD34+ cells were electroporated with either TERT mRNA or mCherry mRNA using the Thermo Neon electroporation system, and mCherry expression was monitored by flow cytometry at Day 2 and Day 14 post-transfection. Representative flow cytometry plots (left) show mCherry fluorescence on Day 2 and Day 14 in TERT- and mCherry-transfected cells. Quantification of live mCherry+ CD34+ cells is shown (right), demonstrating efficient transfection with mCherry mRNA at Day 2 (-100%), followed by a decline in expression by Day 14 (-24%). TERT-transfected cells showed no detectable mCherry signal, as expected.

[0263] As depicted in FIG. 9, CD34+ cell viability of cells following electroporation on Day 0 with either mCherry or TERT encoding mRNA measured with Acridine Orange and Propidium Iodide using the RWD C100 cell counter.

[0264] As depicted in FIG. 10, Flow cytometry plots for CD34 expression 48-hours and 14-days post-electroporation with mCherry- or TERT-encoding mRNA.

[0265] As depicted in FIG. 11, Mobilized peripheral blood (mPB) human CD34 cells electroporated with 0.15 mg / ml TERT mRNA exhibited increased telomerase activity as detected by the TRAP assay, compared to mCherry mRNA-treated controls.

[0266] As depicted in FIG. 12, Day 19-fold change in expansion relative to mCherry after one or two mCherry or TERT transfections on Day 0 and Day 16, respectively (left). CD34 expansion postelectroporation with mCherry, TERT, or catalytically inactive (CI)-TERT on thawed cells previously cultured for 21-days. Fold change is relative to Day 0 starting cell count (right).P A T E N T Docket No. REJU14PCT

[0267] As depicted in FIG. 13, a) Brightfield images of colony-forming units after 10 days between mCherry- or TERT-treated CD34 cells widi b) quantification of colony morphology and fold change. CFU-E = colony-forming unit-erythroid; BFU-E = burst-forming unit-erythroid; CFU-GM = colony-forming unit-granulocyte, macrophage; CFU-GEMM = colony-forming unit-granulocyte, erythroid, macrophage, megakaryocyte.

[0268] As depicted in FIG. 14. CFU-E = colony-forming unit-erythroid; BFU-E = burst-forming unit-erythroid; CFU-GM = colony-forming unit-granulocyte, macrophage; CFU-GEMM = colonyforming unit-granulocyte, erythroid, macrophage, megakaryocyte.

[0269] As depicted in FIG. 15, CD34+ cell (left) and CD34-differentiated cell (right) relative telomere length across different time points post-electroporation with mCherry- or TERT-encoding mRNA using flow-FISH.

[0270] Since, plerixafor is used in telomeropathy patients to mobilize HSCs for apheresis and to facilitate engraftment, and there is limited pharmacological data on plerixafor in subjects with short telomeres, use of plerixafor mobilization and engraftment effects in short telomere TERT KO mice has been investigated, with results presented in FIGS. 16 and 17. As depicted in FIG. 16, circulating levels of mobilized lineage / Sca-l+ / c-Kit+bone marrow cells in C57B1 / 6 mice either wild-type for die Tert locus or 5thgeneration Tert knockout (G5 TERT-KO) at different hours post-plerixafor treatment, with representative flow cytometry plots at die 1-hour peak. As depicted in FIG. 17, normal lengdi telomere donor (CD45.1) bone marrow lineage / Sca-17c-Kit+(LSK) expression after transplant 1-hour postmobilization with plerixafor and then analyzed 72-hours later in normal (WT) and short telomere (G5 TERT-KO) mouse recipients.

[0271] Electroporation of TERT mRNA in human primary CD34+ hematopoietic stem and progenitor cells increased telomerase activity, telomere length, proliferative capacity, and colony formation capacity. CD34+ expression was maintained, and viability was negligibly affected following electroporation. Plerixafor increased the engraftment of long-telomere primary murine LSK HSPCs in short telomere recipient mice, but not long-telomere wild-type C57B1 / 6 recipient mice. These results motivate continued development of Telo-EP-CD34 for treatment of TC, and support the use of plerixafor just before drug product administration to improve engraftment.1.8. T elomerase Activity T ime Course

[0272] To potentially refine the timeline of the ex vivo clinical process, this example aims to evaluate the dynamics of telomerase activity in human CD34+ HSPCs ex vivo following electroporation with TERT mRNA. The example uses human CD34+ HSPCs isolated from healthy donors. These cells undergo electroporation to introduce TERT mRNA (Group 1) or are left untreated (Group 2). The experimental timeline spans 10 days. Telomerase activity and telomere length are measured before electroporation, and at 2, 8, and 16 hours post-electroporation, and then each day for 10 days. TelomeraseP A T E N T Docket No. REJU14PCT activity is assessed using the TRAP assay, while telomere length is measured using Flow-FISH (fluorescence in situ hybridization).1.9. Effect of TERT mRNA Electroporation on Engraftment of Human CD34+ Cells in Immunocompromised Mice

[0273] This example was designed to evaluate the effects of telomerase mRNA electroporation in human CD34+ HSPCs isolated from healthy donors. Electroporation was performed using the Neon and MaxCyte GTx electroporators with TERT mRNA with mCherry mRNA as a control, and the example is being conducted over a four-month period.

[0274] Cell counts and viability were assessed using the RWD Cl 00 automated cell counter with acridine orange and propidium iodide nucleic acid-binding dyes. Transfection efficiency and cell phenotype were analyzed using the Cytek Aurora multi-color flow cytometer. For expansion and differentiation, HSPCs were cultured in StemSpan SFEM II medium supplemented with StemSpan CD34+ Expansion Supplement. Electroporation was performed using the Neon or MaxCyte GTx electroporator with telomerase, mCherry, and eGFP mRNA at a dose of 0.15mg / ml, except for donor 6102 receiving 0.10 mg / ml of eGFP. The Neon system utilized Invitrogen Neon Resuspension R Buffer and Electrolyte Buffer E2, while the MaxCyte system employed its proprietary Electroporation Buffer.

[0275] For in vivo evaluation, 7x10* G-CSF-mobilized CD34+ HSPCs from healthy donors were retro-orbitally injected into 8-wcck-old immunocompromised NBSGW mice for bone marrow reconstitution (approximately 3xl06cells per kg). Humanization was assessed by evaluating peripheral blood every two weeks post-injection, measuring human CD45 expression using flow cytometry. Additionally, hematological analysis was conducted six weeks post-injection, with peripheral blood samples submitted for an extra stained blood smear to assess complete blood count and cell morphology.

[0276] Preliminary NBSGW humanization data reveals between 2.5 to 4-fold higher engraftment between weeks 4 and 8 of injection in mice injected with human CD34 cells treated with TERT mRNA compared to treatment with fluorescent protein-encoding mRNA, as depicted by circulating levels of cells expressing human CD45 (FIG. 18). As depicted in FIG. 18, flow cytometry quantification of proportion of circulating human CD45 in peripheral blood of NBSGW mice 8-weeks post-injection with 70,000 TERT mRNA-treated or mCherry / eGFP mRNA-treated CD34 cells for n = 14 animals. Percent chimerism quantified between groups for two independent donors. Cells from donor 6102 (D6102) and 4669 (D4669) were electroporated using the MaxCyte GMP-grade GTx and Thermo Neon electroporators, respectively.

[0277] The infused dose of 7xl04HSPCs / mouse is equivalent to approximately 3xl06cells / kg in human subjects, a dose achievable in patients experiencing bone marrow failure, particularly with the benefit of ex vivo expansion, supporting further development. Doses of HSPCs in humans may range from below 1 million to over 20 million cells per kg of patient body weight. Next steps continue evaluating chimerism at bi-weekly time points up to 4-month post-injection, after which a thorough histological analysis is carried out on several organs, including quantification of human CD34+ cells inP A T E N T Docket No. REJU14PCT the bone marrow. Lastly, data presented herein are used to design and optimize an engraftment example using HSPCs with short telomeres obtained from donors with a telomeropathy, with or without treatment with TERT mRNA.1.10. Effect of TERT mRNA on Long-Term Engraftment and Serial Transplantation of Human CD34+ Cells

[0278] This example evaluates the long-term functional potency and self -renewal capacity of TERT mRNA-treated human CD34+ HSPCs using NBSGW xenotransplantation assays, including serial transplantation.Materials and Methods

[0279] Mobilized peripheral blood CD34+HSCs were obtained from STEMCELL Technologies and expanded in StemSpan SFEM II (STEMCELL Technologies, 09655) with StemSpan CD34+ Expansion Supplement (STEMCELL Technologies, 02691) and IpM IJM729 (STEMCELL Technologies, 72332) in 24-well G-Rex multi-well plates (Wilson Wolf, 80192M).

[0280] Human TERT mRNA was in vitro transcribed (3.5 kb coding sequence) with a T7 polymerase-driven kit, incorporating NLmethylpseudouridine and 5 -methylcytosine modifications to enhance stability and reduce immunogenicity (Kariko et al., 2005). A catalytically inactive TERT mRNA was generated by introducing a point mutation in the reverse transcriptase active site (D712A), analogous to known dominant-negative hTERT mutants (Zhang ct al., 1999; Masutomi ct al., 2000). Control mRNA encoding the fluorescent protein mCherry was used to control for electroporation effects. Purified mRNAs were capped and polyadenylated, then concentrated to 1 j g / j.tL. CD34+HSCs were resuspended in serum-free buffer at 2xl07cells / mL and electroporated with 5-10 pg of mRNA using a square-wave pulse protocol (Thermo Fisher Neon Transfection System, program optimized for human CD34 cells). Post-electroporation, cells were immediately transferred to pre-warmed media for recovery and kept at 37°C, 5% CO2 in a humidified incubator.

[0281] For Telo-Seq, genomic DNA was extracted from cells (pre- and post-treatment) using a Qiagen kit. Telo-Seq, a high-resolution long-read telomere sequencing method (Schmidt et al., 2024) was used to directly measure telomere lengths. Briefly, telomeric fragments were enriched from genomic DNA and sequenced on an Oxford Nanopore platform. Telo-Seq reads were aligned to a (TTAGGG)n reference to compute length distributions for each sample. We obtained read coverage sufficient to assess bulk telomere length and the length of individual chromosomal telomere ends. As a complementary method, we also measured telomere length by standard quantitative PCR (qPCR) (Cawthon, 2002) and Flow-FISH using the Telomere PNA Kit (Agilent Technologies, K532711-8) for selected samples to validate trends. For single telomere length analysis, flash frozen cell pellets (IxlO5cells) were submitted to TeloNostiX.

[0282] To evaluate progenitor function, we performed CFU assays 3 days after mRNA electroporation. CD34+cells were plated in MethoCult H4435 methylcellulose medium (STEM CELL Technologies, 04434) in triplicate at 150 cells per 35 mm dish to evaluate functional progenitorP A T E N T Docket No. REJU14PCT capacity (Eaves, 2015). After 14 days, colonies were counted and classified by morphology as CFU-GM (granulocyte-macrophage), BFU-E / CFU-E (erythroid bursts / colonies), or CFU-GEMM (granulocyte-erythrocyte-monocyte-megakaryocyte mixed colonies). Colony counts for each subtype and total CFU were compared between treatment groups.

[0283] The NB SGW mouse ( NOD / Scid-II .2 Ry ' KitW41 / W41) is a highly immunodeficient strain permissive for human HSC engraftment without requiring irradiation (McIntosh et al., 2015). We transplanted 7.5xl04treated CD34+cells intravenously into young adult NBSGW mice (8-10 weeks old, female, n=5 per group). Engraftment of human cells was assessed every 2-4 weeks post-transplant by flow cytometry for human CD45+cells in mouse peripheral blood and bone marrow at termination. Serial transplantation was performed 6-months after the initial transplant by sorting for CD34+cells from bone marrow (Miltenyi Biotec, 130-100-453) and transplanting 7.5xl04CD34 cells intravenously into new young adult NBSGW recipients. Mice were maintained under pathogen-free conditions and monitored for signs of illness. All animal procedures were approved by the institutional IACUC.

[0284] Multi-color flow cytometry was performed on the Cytek Aurora using hCD45 (1:200, BioLegend, 304016), CD34 (1:200, BioLegend, 343512), Zombie NIR (1:500, BioLegend, 423105), CD4 (1:200, BioLegend, 300530), CD8 (1:200, BioLegend, 344730), CD3 (1:200, BioLegend, 317344), CD27 (1:200, BioLegend, 356416), CD45RA (1:200, BioLegend, 304142), CD56 (1:200, BioLegend, 304142), mCD45 (1:200, BioLegend, 103147). Single color controls were calibrated using Cytek FSP CompBeads (Cytek, B7-10011).

[0285] Fixed cell pellets in 2% paraformaldehyde (IxlO6cells) were submitted to HistoWiz for immunohistochemistry. Immunofluorescence examining senescence was performed using CellEvent Senescence Detection Kit (Thermo Scientific, Cl 0851) according to manufacturer instructions.

[0286] Plasma from humanized NBSGW 6-months post-transplant with CD34+stem cells was analyzed using the Humanized Mouse 41-Plex Discovery Assay Array (Eve Technologies, HUMU41).

[0287] Mouse carcasses 6-months post-humanization with TERT mRNA-treated CD34+cells were submitted to the Stanford University School of Medicine for necropsy and histopathology.

[0288] Fresh peripheral blood from humanized NBSGW 6-months post-transplant with TERT mRNA-treated CD34+cells was collected in EDTA-lined tubes and submitted to the Stanford University Diagnostic Laboratory for a complete blood count.

[0289] Cryopreserved TERT mRNA-treated CD34 cells used to humanize NBSGW mice were submitted to KaryoLogic for karyotype analysis.Data are presented as mean ± s.e.m. Two-group comparisons used unpaired Student’s Wests, while multiple group comparisons used one- or two-way ANOVA with Tukey’s post-hoc test. P < 0.05 was considered significant. All experiments included at least three biological replicates.Results

[0290] The rate of expansion of mobilized CD34+HSCs significantly decreased over prolonged culture with an average telomere shortening of 600bp over six days (FIGS. 20A, 20B). AfterP A T E N T Docket No. REJU14PCT a single transfection with active TERT mRNA (FIGS. 20C, 20D), STELA demonstrated elongation of telomeric repeats in TERT -treated HSCs relative to controls by an average of 1.4kb irrespective of time of transfection within the first week of culture (FIG. 20E), corresponding to approximately 42 years of chronological aging (Rufer et al., 1999). Shortly after introduction of TERT mRNA, HSCs demonstrated a significant increase in their early rate of expansion, followed by a plateau in growtii two weeks post-transfection with TERT mRNA, only to rapidly resume expansion following a second TERT transfection (FIG. 20F). Lastly, larger changes in telomere extension were observed in older donors when compared to younger donors, presumably due to shorter starting telomere length (FIG. 20G). These findings confirmed that the telomerase mRNA was functionally active and able to add telomeric DNA to human HSCs, with preferential rescue of aged HSCs. To our knowledge, this is the first direct demonstration of telomere extension in primary HSCs via TERT-driven mRNA-based intervention.

[0291] Immunohistochemistry of CD34+HSCs after transfection with TERT mRNA revealed significandy lower PD-1, P53, P21, and the DNA damage marker phosphorylated-y-H2A.X relative to cells transfected with control mRNA (FIGS. 21A-21C). Moreover, immunofluorescent staining for senescence-associated |3-galactosidase demonstrated significandy lower levels after TERT mRNA treatment relative to control (FIGS. 2 ID, 2 IE). Taken together, TERT mRNA largely attenuated in vitro markers of exhaustion, senescence, and cell cycle arrest after prolonged culture of CD34+HSCs.

[0292] Whether telomere rejuvenation translated into better functional output of HSCs in vitro was next investigated. Using colony-forming unit (CFU) assays, CD34+cells that received active TERT mRNA increased colony formation across CFU subtypes (approximately 1.3-2.6x in vitro; largest effect in CFU-GEMM)” compared to control mRNA-treated cells (FIGS. 22A, 22B) witiiout perturbing homeostatic composition of CFUs (FIG. 22C). This increase was observed across all colony subtypes, indicating a broad improvement in progenitor function. Telomere lengtii analysis from differentiated CD 4+cells collected 2-weeks post-CFU assay that were originally treated with telomerase mRNA as CD34+cells demonstrated significantly longer telomeres and less critically short telomeres after differentiation (FIGS. 22D-22H). Thus, TERT mRNA treatment boosted colony formation by approximately 100% across erythroid and myeloid progenitors. In striking contrast, cells transfected with the catalytically-inactive form of TERT mRNA failed to form any significant colonies; colony numbers were near zero in all dishes for dtese cells, indicating a severe proliferative defect (FIG. 221). This suggests that the catalytically-inactive TERT protein acted in a dominant-negative manner, perhaps by occupying telomere ends or telomerase RNA components without adding repeats, thereby blocking residual telomerase activity or telomere maintenance in these cells (Zhang et al., 1999;Masutomi et al., 2000). These results establish that transient telomerase activity is sufficient to enhance the clonogenic capacity of CD34+HSCs, whereas a nonfunctional telomerase exerts a toxic, antiproliferative effect on these cells.P A T E N T Docket No. REJU14PCT

[0293] To evaluate the immediate functional potency of the hematopoietic stem and progenitor cell (HSPC) pool, the gold-standard colony -forming unit (CFU) assay was used, which remains the definitive method for quantifying the proliferative and differentiative potential of individual progenitors (Metcalf, 2007). TERT mRNA-treated CD34+ cells exhibited a significant expansion in the frequency of both early erythroid (BFU-E) and multilineage (CFU-GEMM) progenitors. The visual density of these colonies (FIG. 23E) and the quantitative fold-change (FIG. 23F) reflect a robust enhancement of the myelo-erythroid potential, suggesting a reversal of the progenitor exhaustion and diminished clonal diversity typically observed in aged human marrow (Rossi et al., 2005).

[0294] Upon transplantation into the immunodeficient NBSGW (NOD,B6.SCID I12rg— / — KitW41 / W41) xenograft model, we assessed the long-term fitness of the stem cell niche. The NBSGW mouse is particularly advantageous as its endogenous c-Kit mutation provides a competitive advantage to transplanted human HSCs without the need for pre-conditioning irradiation, which can alter the bone marrow microenvironment and confound results (McIntosh et al., 2015). TERT treatment resulted in significantly higher hCD45+ occupancy within the marrow niche compared to control mRNA (FIG. 23C). Despite this dramatic increase in cell numbers, the complete blood count (CBC) distribution remained indistinguishable from controls (FIG. 23B). This is a critical clinical indicator; it demonstrates that telomere modulation does not induce the pathological myeloid skewing that defines human immunosenescence — a phenomenon commonly observed with inflammaging (Pang et al., 2011 ;Kovtonyuk et al., 2016). Analysis of human CD34+ cells harvested 6 months post-engraftment confirmed that TERT -treated cells maintained significantly longer telomeres (FIG. 23D), providing a molecular buffer to withstand the massive proliferative stress required for hematopoietic reconstitution.

[0295] The ultimate hallmark of a hematopoietic stem cell (HSC) is its capacity for selfrenewal and long-term repopulation, which requires maintaining the delicate balance between quiescent and proliferative states (Eaves, 2015). TERT-treated HSCs achieved roughly 3 -fold higher engraftment levels in the peripheral blood, a trend that remained stable through 16 weeks post-injection (FIG. 23A). The most compelling evidence of HSC preservation is found in the 9-month serial transplant data (FIG.23G). The TERT-treated cells maintained their competitive advantage in secondary recipients, proving that the treatment acts on the long-term repopulating (LT-HSC) fraction rather than merely transient progenitors. By utilizing a transient, non-integrating mRNA approach, a rejuvenation of the hematopoietic system was achieved without the oncogenic risks of constitutive telomerase expression, consistent with the transient nature of the telomerase mRNA approach (Extended Fig. la-c). This provides a sophisticated roadmap for treating bone marrow failure and enhancing the success of autologous transplants in the elderly population.1.11. Ex Vivo Toxicology with TERT Treated Human Cells

[0296] This aim of this example is to perform standard ex vivo toxicology assessments for TERT mRNA-electroporated human CD34+ HSPCs prior to in vivo transplantation. Tire example evaluates theP A T E N T Docket No. REJU14PCT viability, DNA damage, and differentiation capacity of TERT mRNA-electroporated CD34+ HSPCs in vitro.

[0297] The test article is TERT mRNA, with human CD34+ HSPCs sourced from healthy donors as the target cell type. Controls include untreated CD34+ cells as a baseline, and a positive control, such as doxorubicin or mitomycin C, for cytotoxicity and genotoxicity assays.

[0298] Human CD34+ HSPCs are isolated using immunomagnetic separation or FACS sorting and maintained in serum-free hematopoietic expansion media such as StemSpan SFEM. The TERT mRNA solution, typically 1-5 pg mRNA per 1 x 106cells, is prepared for electroporation using the MaxCyte STX platform, which is optimized for large-scale transfection of primary human cells. The MaxCyte CL-1 processing assembly and manufacturer-recommended protocol for CD34+ cells are followed. Voltage and pulse duration are set according to MaxCyte’ s validated GMP electroporation conditions to achieve high-efficiency transfection while maintaining cell viability. Post-electroporation, cells are immediately transferred to pre-warmed media for recovery before functional analysis.Endpoints:

[0299] Cell viability & apoptosis: Cell viability and apoptosis are assessed using flow cytometry widi Annexin V / PI staining at 24, 48, and 72 hours post-electroporation. Endpoints include the percentage of viable, apoptotic, and necrotic cells.

[0300] Proliferation & colony formation: Cell proliferation is evaluated using Ki-67 staining for the proliferative index and a colony-forming unit (CFU) assay in methylcellulose media for CFU-GM, CFU-E, and CFU-Mix. Timepoints shall include 7- and 14-days post-electroporation, with endpoints measuring expansion rate and multilineage differentiation capacity.

[0301] Genotoxicity & DNA damage: Genotoxicity is examined using yH2AX staining for DNA double-strand breaks, the TUNEL assay, and chromosomal aberration analysis via karyotyping. Endpoints focus on detecting DNA damage and chromosomal instability.

[0302] Telomere length: Telomerase activity and telomere length shall be assessed using the telomere repeat amplification protocol (TRAP) assay and flow-FISH. Endpoints measure telomerase activity levels and telomere elongation profiles.

[0303] Tumorigenicity risk (soft agar assay): Tumorigenicity risk is evaluated using a soft agar colony formation assay, widi anchorage-independent growth serving as an indicator of transformation potential.

[0304] The example scope is designed to focus on assays relevant to telomerase activation, hematopoietic stem cell safety, and in vivo transplant feasibility. Long-term, in vitro proliferation assays beyond 14 days and deep whole-genome sequencing were excluded for several reasons. First, MaxCyte STX and GTX electroporation have been extensively validated for HSCs, reducing the need for additional electroporation-specific toxicology studies. Second, standard DNA damage assays are sufficient to detect potential mutagenic effects since telomerase activation does not inherently alter genomic integrity. Thirdly, hematopoietic function is best assessed in vivo, as extended in vitro assays may introduceP A T E N T Docket No. REJU14PCT artifacts unrelated to clinical relevance. Finally, tire soft agar assay provides an efficient tumorigenicity screening tool. The example is designed to align with FDA and ICH S6R1 guidelines in order to ensure regulatory compliance.1.12. Effects of human CD34+ cell dose and plerixafor on engraftment in immunocompromised mice

[0305] This example aims to quantify the effect of plerixafor on the engraftment of a range of doses of human C 34+ hematopoietic stem and progenitor cells (HSPCs) into immunocompromised mice with and without pretreatment with plerixafor to free up HSPC niches. Plerixafor is an exemplary CXCR4 antagonist that mobilizes CD34+ cells by disrupting their retention in the bone marrow niche, potentially improving the homing and engraftment of transplanted cells. In this example, NBSGW mice (immunodeficient mice that support efficient human hematopoiesis) are used as the transplantation model.

[0306] Human CD34+ cells are isolated from mobilized peripheral blood of healthy donors, enriched using immunomagnetic selection, electroporated with TERT mRNA, and cryopreserved until use. On tire day of transplantation, 36 mice are randomly assigned to six groups (n = 6 per group) receiving an intravenous infusion of 1, 2, 6, 12, or 24 x 106human CD34+ cells / kg. The sixth group 2 x 106untreated human CD34+ cells / kg. Engraftment is assessed over a 12-week period by serial blood sampling to quantify human CD45+ chimerism via flow cytometry.

[0307] At the 12-week example endpoint, bone marrow and spleens are harvested to measure the frequency of human CD34+, CD33+ (myeloid), and CD19+ (lymphoid) cells. Additionally, homing efficiency is evaluated by analyzing bone marrow cell composition 24 hours post-transplant in a subset of animals. The primary endpoint is the percentage of human CD45+ cells in peripheral blood at 6- and 12-weeks post- transplant, with secondary endpoints including total human cell engraftment in bone marrow and spleen, lineage distribution, and early homing efficiency. This example determines the dosedependence of engraftment of TERT mRNA treated CD34+ cells, providing valuable insights for optimizing human hematopoietic stem cell transplantation strategies.1.13. Four-Month IV Safety Example of Telo-EP-CD34 in NBSGW Mice

[0308] This example assesses the safety of Telo-EP-CD34 in a GLP-compliant toxicology using an immunocompromised NBSGW mouse model that supports myeloid and lymphoid human cell engraftment. The example evaluates both acute and long-term toxicology, including hematopoietic cell engraftment, systemic toxicity, and tumorigenicity.

[0309] The NBSGW mouse strain is used due to its high degree of immunodeficiency, which allows for efficient engraftment of human hematopoietic cells. This strain lacks T cells, B cells, and NK cells, preventing immune rejection of human cells. Additionally, human cytokine knock-in modifications support the survival and differentiation of both lymphoid and myeloid human cells, making this modelP A T E N T Docket No. REJU14PCT ideal for evaluating the persistence and function of TERT mRNA-treated CD34+ hematopoietic stem cells (HSCs).Example Design

[0310] Test Article: Telo-EP-CD34 generated using normal mobilized and apheresed CD34+ cells and the clinical process.

[0311] Species: NBSGW immunocompromised mice (equal numbers of males and females) o Group 1 (Control): Vehicle (PBS) onlyo Group 2 (Untreated Cells): 4 x 107cells / kg human CD34+ HSCso Group 3 (Low Dose Telo-EP-CD34s): 1 x 107cells / kg human CD34+ HSCs transfected with TERT mRNAo Group 4 (High dose Telo-EP-CD34s) 4 x 107cells / kg human CD34+ HSCs transfected with TERT MrnaDosing & Administration:o The maximum dose was chosen because it is over twice tire maximum anticipated clinical dose, based in part upon historical precedents (FDA-approved Casgevy)o The dose of TERT mRNA per cell is the same in both arms. This dose is based on preclinical pharmacology testing.o The treated cells are administered via single intravenous tail vein injection.o Mice are monitored for acute and chronic toxicity over a 4-month period.

[0312] The overall design of this example is summarized below in Table 7.Table 7 Design of GLP IV-Dose Safety Example of Telo-EP-CD34 in NBSGW MiceGroup Treatment Cell Dose Level Number of mice per Number of mice per (Cells / kg) group Day 15 group Month 4 1 Vehicle (PBS) - 10M / 10F 10M / 10F 2 Untreated Cells 4 x 10710M / 10F 10M / 10F 3 Telo-EP- 1 x 10710M / 10F 10M / 10F CD34s4 Telo-EP- 4 x 10710M / 10F 10M / 10FCD34sTotal: 160 mice

[0313] Half of the mice in each group are sacrificed on day 15 and the remaining mice are sacrificed at 4 months. Mice are monitored daily for survival and in-life endpoints including weekly clinical observations, food consumption and body weight assessments.

[0314] At terminal sacrifices on day 15 and month 4, blood is collected from all mice for clinical pathology assessments (clinical chemistry and hematology), as well as cytokine assessments for a standard panel of human and mouse inflammatory cytokines. Surviving mice are euthanized and full gross necropsies is performed and tissues collected, organs weighed, and tissues processed forP A T E N T Docket No. REJU14PCT histological analysis. Hematopoietic engraftment is assessed, and assessment for possible tumorigenicity is also performed (at the terminal 4-month endpoint). Tissues are assessed for engraftment efficiency and differentiation potential of human cells. Human hematopoietic cells are identified using antibodies specific to the human versions of CD45.1.14. Protocol Synopsis - An Open- label. Single Dose Phase 1 / 2 Example to Evaluate the Safety and Tolerability of TERT mRNA in Subjects with Telomeropathy and Cytopenia 1.14.1. Investigational product

[0315] Telo-EP-CD34 (autologous CD34+ cells electroporated ex vivo with TERT mRNA) 1.14. . Primary Ob j ecti ve

[0316] To assess the safety and tolerability of autologous CD34+ cells electroporated ex vivo with TERT mRNA in subjects with telomeropathies with cytopenia.1.14.3. Secondary Objectives

[0317] To assess the feasibility of ex vivo transduction and reinfusion of TERT mRNA-transduced CD34+ cells; and to assess efficacy via measurement of telomere extension and full blood count parameters over time.1.14.4. Example Design

[0318] This is a Phase 1 / 2. open-label example of Telo-EP-CD34 in up to 12 subjects with telomeropathies with cytopenia. All subjects are planned to receive at least 1 * 106Telo-EP-CD34 cells / kg. Previous clinical studies of autologous CD34+ cells predict an approximate dose range of l*106-16*106cells / kg. Fewer or more cells may be administered at the discretion of the physician in charge. The target range in the final protocol is informed by both ongoing nonclinical studies of Telo-EP-CD34 and the ongoing clinical experience with CD34+-based therapeutics.

[0319] Meetings of a Data Safety Monitoring Board are scheduled to examine >30 days of posttreatment safety data after 1, 3, 6, and 9 participants have been treated and prior to any interventions in additional participants.

[0320] Example participants are monitored in-house for >36 hours after the completion of treatment (cell infusion) and then followed at regular intervals for 12 months.

[0321] The treatment of each subject compromises four principal stages (also see FIG. 15):

[0322] Stage 1: CD34+ hematopoietic progenitor cell collection: Enrolled subjects undergo HPC mobilization using granulocyte colony stimulating factor (G-CSF; lOmcg / kg / day Dl-4)) and plerixafor (0.24mg / kg D2-4). Doses of plerixafor in humans can range from 0.04 mg / kg up to 0.75 mg / kg. Leukapheresis commences from D5 or when CD34+ peripheral blood progenitor cell (PBPC) levels reach 5 x 106cells / kg, for a maximum of 2 apheresis sessions.

[0323] Stage 2: Ex vivo cell processing: Following successful apheresis of peripheral blood leukocytes (PBMC), the subject’s CD34+ PBPCs are isolated from the PBMCs using the MiltenyiP A T E N T Docket No. REJU14PCT CliniMACS Prodigy. The CD34 cells undergo ex-vivo TERT mRNA electroporation using the MaxCyte GTX. The cells are cultured for 1 day before and 3 days post electroporation.

[0324] Stage 3: Processed cell infusion and post-infusion safety monitoring: Subsequently, subjects whose CD34+ HPC were successfully harvested and treated with TERT mRNA, receive a subcutaneous injection of plerixafor 6 hours prior to intravenous infusion of their fresh autologous TERT mRNA treated cells. Subjects are monitored in-house for safety at least 36 hours post-dosing prior to discharge from the clinic.

[0325] Stage 4: Follow-up (Weeks 2-5. Months 2. 3, 4, 5, 6, 9. and 12): Post-infusion follow-up includes vital signs, adverse events, concomitant medication use and periodic blood draws to measure CBCs and telomere length to monitor hematologic recovery, CD34+ engraftment, and treatment durability.1.14.5. Cell Harvesting, Processing, and Reinfusion

[0326] The handling of the collected HPCs comprises mobilization, apheresis, CD34+ selection, ex vivo expansion and TERT mRNA-mRNA electroporation, followed by autologous reinfusion (FIG.19).

[0327] Following the signing of informed consent, the example subject’s participation begins with screening and baseline assessments including complete blood counts (CBC) and telomere lengdr. CD34+ cell mobilization is achieved using a combination of granulocyte colony-stimulating factor (G-CSF) administered over four days, followed by a single dose of plerixafor. G-CSF stimulates HSPC proliferation and disrupts interactions between CD34+ cells and the bone marrow niche, while plerixafor directly antagonizes CXCR4-SDFla signaling, causing rapid egress of CD34+ cells into circulation. This combination approach is well-established in hematopoietic stem cell transplantation (HSCT) and is intended to ensure sufficient mobilization of CD34+ cells for apheresis.

[0328] Apheresis is performed to collect PBMCs while returning red blood cells (RBCs) to the subject. This is to minimize anemia and ensure that only the necessary cellular fraction is processed. The collected PBMCs undergo CD34+ enrichment using CliniMACS Prodigy, which selectively isolates HSPCs. The remaining PBMCs are reinfused to help maintain immune function. CD34+ cells are then cultured in hematopoietic growth media to induce mitosis, ensuring that the cells are in an active proliferative state before TERT mRNA is delivered.

[0329] Cell culture is performed using G-RexlOOM-CS closed-system culture devices, which are manufactured from USP Class VI materials and are suitable for use in GMP-compliant processes. G-RexlOOM-CS supports sterile, closed-system manipulation, minimizing contamination risk and enabling aseptic cell expansion in accordance with GMP guidelines. HSCs can be expanded in the same G-Rex100M-CS container for up to two weeks, which is longer than is necessary in this exemplary use case.

[0330] To extend telomeres, CD34+ cells are electroporated with TERT mRNA using the MaxCyte GTX. This approach is intended to enable transient expression of telomerase without the risksP A T E N T Docket No. REJU14PCT associated with permanent genetic modification, allowing for controlled telomere elongation. Following electroporation, cells are expanded ex vivo in specialized growth conditions to support telomere extension and ensure a sufficient number of cells for reinfusion.

[0331] To facilitate engraftment, a second dose of plerixafor is administered intravenously three to six hours before infusion. This step is aimed at temporarily opening CD34+ cell niches in the bone marrow, creating an optimal environment for the reinfused cells to home and integrate. Unlike traditional HSCT, myeloablative conditioning is not proposed in the current methods, thereby reducing toxicity and making the therapy accessible to subjects with fragile hematopoiesis. Fresh (non-cryopreserved) CD34+ cells modified by telomere extension using TERT mRNA are infused back into the subject during this window.

[0332] While a time period between three to six hours between administration of the CXCR4 antagonist and CD34+ cell infusion is exemplified, this time range may vary. In particular, in certain embodiments CD34+ cells are infused between 1 hour and 20 hours after administration of the CXCR4 antagonist. + Examples of CXCR4 antagonists that are administered in this regard include Examples of CXCR4 antagonists contemplated for use in embodiments described herein include, but are not limited to the following: BMS-936564 / MDX-1338, LY2510924, l,l'-[l,4-phenylenebis(methylene)]bis [1,4,8,11-tetraazacyclotetradecane] (AMD3100; Plerixafor), N, N-dipropyl-N-[4-({[(lH-imidazol-2-yl)methyl)benzyl] [(1 -methyl- 1 H-imidazol-2-yl)methyl] amino] methyljbenzyl] -N-methylbutane- 1 , 4-diamine tri(2R, 3R)-tartrate (KRH-3955), ([5-(4-methyl-l-piperazinyl)-2-({methyl[(8S)-5, 6,7,8-tetrahydro-8-quinolinyl]amino}methyl)imidazo[l,2-a]pyridin-3-yl]methanol) (GSK812397), N-( III-benzimidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-l,4-diamine (AMD11070), BKT140 (4F-Benzoyl-TN14003), MSX-122, TN14003, Mab-CXCR4, CQC-01, and / or BL-8040 (Motixafortide), including derivatives thereof any of the foregoing, and / or G-CSF.

[0333] Post-infusion follow-up includes, for example, safety assessments (adverse events), and periodic blood draws to measure CBC and telomere length to monitor hematologic recovery, CD34+ engraftment, and treatment durability. These data provide insights into the longevity of telomere restoration, the safety of transient telomerase activation, and the overall hematopoietic benefit. The example is designed to provide a well-tolerated yet effective strategy for restoring telomere function in subjects with telomeropathy while leveraging established clinical workflows for CD34+ cell mobilization and reinfusion.

[0334] According to embodiments contemplated herein the CXCR4 antagonist is administered concurrently with or after infusion of the CD34+ cells modified by telomere extension using TERT mRNA. When administered after infusion of the CD34+ cells modified by telomere extension using TERT mRNA, the CXCR4 antagonist is administered between 1 hour and 20 hours after infusion of the CD34+ cells modified by telomere extension using TERT mRNA. In certain embodiments the CXCR4 antagonist is administered between 6 hours and 9 hours after infusion of the CD34+ cells modified by telomere extension using TERT mRNA. In certain embodiments tire CXCR4 antagonist is administeredP A T E N T Docket No. REJU14PCT between 10 hours and 14 hours after infusion of the CD34+ cells modified by telomere extension using TERT mRNA. In certain embodiments tire CXCR4 antagonist is administered between 4 hours and 18 hours after infusion of the CD34+ cells modified by telomere extension using TERT mRNA. In certain embodiments tire CXCR4 antagonist is administered between 6 hours and 14 hours after infusion of the CD34+ cells modified by telomere extension using TERT mRNA. In certain embodiments the CXCR4 antagonist is administered at or about 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours. 19 hours, 20 hours, or between 20 hours and 36 hours after infusion of tire CD34+ cells modified by telomere extension using TERT mRNA to the subject.1.14.6. Example Population

[0335] Up to 12 subjects with a telomeropathy and a cytopenia. The example is open to all participants regardless of gender or ethnicity. Subjects who are enrolled but not evaluable are replaced.1.14.7. Inclusion criteria

[0336] 1) Willing and able to provide written informed consent;

[0337] 2) Age > 12 years; Adolescents with symptomatic telomeropathy often exhibit especially rapid disease progression, with bone marrow failure a potential cause of mortality within the first three decades of life, and therefore may benefit from telomere extension within a relatively narrow window of time to delay or prevent bone marrow failure or malignancy.

[0338] 3) A cytopenia defined by: within the past 4 months: peripheral blood neutrophils (ANC) < 1.5 x 107L; platelets < 100 x 10VL; or Hemoglobin <10 g / dL.

[0339] 4) Diagnosis of telomeropathies defined by at least one of the following: Age-adjusted mean telomere length < 10thpercentile (by flow-FISH, Q-FISH, or long-read sequencing); a pathogenic loss of function mutation in DKC1, TERC, TERT, NOP10, NHP2, TINF2, CTC1, PARN, RTEL1, ACD, NAF1, ZCCHC8, or WRAP53.1.14.8. Exclusion criteria

[0340] 1) Women of childbearing potential not willing to follow birth control as described or who are breastfeeding;

[0341] 2) Subjects with cancer who are on active chemotherapeutic treatment;

[0342] 3) Neutrophil count persistently < 0.5 x 10'71.; or platelets < 20 x 109 / L);

[0343] 4) Known presence of clonal hematopoietic abnormalities (blast excess, cytogenetic and / or somatic gene mutations) defining risk of secondary myeloid or lymphoid malignancy.

[0344] 5) Uncontrolled bacterial, viral or fungal infection;

[0345] 6) Prior allogeneic hematopoietic stem cell transplantation;

[0346] 7) Contraindication to G-CSF and / or plerixafor;

[0347] 8) Medical contraindication to apheresis;P A T E N T Docket No. REJU14PCT

[0348] 9) Subjects currently taking or have taken danazol or other androgens, or other growth factors within 60 days, or 5 half-lives (whichever is longer) prior to Day 1;

[0349] 10) Subjects with any other clinically relevant acute or chronic diseases which could impact subject safety;

[0350] 11) Subjects who have participated in another clinical trial with an investigational drug within the previous 30 days or more than 5 half-lives, whichever is longer.1.14.9. Baseline Disease Characteristics

[0351] Known clonal hematopoiesis driver mutations are captured by somatic sequencing, including U2AF1 , TP53, PPM1D, DNMT3, and TET2 (if subject does not have genetic information, these are collected during screening).1.14.10. Clinical Endpoints and Evaluations1.14.10.1. Primary Endpoints

[0352] Safety and tolerability as assessed by Physical examination, Clinical laboratory tests (hematology, blood chemistry, and urinalysis), Vital signs, Adverse events, Standard 12-lead electrocardiogram (ECG)1.14.10.2. Secondary Endpoints

[0353] Change in average telomere length and change in % of short telomeres in die following: lymphocytes, granulocytes, B-cells, naive T-cells, memory T-cells, and NK cells.

[0354] Change in bone marrow synthetic function assessed by neutrophil count, platelet count, lymphocyte counts and hemoglobin.1.14.11. Statistical Methods

[0355] Data are analyzed by means of descriptive statistics (including means and standard deviations, medians and inter-quartile ranges, and tabulations as appropriate) to reveal trends that guide the design of follow-on studies.1.14.12. Schedule of VisitsTable 8 Schedule of VisitsVisit Detail AssessmentsScreening Up to 30 days before Medical history, eligibility, baseline assessments, CBC Day 1 and telomere length 3x, 1 week apartDays 1-4 Pre-treatment G-CSF and plcrixafor administration, vital signs mobilizationApheresis and cell Apheresis (1-2 procedures), CD34+ cell counts; cell Days 5-9processing activation; electroporation; telomere extension Plerixafor administration 3-6 h prior to TERT mRNA Example drug infusionDay 10 (single infusion) treated autologous CD34+ cell administration, safety monitoringPost-infusion safety Safety labs, adverse events (AEs)*, discharge when +36 hmonitoring appropriateP A T E N T Docket No. REJU14PCT Visit Detail AssessmentsWeek 2** 14 days (±3 days) fromSafety labs, AEs. physical exam, vital signsDay 1Week 3** ±3 days Safety labs, AEs. physical exam, vital signsWeek 4 +3 days Safety labs, AEs, telomere length, immunogenicity Week 5** ±3 days Safety labs, AEs, physical exam, vital signsWeek 8** ±7 days Safety labs, AEs. physical exam, vital signsWeek 13 ±7 days Safety labs, AEs, telomere length, iimnunogenicity Week 17** ±7 days Safety labs, AEs. physical exam, vital signsWeek 22** ±7 days Safety labs, AEs, physical exam, vital signsWeek 26 ±14 days Safety labs, AEs. telomere lengtii. immunogenicity Week 39** Safety labs, AEs, physical exam, telomere length ±14 days(optional)Week 52 Safety labs, AEs. telomere length, immunogenicity, Exit ±14 daysvisit* AE reporting includes severity grade, seriousness rating, investigator’s assessment of causality, outcome, and treatment.** These visits may be conducted via telemedicine rather than requiring a clinic visit.

[0356] The above examples utilize plerixafor as the exemplary CXCR4 antagonist. It is specifically contemplated herein that additional or different CXCR4 antagonists contemplated herein are used in a similar manner and in examples with similar experimental protocols. Therefore, for efficiency purposes, according to certain embodiments contemplated herein, the above experiments are repeated while utilizing one or more of the following CXCR4 antagonist in replacement of plerixafor: BMS- 936564 / MDX-1338, LY2510924, N, N-dipropyl-N-[4-({[(lH-imidazol-2-yl)methyl)benzyl][(l-methyl- 1 H-imidazol-2-yl)methyl]amino]methyl)benzyl]-N-methy]butane-l , 4-diamine tri(2R, 3R)-tartrate (KRH-3955), ([5-(4-methyl-l-piperazinyl)-2-({methyl[(8S)-5,6,7,8-tetrahydro-8- quinolinyl] amino }methyl)imidazo[l,2-a]pyridin-3-yl]methanol) (GSK812397), N-(lH-benzimidazol-2- ylmethyl)-N'-(5 ,6, 7, 8-tetrahydroquinolin-8-yl)butane-l , 4-diamine (AMD11070), BKT140 (4F-Benzoyl- TN14003), MSX-122, TN14003, Mab-CXCR4, and / or CQC-01, or a derivative thereof any of the foregoing.

[0357] The above examples are included for illustrative purposes only and are not intended to limit the scope of the invention. Many variations to those described above are possible. Since modifications and variations to die examples described above will be apparent to those of skill in dais art, it is intended that tins invention be limited only by die scope of die appended claims.

[0358] Citation of the above publications or documents is not intended as an admission that any of die foregoing is pertinent prior art, nor does it constitute any admission as to the contents or date of these publications or documents.

Claims

PCT / US26 / 26829 06 May 2026 (06.05.2026)P A T E N TDocket No. REJU14PCT CLAIMSWe claim:

1. A method of treating cytopenia and / or age-associated hematopoietic decline in a subject, comprising administering Telo-EP-CD34 cells to a subject having, suspected of having, or at risk of cytopenia, a bone marrow disease or disorder, or age-associated hematopoietic decline, wherein the Telo-EP-CD34 cells are prepared from autologous CD34+ cells treated with nucleoside -modified mRNA encoding human telomerase reverse transcriptase.

2. The method of claim 1 , wherein the treatment comprises electroporation of the cells with the nucleoside-modified mRNA.

3. The method of claim 1, further comprising administering a CXCR4 antagonist to the subject before or after administering the Telo-EP-CD34 cells.

4. The method of claim 3, further comprising administering a CXCR4 antagonist to the subject between 20 hours before and 20 hours after administering the Telo-EP-CD34 cells.

5. The method of claim 1, wherein the subject has shortened telomeres.

6. The method of claim 1, wherein the subject has bone marrow failure.

7. The method of claim 1, wherein the subject has a telomere biology disorder caused by a germline mutation in one or more of TERT, TERC, DKC1, NOPIO, NHP2, TINF2, CTC1, PARN, RTEL1, ACD, NAF1, ZCCHC8, or WRAP53.

8. The method of claim 5, wherein the shortened telomeres are in lowest 1st, 5th, 10th, 15th, 20th, 25th, 30th, 35th, 40th, 45th, or 50thpercentile among the age-matched general population, as measured by mean telomere length, median telomere length, 10th, or 20thpercentile telomere length.

9. The method of claim 5 or 8, wherein the subject is identified as having shortened telomeres by TeSLA, STeLA, Telo-Seq, Q-FISH, long-read sequencing, qPCR, Oxford nanopore long-read sequencing (TeloSeq), PacBio sequencing, TRF qPCR, and / or flow-FISH.

10. A method of increasing engraftment of blood cells in bone marrow of a subject comprising administering a CXCR4 antagonist to the subject prior to intravenously infusing blood cells into the subject.

11. The method of claim 10, wherein the CXCR4 antagonist is plerixafor.

12. The method of any one of claim 3, 4 or 10, wherein the CXCR4 antagonist is selected from one or more of: BMS-936564 / MDX-1338, LY2510924, l,l'-[l,4-phenylenebis(methylene)]bis [1,4,8,11-tetraazacyclotetradecane] (AMD3100; Plerixafor), N, N-dipropyl-N-[4-({[(lH-imidazol-2-yl)methyl)benzyl] [( 1 -methyl- 1 H-imidazol-2-yl)methyl]amino] methyljbenzyl] -N-methylbutane- 1 , 4-diamine tri(2R, 3R)-tartrate (KRH-3955), ([5-(4-methyl-l-piperazinyl)-2-({methyl[(8S)-5, 6,7,8-PCT / US26 / 26829 06 May 2026 (06.05.2026)P A T E N TDocket No. REJU14PCT tetrahydro-8-quinolinyl]amino}methyl)imidazo[l,2-a]pyridin-3-yl]methanol) (GSK812397), N-(1H-benzimidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-l,4-diamine (AMD11070), BKT140 (4F-Benzoyl-TN14003), MSX-122, TN14003, Mab-CXCR4, CQC-01, BL-8040 (Motixafortide), and / or G-CSF.

13. The method of claim 10, wherein the CXCR4 antagonist is administered no more than 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, 18, 20, 22, 24, 36 or 48 hours before infusion of the cells.

14. The method of claim 10, wherein the blood cells are CD34+ cells.

15. The method of claim 10, wherein the blood cells are CD34+ hematopoietic stem and progenitor cells, CD133+ / CD34- progenitors, CD34+ / CD38- primitive HSCs, granulocyte-macrophage progenitors (GMPs), megakaryocyte-erythroid progenitors (MEPs), B cells, T cells (naive and central memory), NK cells, classical monocytes, intermediate monocytes, plasmacytoid dendritic cells (pDCs), conventional dendritic cells (eDCs), endothelial progenitor cells (EPCs), and / or mesenchymal stromal cells (MSCs).

16. The method of claim 10, further comprising administering a CXCR4 antagonist to the subject after intravenously infusing blood cells to the subject.

17. The method of claim 10, wherein a CXCR4 antagonist is administered to the subject between 0 hours and 20 hours after intravenously infusing blood cells to the subject.

18. The method of claim 10, wherein the subject has shortened telomeres.

19. The method of claim 18, wherein the shortened telomeres are in lowest 1st, 5th, 10th, 15th, 20th, 25th, 30th, 35th, 40th, 45th, or 50thpercentile among the age-matched general population, as measured by mean telomere length, median telomere length, 10th, or 20thpercentile telomere length.

20. The method of claim 10, wherein the subject has bone marrow failure.

21. The method of claim 10, wherein the subject has a telomere biology disorder.

22. The method of claim 16 or 17, wherein the subject is identified as having shortened telomeres by TeSLA, STeLA, Q-FISH, long-read sequencing, qPCR, Oxford nanopore sequencing, PacBio sequencing, TRF qPCR, and / or flow-FISH.

23. A composition comprising a Telo-EP-CD34 cell.

24. The composition of claim 23, wherein the Telo-EP-CD34 cell comprises telomerase mRNA.

25. The composition of claim 24, wherein the telomerase mRNA comprises SEQ ID NOS: 1-5, 7, 9, 11, 13, 15, 17, 19 or 21.

26. The composition of claim 24, wherein the telomerase mRNA encodes telomerase having a sequence defined by SEQ ID NOS: 6, 8, 10, 12, 14, 16, 18, or 20.PCT / US26 / 26829 06 May 2026 (06.05.2026)P A T E N TDocket No. REJU14PCT 27. A method of producing a Telo-EP-CD34 cell, comprising contacting a CD34+ cell with a composition comprising telomerase mRNA under conditions such that the CD34+ cell is transfected with the telomerase mRNA in a manner such that the telomerase mRNA is capable of expression.

28. The method of claim 27, wherein the conditions such that the CD34+ cell is transformed with the telomerase mRNA comprise electroporation conditions.

29. The method of claim 27, wherein the conditions such that the CD34+ cell is transformed with the telomerase mRNA comprise squeeze transfection, calcium phosphate mediated transfer, nucleofection, sonoporation, heat shock, magnetofection, microprojectile mediated transfer, or cationic polymer mediated transfer conditions.

30. The method of any one of claims 27 to 29, wherein the telomerase mRNA comprises SEQ ID NOS: 1-5, 7, 9, 11, 13, 15, 17, 19 or 21.

31. The method of any one of claims 27 to 29, wherein the telomerase mRNA encodes telomerase having a sequence defined by SEQ ID NOS: 6, 8, 10, 12, 14, 16, 18, or 20.

32. A method of rejuvenating long-term repopulating hematopoietic stem cells (LT-HSCs) in a subject, comprising administering Telo-EP-CD34 cells to the subject, wherein the Telo-EP-CD34 cells are prepared from autologous CD34+ cells treated with nucleoside-modified mRNA encoding human telomerase reverse transcriptase, and wherein the Telo-EP-CD34 cells, upon engraftment, maintain a competitive repopulation advantage through at least one round of serial transplantation.

33. The method of claim 32, wherein the Telo-EP-CD34 cells achieve at least a 3-fold increase in engraftment levels relative to control cells in an immunodeficient xenotransplantation model.

34. The method of claim 32, wherein the Telo-EP-CD34 cells maintain enhanced multilineage colony-forming capacity at 6 months post-engraftment.

35. A method of treating age-associated hematopoietic decline in a subject, comprising administering Telo-EP-CD34 cells to the subject, wherein the Telo-EP-CD34 cells are prepared from autologous CD34+ cells treated with nucleoside-modified mRNA encoding human telomerase reverse transcriptase, and wherein the treatment reduces the proportion of critically short telomeres in the CD34+ cells.

36. The method of claim 35, wherein the critically short telomeres are extended by an average of approximately 0.1 to 0.5, 0.5 to 2.0, or 2.0 to 4.0 kilobases.

37. A method of reducing cellular senescence in CD34+ hematopoietic stem cells, comprising treating the CD34+ cells ex vivo with nucleoside-modified mRNA encoding human telomerase reverse transcriptase, wherein the treatment reduces expression of one or more of p53, p21, PD-1, phosphorylated-y-H2A.X, or senescence-associated P-galactosidase relative to untreated control cells.PCT / US26 / 26829 06 May 2026 (06.05.2026)P A T E N TDocket No. REJU14PCT 38. The method of claim 37, further comprising administering the treated CD34+ cells to a subject having, suspected of having, or at risk of a telomere biology disorder or age-associated hematopoietic decline.

39. A method of enhancing colony -forming capacity of CD34+ hematopoietic stem cells, comprising treating the CD34+ cells ex vivo with nucleoside-modified mRNA encoding human telomerase reverse transcriptase, wherein the treatment increases colony formation across CFU-GM, BFU-E, and CFU-GEMM subtypes relative to untreated or control mRNA-treated cells.

40. The method of claim 39, wherein the colony formation is increased by approximately 1.3- to 2.6-fold relative to control mRNA-treated cells.

41. The method of claim 1 , wherein the treatment further results in a reduction of senescence-associated markers in the Telo-EP-CD34 cells relative to untreated autologous CD34+ cells, the senescence-associated markers selected from one or more of p53, p21, PD-1, phosphorylated-y-H2A.X, and senescence-associated P-galactosidase.

42. The method of claim 1, wherein the Telo-EP-CD34 cells, upon administration, engraft in the subject's bone marrow and maintain multi-lineage hematopoietic reconstitution capacity through at least one round of serial transplantation in an immunodeficient xenotransplantation model.

43. The method of claim 1, wherein the nucleoside-modified mRNA comprises Nl-methylpseudouridine substituted for uridine at about 100% substitution.

44. The method of claim 43, wherein the nucleoside-modified mRNA further comprises a 5' cap, 5' and 3' untranslated regions derived from human P-globin, and a poly-adenosine tail of between 80 and 100 nucleotides.

45. The method of claim 1, further comprising, prior to administering the Telo-EP-CD34 cells, mobilizing CD34+ cells from the subject using a combination of granulocyte colony-stimulating factor (G-CSF) and plerixafor, followed by apheresis and isolation of CD34+ cells.

46. The method of claim 1, wherein the method does not comprise myeloablative conditioning of the subject prior to administering the Telo-EP-CD34 cells.

47. The method of claim 1, further comprising administering a CXCR4 antagonist to the subject prior to administering the Telo-EP-CD34 cells, optionally no more than 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, 18, 20, 22, 24, 36, or 48 hours before infusion of the Telo-EP-CD34 cells.

48. The method of claim 1, wherein the Telo-EP-CD34 cells are administered at a dose of about IxlO6to about 16xl06cells per kilogram of subject body weight.

49. The method of claim 27, wherein the CD34+ cells are cultured ex vivo for one day prior to and three days post treatment with the telomerase mRNA to allow telomere extension during S-phase of the cell cycle.PCT / US26 / 26829 06 May 2026 (06.05.2026)P A T E N TDocket No. REJU14PCT 50. The method of claim 27, wherein the electroporation is performed using the MaxCyte GTX electroporation platform.

51. The composition of claim 23, wherein the Telo-EP-CD34 cells are suspended in Plasma-Lyte A as a fresh, non-cryopreserved product.

52. The method of claim 1, wherein the telomerase mRNA is a codon-optimized TERT mRNA comprising a nucleic acid sequence at least 90% identical to SEQ ID NO: 1.

53. A method of treating a telomere biology disorder in a subject, the method comprising: (a) mobilizing CD34+ cells from the subject using a combination of G-CSF and a CXCR4 antagonist; (b) collecting CD34+ cells by apheresis; (c) treating the CD34+ cells ex vivo with nucleoside-modified mRNA encoding human telomerase reverse transcriptase to produce Telo-EP-CD34 cells; (d) administering a CXCR4 antagonist to the subject; and (e) infusing the Telo-EP-CD34 cells into the subject.

54. The method of claim 53, wherein the CXCR4 antagonist of step (d) is plerixafor administered subcutaneously 3 to 6 hours prior to infusion of the Telo-EP-CD34 cells.

55. The method of claim 53, wherein step (c) comprises electroporating the CD34+ cells with the nucleoside-modified mRNA and expanding the electroporated cells ex vivo for approximately three days to allow telomere extension.